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 Summary 
Specific interactions of biomolecules are central to cellular processes, drug discovery and 
immunodiagnostics. Such biological binding events are quantifiable via thermophoresis, the 
directed molecule movement driven by a temperature gradient. Biomolecule thermophoresis 
can be induced by infrared laser heating and analyzed using fluorescence. The objective of 
this thesis was to enhance and optimize these all-optical measurements, regarding instru-
mentation, assay design and biomedical applications. 
In the first part, a novel measurement device and approach are presented, which cut down 
sample consumption 50-fold compared to established capillary thermophoresis. Instead of 
capillaries, analysis was performed in 10 nl-sample droplets transferred into standard 1536-
well plates with a non-contact liquid handler (Labcyte). To prevent evaporation, the aqueous 
sample droplets were stabilized in an oil-surfactant mix. Temperature induced effects in this 
water-in-oil system were experimentally characterized and the results agreed with numerical 
simulation. The system’s applicability for biomolecular interaction analysis was confirmed 
with a DNA aptamer. The achieved miniaturization and the easy-to-handle multi-well plate 
format promote automated high-throughput screens. Besides aptamers, proteins should also 
be measurable very well when judging from the application depth of capillary measurements. 
This versatility of protein investigation via capillary thermophoresis is demonstrated in the 
second part. Successful experiments were not only conducted in diverse liquids including 
crude cell lysate, but also for binding partners with a broad range of molecular weight ratios. 
Affinities between protein and protein, protein and peptide, as well as protein and small 
molecule were determined with high accuracy. Further flexibility arises from the herein 
presented label free approach which utilizes protein intrinsic UV fluorescence. It is caused 
by aromatic amino acids with tryptophan being the major intrinsic fluorophore. This 
approach exempts from the need to attach a dye, which saves time and excludes labeling 
artifacts. 
The wide variety of proteins that can be analyzed with thermophoresis also includes anti-
bodies. Two applications of such thermophoretic immunoassays are introduced in the third 
part. Firstly, the therapeutically interesting antibody MCPR3-7 was assessed. MCPR3-7 
binds proteinase 3 (PR3), the major autoimmune target in granulomatosis with polyangiitis. 
Thermophoresis allowed to quantified MCPR3-7’s affinity and selectivity for different PR3 
forms. In addition, it revealed that the antibody interferes with the complexation of PR3 and 
α1-proteinase inhibitor (α1PI).  Secondly, a diagnostic autocompetition assay is described, 
which directly determines affinity and concentration of disease related biomarkers. It was 
applied for autoantibodies against the cardiac β1-adrenoceptor found in patients suffering 
from dilated cardiomyopathy. To detect these autoantibodies, the small peptide COR1 
mimicking the adrenoceptor’s dominant epitope served as an artificial antigen. This tracer 
was labeled with a red-fluorescent dye, which ensured selectivity for measurements directly 
in untreated human blood serum. The results prove that thermophoresis is a valuable tool to 
characterize antibodies including those of diagnostic value and those with a therapeutic 
potential.  
Taken together, the presented innovations in assay design and the novel nl-droplet approach 
can be expected to considerably widen the application spectrum of thermophoresis in 
fundamental research, industrial drug discovery and clinical laboratory diagnostics. 
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 Zusammenfassung 
Spezifische Interaktionen von Biomolekülen sind von zentraler Bedeutung für zelluläre Pro-
zesse, die Entwicklung neuer Medikamente und die Immundiagnostik. Solche biologischen 
Bindungsvorgänge lassen sich mittels Thermophorese, der gerichteten Molekülbewegung 
entlang eines Temperaturgradienten, quantifizieren. Die Thermophorese von Biomolekülen 
kann durch Infrarotlaser-Heizen induziert und mittels Fluoreszenz analysiert werden. Die 
Weiterentwicklung dieses optischen Verfahrens bezüglich des Messinstruments, des Ver-
suchsdesigns und der biomedizinischen Anwendungen war das Ziel der vorliegenden 
Dissertation. 
Im ersten Teil wird eine neuartige Technik vorgestellt, die den Probenverbrauch verglichen 
mit etablierten Kapillarmessungen um den Faktor 50 verkleinert. Statt in Kapillaren wurde in 
10 nl-großen Probentropfen gemessen, die mit einem kontaktfreien Liquid-Handler (Lab-
cyte) in eine 1536-Well-Platte übertragen wurden. Zum Schutz vor Verdunstung wurden die 
Tropfen in eine Öl-Tensid-Schicht transferiert. Temperaturinduzierte Effekte in diesem 
Wasser-in-Öl-System wurden experimentell charakterisiert, wobei die Ergebnisse durch 
numerischen Simulationen bestätigt wurden. Dass sich die Methode für biomolekulare Inter-
aktionstests eignet, wurde anhand eines DNA-Aptamers belegt. Die Miniaturisierung und die 
einfache Handhabung der Multi-Well-Platten ermöglichen automatisierte Hochdurchsatz-
Screens. Neben Aptameren sollten sich auch Proteine sehr gut untersuchen lassen, wenn man 
von einer ähnlichen Anwendungsbreite wie bei Kapillarmessungen ausgeht. 
Auf derartige Proteinuntersuchungen mittels Kapillarthermophorese wird im zweiten Teil 
eingegangen. Analysen wurden nicht nur in diversen Puffern und sogar in rohem Zelllysat 
durchgeführt, sondern auch mit unterschiedlichsten Bindungspartnern. So wurden Affinitä-
ten zwischen Protein und Protein, Protein und Peptid, sowie Protein und niedermolekularer 
Verbindung mit hoher Genauigkeit bestimmt. Thermophoresetests gewinnen durch das in 
dieser Arbeit präsentierte, markierungsfreie Verfahren zusätzlich an Flexibilität. Es basiert 
auf der intrinsischen UV-Fluoreszenz von Proteinen, die auf aromatische Aminosäuren, 
hauptsächlich Tryptophan, zurückzuführen ist. Somit müssen Proteine nicht mehr mit Fluo-
reszenzfarbstoffen markiert werden, was Zeit spart und Artefakte ausschließt. 
Der dritte Teil behandelt die Quantifizierung von Antikörpern. Thermophoretische Immun-
assays wurden für zwei biomedizinische Fragestellungen eingesetzt. Zunächst wurde der aus 
therapeutischer Sicht interessante Antikörper MCPR3-7 untersucht. Er ist gegen Proteinase 3 
(PR3) gerichtet, das Hauptepitop autoimmuner Antikörper bei der granulomatösen Polyangi-
itis. Mithilfe der Thermophorese wurde sowohl die Affinität von MCPR3-7 für verschiedene 
PR3-Formen quantifiziert, als auch gezeigt, dass der Antikörper die Komplexierung von PR3 
und α1-Proteinaseinhibitor (α1PI) stört. Ferner wird ein diagnostisches Autokompetitions-
verfahren vorgestellt, das gleichzeitig die Affinität und die Konzentration von Biomarkern in 
humanem Blutserum quantifiziert. Autoantikörper gegen den kardialen β1-Adrenozeptor, die 
mit der dilatativen Kardiomyopathie assoziiert sind, wurden mithilfe des kurzen Peptides 
COR1 analysiert, das das dominante Epitop nachstellt. Die Ergebnisse belegen, dass die 
Thermophorese ein wertvolles Werkzeug für die Antikörpercharakterisierung ist. 
Zusammengefasst lassen die vorgestellten Neuerungen eine umfangreiche Erweiterung des 
Anwendungssprektrums der Biomolekülthermophorese in der Grundlagenforschung, der in-
dustriellen Wirkstoffsuche und der klinischen Labordiagnostik erwarten. 
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1 Introduction: Biomolecular Interaction 
1.1 Relevance 
Cellular processes are mainly based on molecular recognition and interaction, e.g. between 
cell surface receptors and ligands, enzymes and substrates, transcription factors and DNA, or 
antibodies and antigens. Elucidating these biological binding events is essential to under-
stand physiological and pathological mechanisms on a molecular level.1,2 
This understanding allows to identify novel target structures for pharmacological treat-
ment.3,4 By testing the binding of a disease specific target to large libraries of chemical 
compounds, candidate medications are discovered. In fact, molecular interaction does not 
only drive the development of medications, but also represents their mechanism of action. 
The effect of a pharmaceutical drug relies on its interaction with one or a few specific 
cellular targets. The vast majority of today’s drugs target proteins: cell surface receptors 
(60%), ion channels, or enzymes.5 
Biomolecule interaction is also utilized in clinical laboratory diagnostics. Immuno-
diagnostics rely on the interaction of antibodies and antigens. These protein biomarkers 
report on a patient’s status regarding e.g. viral or bacterial infections, vaccine response, 
allergies, or autoimmune diseases.6–9 Depending on the type of condition, specific antigens 
or antibodies can be detected in different body fluids, often in blood serum or plasma.10 
1.2 Analysis 
The above considerations demonstrate the central role of biomolecular interaction analysis in 
fundamental life science research, industrial drug discovery and clinical diagnostics. Accor-
dingly, biomolecule binding is routinely studied with a variety of methods. 
Classical biochemical methods are straightforward to perform and comparably low in cost 
and effort. They include antibody-based techniques such as enzyme linked immunosorbent 
assays (ELISA).11 In basic ELISAs, surface-attached antibodies capture antigens within the 
test sample. The captured antigens bind to secondary antibodies, which carry an enzyme, 
catalyzing a detectable color reaction. ELISAs are highly popular, especially in serological 
diagnostics. However, they are typically limited to semiquantitative analysis due to several 
steps, which influence the result in a hardly predictable way. These include initial strong 
sample dilution, washing steps, enzymatic signal amplification, and normalization to a 
standard curve.  
Just like ELISA, surface plasmon resonance (SPR) relies on immobilizing one of the binding 
partners to a surface.12,13 SPR is, however, a biophysical technique that allows for absolute 
quantification of association and dissociation rates and affinities of a binding event. Thus, 
the method is widely used in pharmaceutical compound screening. In SPR, the target 
biomolecule is tethered to a thin noble metal film on top of a glass prism, which is 
illuminated by a polarized light source. Light at the resonance angle is absorbed by the metal 
electrons, which induces surface plasmons. When the metal-attached biomolecules bind to a 
compound, the resonance angle is measurably shifted. Complications for kinetic SPR 
measurements include mass transport and rebinding.14,15 An additional disadvantage of 
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surface-bound techniques like SPR and ELISA is their often time-consuming design and 
preparation. Furthermore, surface immobilization may affect the bound molecules’ dynamics 
and thus alter the binding event.16 
Such surface artifacts can be excluded for techniques, in which both binding partners are 
present in free solution. The probably most accepted free-solution method is isothermal 
titration calorimetry (ITC).17 In ITC, the heat change upon binding is measured. To achieve 
this, a thermally conducting sample cell surrounded by an adiabatic jacket is filled with a 
constant amount of the biomolecule of interest. The binding partner is then titrated into the 
sample cell, which leads to a heat increase (exothermic binding reaction) or decrease 
(endothermic). The temperature difference in the sample cell is measured relative to a 
reference cell filled with buffer or water. To generate a sufficiently strong heat signal, 
relatively high sample amounts are required. If enough sample is available, ITC gives direct 
access to affinity, stoichiometry and thermodynamic parameters.18,19 
The main advantages of ITC, SPR and ELISA are combined in a recent biophysical tech-
nique: thermophoretic binding quantification, also referred to as microscale thermophoresis 
(MST).20,21 MST benefits from its low sample consumption, its free solution format, its 
flexible and simple assay design and its ability to quantify binding events absolutely and 
directly. 
This thesis introduces key innovations in thermophoretic binding quantification, which 
comprise automation-friendly, nanoliter-volume measurements (chapter 3) and versatile 
protein assays including label free studies (chapter 4). In addition, thermophoresis was 
utilized for antibody characterization and a quantitative diagnostic assay (chapter 5). Before 
these new developments are addressed, the theoretical background and the measurement 
principle of biomolecule thermophoresis are outlined (chapter 2). 
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2 Background: Biomolecule Thermophoresis 
2.1 Thermophoresis 
Thermophoresis is the directed molecule movement along a temperature gradient. For 
liquids, this effect was initially described by Carl Ludwig in 1856, and further characterized 
by Charles Soret in 1879.22,23 In a locally heated solution, thermophoresis depicts a 
molecular flux ݆஽், which is directly proportional to the temperature gradient ׏ܶ with the 
proportionality constant ܦ், the thermal diffusion coefficient: 
݆஽் ൌ െܿܦ்ߘܶ.     1 
Here, ܿ denotes the molecule concentration. This thermophoretic flux is counteracted by 
mass diffusion ݆஽ with the diffusion coef ic nf ie t ܦ: 
݆஽ ൌ െܦߘܿ.     2 
In steady state, thermophoresis and backdiffusion compensate: ݆ ൌ ݆஽் ൅ ݆஽ ൌ 0. For small 
temperature gradients this leads to: 
݀ܿ
ൌ െ
ܦ்
ܦ
݀ܶ ൌ െ்ܵ݀ܶ.     3 ܿ
The Soret coefficient ்ܵ ൌ ܦ் ܦ⁄  determines the thermophoretically induced change in 
concentration.  
To predict thermophoresis in solution, several models are still under debate. Among these 
different theories, Duhr and Braun suggested a thermodynamic approach to derive ்ܵ and 
experimentally proved it e.g. for DNA.24,25 This approach considers thermophoresis along 
moderate temperature gradients (׏ܶ ൏ ሾ்ܽܵሿିଵ with the molecule radius ܽ) as a local 
equilibrium system. This allows to relate ்ܵ with the temperature derivative of the Gibbs 
free enthalpy ܩ: 
்ܵ ൌ
1
݇ܶ
݀ܩ
݀ܶ
ൌ െ
ܵ
݇ܶ
 .    4 
Following equation 4, ்ܵ is determined by the entropy ܵ of the solute-solvent system. 
Contributions to ܵ from solute-solute interactions are negligible for highly dilute solutions. 
Only solute-solvent interactions have to be considered, which are the hydration entropy ܵ௛௬ௗ 
and the ionic shielding entropy ௜ܵ௦. ௜ܵ௦ is calculated from the temperature derivative of Gibbs 
free enthalpy, which can be depicted as the electric energy stored in a capacitor consisting of 
the molecule’s surface and the surrounding ion cloud.26 Based on these contributions, ்ܵ can 
be expressed as: 
்ܵ ൌ െ
ܵ
݇ܶ
ൌ  െ
ܵ௛௬ௗ ൅ ௜ܵ௦
݇ܶ
ൌ
ܣ
݇ܶ
ቆെݏ௛௬ௗ ൅
ߚߪ௘௙௙
ଶ
4ߝߝ଴ܶ
ߣ஽ுቇ   5 
 
7 
2.2 All-optical Measurement 2 Background: Biomolecule Thermophoresis 
with: 
ݏ௛௬ௗ: hydration entropy per molecule surface area ܣ  
݇ܶ: thermal energy  
ߪ௘௙௙: effective charge per molecule surface area ܣ  
ߝ and ߝ଴: relative permittivity of water and vacuum permittivity  
ߣ஽ு: Debye length given by the solution’s salt concentration  
ߚ: factor describing the temperature dependence of ߝ and ߣ஽ு  
 ߚ ؠ 1 െ ሺܶ ߝ⁄ ሻሺ݀ߝ ݀ܶ⁄ ሻ. 
Equation 5 applies for all measurements in this thesis, as they were performed under highly 
dilute conditions and in moderate temperature gradients. These conditions, in the first place, 
guarantee biomolecule stability throughout analysis. Equation 5 illustrates that under 
constant buffer conditions ்ܵ probes various molecular properties including size, charge, 
hydration entropy, and conformation. These parameters typically differ between an unbound 
biomolecule and its bound complex with a ligand. Thus, thermophoresis discriminates bound 
and unbound state, which qualifies it for biomolecular interaction analysis.20,21 
2.2 All-optical Measurement 
For all measurements in this thesis, thermophoresis was induced with an infrared (IR) laser, 
as Figure 1A shows. The focused IR radiation with a wavelength of 1480 nm is absorbed by 
the sample buffer’s water molecules to create a localized temperature gradient.20,21 Typically, 
a volume of 2 nl is heated by 1-10 K. The resultant thermophoretic molecule motion leads to 
a concentration change in the heat spot. This change was detected via fluorescence. For this, 
the biomolecules either were equipped with a fluorescent label or fluorescent fusion protein, 
or they exhibited a sufficient intrinsic UV fluorescence. Fluorescence was excited with a 
light emitting diode (LED) of a suitable wavelength and recorded with a photomultiplier tube 
(PMT) or a charge coupled device (CCD) camera. 
 
FO
IR
Hot 
mirror
Objective
TC
Fl
uo
re
sc
en
ce
t / s
B)
F0
IR on IR off
10 20 30 40
F0 F
I
II
III
IV
V
A)
→
‘
Figure 1. Biomolecule thermophoresis studies. (A) All-optical measurement. A focused infrared laser (IR) 
induces thermophoresis in a biomolecule solution. The molecule motion in the heat spot is detected via 
fluorescence excited with an LED and recorded with a fluorescence observation (FO). A thermoelectric 
cooler (TC) provides a constant basis temperature. (B) Fluorescence time trace. When turning on the IR 
(t=5 s), the initial fluorescence (I) decreases due to the fluorophore’s temperature response (FTR, II) and 
thermophoretic depletion (III). When turning off the IR (t=35 s), the fluorescence recovers due to FTR (IV) 
and backdiffusion (V). 
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Figure 1B shows a schematic fluorescence time trace, which results from a series of 
separable processes. Before heating, the initial fluorescence (region I in Figure 1B) is 
recorded. Turning on the IR-laser (t=5 s) leads to an abrupt change in fluorescence intensity 
(region II), caused by the inherent temperature dependence of the fluorophore.27 This 
temperature response is sensitive to the fluorophore’s local environment and thus to ligand-
binding in close proximity or to conformational changes.28 The fluorophore’s temperature 
response (FTR) occurs on a 100 ms timescale. Hence, it can easily be distinguished from the 
subsequent diffusion limited thermophoresis, which for the measured large biomolecules last 
several seconds (region III). Thermophoresis creates a concentration gradient of the 
fluorescent molecules leading to a slow change in the recorded fluorescence. Finally, 
fluorescence intensity reaches the steady state plateau, in which thermophoresis is 
counterbalanced by ordinary diffusion. Immediately after the heating laser is turned off 
(t=35 s), the fluorescence recovers due to the FTR (region IV), and backdiffusion driven by 
pure mass diffusion (region V). 
2.3 Binding Quantification 
As explained in the previous chapter, the biomolecules’ fluorescence was recorded to 
measure the concentration change due to thermophoresis. This concentration change is 
described by equation 3 in chap e  t r 7, which after integration yields:
ܿ
ܿ଴
ൌ expሺെST∆ܶሻ ؆ 1 െ ST∆ܶ.   6 
In this exponential steady state distribution, the concentration after heating ܿ is normalized to 
the concentration without heating ܿ଴. The normalized concentration can be approximated by 
linearization for small temperature and concentration changes, as they are used in 
biomolecule thermophoresis. To extract this concentration change from the fluorescence 
time trace in Figure 1B, the fluorescence after thermophoresis ܨ is normalized to the fluore-
scence before thermophoresis, but after the fluorophore’s temperature response (FTR) ܨ଴ᇱ: 
ܨ௡௢௥௠ᇱ ൌ
ܨ
ܨ଴
ᇱ ؆ 1 െ ்ܵ∆ܶ.    7 
As mentioned in chapter 2.2, FTR is often influenced by binding event. When the binding-
induced change in FTR and in thermophoresis have an amplitude with the same sign, they 
add up to an enhanced binding signal. For this combined analysis, the fluorescence after 
thermophoresis ܨ is normalized to the fluorescence before heating ܨ଴, with ߜܨ ߜܶ⁄  denoting 
the contribution of FTR: 
ܨ௡௢௥௠ ൌ
ܨ
ܨ଴
؆ 1 ൅ ൬
ߜܨ
ߜܶ
െ ்ܵ൰ ∆ܶ.   8 
To quantify biomolecule interaction, a binding partner ܣ is titrated against a constant 
concentration of partner ܤ, whose fluorescence is observed. Consequently, the ratio of 
unbound ܤ and bound complex Aܤ gradually changes. Due to equation 4, ܤ and ܣܤ can be 
expected to differ in ்ܵ. Thus, titration leads to a stepwise change in the ensemble averaged 
9 
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்ܵ, which corresponds to the bound fraction ݔ. As the fluorescence signal linearly reports ்ܵ, 
ܨ௡௢௥௠ is directly fit to a suitable description of the binding process. 
In many cases, a simple model according to the mass action law well describes the binding 
event of two partners ܣ and ܤ forming the complex ܣܤ:    ܣ ൅ ܤ ֖ ܣܤ. The affinity of this 
reaction is quantified by th uili m disse eq briu ociation constant ܭ஽  
ܭ஽ ൌ
ሾܣሿ௙௥௘௘ሾܤሿ௙௥௘௘
ሾܣܤሿ
ൌ
ሺሾܣሿ െ ሾܣܤሿሻሺሾܤሿ െ ሾܣܤሿሻ
ሾܣܤሿ
 .   9 
ሾܣሿ௙௥௘௘ and ሾܤሿ௙௥௘௘ denote the free concentrations of the binding partners, ሾܣܤሿ the 
concentration of the bound complex. The unknown free concentrations of ܣ and ܤ can be 
expressed using the total, initial concentrations ሾܣሿ and ሾܤሿ. The bound fraction ݔ is then 
given by the following equ ܭation, in which ஽ is the single free fit parameter: 
ݔ ൌ
ሾܣܤሿ
ሾܤሿ
ൌ
ሾܣሿ ൅ ሾܤሿ ൅ ܭ஽ െ ඥሺሾܣሿ ൅ ሾܤሿ ൅ ܭ஽ሻଶ െ 4ሾܣሿሾܤሿ
2ሾܤሿ
  .  10 
Many biological binding processes show cooperativity, which means that for a 
macromolecule with several binding sites, binding of one ligand molecule affects the ܭ஽ of 
subsequent binding events. An empirical description of cooperativity was originally 
formulated by Hill for oxygen binding to hemoglobin.29 According to the Hill equation, the 
fraction of occupied sites ݔ௦௜௧௘௦ is given by: 
ݔ௦௜௧௘௦ ൌ
1
1 ൅ ൬ܧܥହ଴ሾܣሿ ൰
௡ .    11 
ܧܥହ଴ denotes the ligand concentration occupying half of the binding sites, which is the 
apparent dissociation constant. The dimensionless Hill coefficient ݊ quantifies the 
cooperativity. A Hill coefficient greater than one indicates positive cooperativity, where 
binding of one ligand molecule increases the affinity for further ligands. The opposite case of 
a Hill coefficient less than one reports negative cooperativity: binding of a ligand molecule 
reduces the affinity for further ligands. A Hill coefficient of one denotes independent binding 
without cooperativity.  
Hill proposed his equation as purely empirical and disavowed a physical interpretation of 
݊.29 Only for extreme positive cooperativity, ݊ accurately estimates the number of binding 
sites, as then ݊ molecules bind in an all-or-non fashion without intermediate states. 
Typically, this cannot be assumed and instead ݊ only provides a lower limit of the number of 
sites.30 For hemoglobin, for instance, ݊ is about 2.7, though the number of oxygen binding 
sites is four.29,31  
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3 Thermophoresis in Nanoliter-Droplets 
Microscale thermophoresis (MST) has been commercialized successfully and received well 
by the life science community. In standard MST, biomolecule solutions are analyzed in 
individual glass capillaries (see Figure 1A). Filling is achieved through capillary action, 
before the samples are put onto a temperature controlled tray on a translation stage. This 
allows for sequential analysis of 16 capillaries equivalent to one binding curve (NanoTemper 
Monolith NT.115). Recently, a medium-throughput MST instrument became available, 
which uses 24-capillary-chips (Monolith NT.Automated). It allows to analyze 96 samples 
equivalent to six binding curves at a time. 
All available MST instruments are based on capillaries, which entails certain disadvantages. 
This includes the sample consumption, which with at least 0.5 µl per capillary is 
unnecessarily high compared to the measurement volume of 2 nl. A further disadvantage is 
the difficult handling of glass capillaries. Individual capillaries in particular, but also 
capillary-chips complicate the implementation into automation platforms, which are 
typically based solely on multi-well plates. Both drawbacks especially hamper 
thermophoresis applications in high throughput screening, e.g. in drug discovery or 
laboratory diagnostics. Thus, a 1536-well plate based, nanoliter-volume approach was 
developed, which is introduced in the following. 
3.1 Sample Preparation 
To miniaturize thermophoresis measurements, samples were prepared with a non-contact 
liquid handling system available commercially (Labcyte ECHO 550). The system delivers 
2.5 nl-portions with a deviation from the target volume of less than 2% for aqueous buffers.32 
The samples are delivered from multi-well source plates into destination plates via acoustic 
droplet ejection (Figure 2A).33 To protect the nl-samples from evaporation, they were 
transferred into standard microbiology mineral oil mixed with a surfactant blend according 
to Tawfik and Griffiths.34 For the measurements presented below, four or eight 2.5 nl-
portions were transferred resulting in 10 nl- (270 µm) or 20 nl-samples (340 µm). Deflection 
by the oil reduced the transfer’s positional accuracy. Thus, to coalesce individual portions, 
destination plates with funnel-shaped wells were used and mildly centrifuged after transfer 
(≤500×g to avoid droplet damage). This optimized protocol reproducibly yielded nl-samples 
that were stable for several hours (Figure 2A, inset). Hence, multiple thermophoretic binding 
assays were possible (10 min each). 
3.2 Inverted Microscopic Setup 
The nl-samples inside the multi-well plates were analyzed on a newly constructed 
microscopic setup (Figure 2B). As in the capillary instrument described in chapter 2.2, 
thermophoresis was induced and analyzed all-optically. A key difference to the capillary 
device is the nl-setup’s inverted configuration, which allowed the sample plate to stay 
upright to prevent oil dripping. The plate was fixed to guarantee, that the droplets retained 
their exact position inside the well. Sequential measurement of multiple droplets was 
achieved by mounting the optical parts onto translation stages in all three directions. 
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Figure 2 Nanoliter-droplet production and analysis. (A) Sample Preparation. A destination plate is 
positioned upside down above a source plate containing a sample stock (purple). An acoustic pulse 
focused to the sample surface leads to the formation of a 2.5 nl-droplet traveling into the destination well. 
Droplets are transferred into an oil-surfactant layer (brown) to prevent evaporation. Inset: Droplets were 
stable for several hours. 5 nl, 50% human serum/ 50% PBS. (B) Inverted microscopic setup. A focused IR 
laser locally heats the droplet center inducing thermophoresis which is analyzed via fluorescence (LED: 
light emitting diode; CCD: charge-coupled device camera). Sequential droplet analysis is achieved by 
moving the optical parts on translation stages. 
3.3 Local Heating in Experiment and Simulation 
The system of locally heated, aqueous nl-droplets in an oil surrounding was characterized 
extensively. The radial temperature profile in a 20 nl-droplet’s central horizontal plane was 
obtained, utilizing the temperature response of the fluorescent dye Alexa 647 (Figure 3A). 
The central heat spot warmed up by ∆Tc=11 K, the droplet periphery by ∆Tp=4 K. A Lorentz 
fit yielded an FWHM of 120 µm. In the following, ∆T denotes the average temperature 
increase in the central (30×30) µm area. 
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Figure 3 Local heating of 20 nl-droplets. (A) Radial temperature profile in the central horizontal plane 
(red). The temperature increased by ∆Tc=11 K in the center and by ∆Tp=4 K in the droplet’s periphery. A 
Lorentz fit (black) revealed FWHM=120 µm. (B) Flow profile of fluorescent polystyrene beads (d=1.0 µm) 
integrated over 7 s during laser heating (∆T=15 K). The beads moved toward the heat spot and out of 
focus with a peak velocity of 15 µm/s. 
Heating induced convective flows, which were visualized with fluorescent polystyrene 
beads. The beads moved toward the central heat spot and out of focus, with peak velocities 
of 5-10 µm/s for ∆T=6 K and 15 µm/s for ∆T=15 K. Figure 3B is an integration over 7 s of 
heating in a 20 nl-droplet. The flows were further characterized with a full numerical 
simulation considering diffusion, convection, thermophoresis, and the temperature 
dependence of the dye. The simulation verified that the observed inward flow can be 
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attributed to Marangoni convection (Figure 4). This type of convection is caused by 
temperature-induced differences in interfacial tension. In our case, local heating decreased 
the interfacial tension between water and oil at the top and bottom of the droplet, triggering 
Marangoni fluid flow along the interface. Due to the cylindrical symmetry, toroidal vortices 
arose in the upper and lower droplet hemisphere. The simulation (Figure 4) shows the tori’s 
cross section in a vertical cut. The dashed line marks the horizontal plane, where the flow is 
directed inward in the upper and lower vortex. This agrees with the experimental observation 
in this plane (Figure 3B). 
 
Figure 4 Numerical simulation of temperature and flow fields in a vertical cut through a 20 nl-droplet 
after 0.2 s of heating. Left: Isotherms indicate the temperature increase. Right: The central horizontal 
plane (dashed) comprises the boundary of two toroidal flow vortices. The vortices are driven by 
Marangoni convection at the water-oil interface and have already reached the steady state. 
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After flow field analysis, fluorescence time traces in 20 nl-Alexa 647 samples were recorded 
(Figure 5). The experimental curves were reproducible and confirmed by simulation. In both, 
experimental and simulated traces, the typical series of events can be identified in agreement 
with standard capillary measurements (see Figure 1). Heating decreases the fluorescence 
intensity due to the fluorophore’s temperature response (FTR) and thermophoretic molecule 
depletion. Thermophoresis and backdiffusion equilibrate within a few seconds. When 
heating is turned off, fluorescence recovers due to FTR and backdiffusion. To assess the 
contributions to the fluorescence signal, simulations excluding Marangoni convection or 
thermophoresis were performed (Figure 5B). Neglecting Marangoni convection lead to 
differences in the flow fields, but only slightly affected the fluorescence signal. In contrast, 
neglecting thermophoresis from the simulation significantly changed the time traces. This 
demonstrates that thermophoresis prevailed against the convective flows. 
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Figure 5 Fluorescence time traces from 20 nl-droplets. (A) Measurements of three Alexa 647-samples 
(grey, blue, red) overlap with minor deviations demonstrating the low batch-to-batch variation. 
Experiments and simulation (black) agree well. After the IR laser is turned on (t=10 s), the fluorescence 
decreases due to FTR and thermophoretic depletion. Thermophoresis and backdiffusion equilibrate within 
a few seconds. After heating (t=50 s), Fnorm recovers due to FTR and isothermal backdiffusion. A larger ∆T 
enhances FTR and thermophoresis. (B) Simulated contributions to the decrease in Fnorm. Neglecting 
Marangoni convection led to a negligible change of 0.008 (dotted); neglecting thermophoresis lead to a 
change of 0.06 (dashed). 
3.4 Aptamer Quantification 
The applicability of nl-droplet thermophoresis for biomolecular interaction studies was 
evaluated with a well characterized aptamer. Aptamers have been discovered more than 20 
years ago.35,36 Owing to their three-dimensional conformation, these single stranded 
oligonucleotides bind various biomedically relevant targets including proteins and small 
molecules.37,38 Just like antibodies, aptamers show high specificity and affinity. At the same 
time, these nucleic acid based ligands are superior to protein based ligands in production 
costs, storage conditions, and chemical modifiability.38 In vivo, their small size facilitates 
good delivery to the target tissue, whereas no immunogenicity and low toxicity have been 
reported.38,39 These benefits and the first marketed aptamer drug demonstrate the high 
potential of aptamers.40  
A 25mer DNA aptamer that binds adenosine and its phosphorylated analogues was 
analyzed.41 This aptamer has previously been studied extensively.20,42 For nl-interaction 
studies, a constant concentration of fluorescently labeled aptamer (c=2 µM) was added to a 
serial dilution of adenosine 5’ monophosphate (AMP). AMP- and aptamer-droplets were 
coalesced by mild centrifugation (see above). Subsequently, the short diffusion times 
through the small 10 nl- or 20 nl-samples guaranteed complete mixing within minutes. As 
measured in these nl-samples, FTR and thermophoretic depletion of free aptamer 
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significantly differed from its bound complex with AMP. After a combined analysis of FTR 
and thermophoresis, the signal was fit to the Hill equation (see chapter 2.3). The fit revealed 
EC50= (116±14) µM in 10 nl-samples and EC50= (104±10) µM in 20 nl-samples for 
measurements in the original selection buffer (Figure 6A).41 Both values agree with each 
other and the literature value of (87±5) µM from capillary thermophoresis.20 The revealed 
Hill coefficients of n=1.2±0.1 (10 nl) and n=1.9±0.3 (20 nl) indicate cooperative binding, 
which is consistent with the previously reported tertiary structure of the complex 
(Figure 6C).43 Moreover, the Hill coefficients only slightly deviate from each other and 
confirm the literature value (n=1.4).20 As a control, a DNA oligonucleotide with the same 
length as the aptamer but two point mutations was analyzed. The dinucleotide mutant’s 
AMP-affinity was reduced 200-fold (EC50؆ 20 mM), which demonstrates the binding 
signal’s specificity. 
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Figure 6 Nanoliter thermophoresis quantifies aptamer binding. The specific signal change in FTR and 
thermophoresis upon AMP titration to labeled aptamer was fit to the Hill equation. Mean values of at least 
two individual nl-samples; error bars: standard deviation. (A) Selection buffer. The fit revealed EC50= 
(116±14) µM and n= 1.9±0.3 in 10 nl (red squares) and EC50= (104±10) µM and n= 1.2±0.1 in 20 nl 
(black circles). A dinucleotide mutant showed a 200-fold increased EC50؆ 20 mM (blue triangles). 
(B) PBS. EC50= (0.90±0.13) mM was found (black circles), confirming the aptamer’s buffer dependence. 
The mutant showed a 130-fold increased EC50؆ 0.12 M (blue triangles). (C) Determined Hill coefficients 
agree with the reported tertiary structure (NDB code 1AW4): an aptamer (grey) binds two AMP molecules 
(red).43 
AMP-aptamer affinity has been reported to depend on the buffer,20 which was analyzed via 
nl-thermophoresis. In PBS, an EC50 of (0.90±0.13) mM was found (Figure 6B), 
corresponding to a 10-fold affinity reduction compared to selection buffer. This reduction 
could be expected, as the aptamer has originally been evolved in and thus optimized for its 
selection buffer.41,44 The crucial difference between the buffers is their Mg2+ content: the 
selection buffer contained 5 mM MgCl2, while PBS without Mg2+ was used. It was exactly 
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this MgCl2 reduction from 5 to 0 mM that has been reported to significantly reduce AMP-
aptamer retention in affinity chromatography.42 Mg2+ affects the binding, as it stabilizes the 
aptamer-DNA and also neutralizes AMP’s phosphate group, which reduces repulsion to 
phosphates in the aptamer backbone.45 Unlike the affinity, the Hill coefficient was unaffected 
by the buffer; it was n=1.6±0.4 in PBS. The mutant control’s affinity was reduced 130-fold 
(EC50؆ 0.12 M) compared to the aptamer. 
3.5 Discussion 
The successful aptamer quantification validates the applicability of nl-droplet 
thermophoresis for bimolecular interaction analysis. Compared to capillary thermophoresis, 
sample consumption was reduced by a factor of 50. This implies an enormous potential for 
high-throughput screens, which are further promoted by the automation-friendly 1536-well 
plate format. 
To achieve automation, a droplet search algorithm has to be implemented into the control 
software, as this search is up to now done manually. Owing to the standardized plates with 
low variations in dimensions, automatic positioning into a specific well is already used in 
many commercial instruments as e.g. the nl-liquid handler. For the nl-thermophoresis 
instrument, positioning presents a major challenge, as the exact location of the droplet inside 
the well needs to be found. Currently, the variations in droplet placement are rather high due 
to deflection by the oil and centrifugation. Additionally, a subset of droplets (10-20%) is 
typically damaged during preparation and cannot be included into analysis. Thus, the 
preparation protocol needs to be optimized. Deflection could be reduced by decreasing the 
thickness of the oil layer. To this end, a low volume oil dispenser would have to be used, as 
the required oil volumes below 0.5 µl cannot reliably be pipetted manually. 
When calculating the total volume consumption, the dead volume of the liquid handler has to 
be taken into account. To date, two source plate types are available for the transfer of 
aqueous solutions on the Labcyte ECHO 550 liquid handler. Both have a dead volume of 
approximately 25%. It is 3 µl from a maximum of 12 µl in 384-well low dead volume plates 
(384LDV) and 15 µl from a maximum of 65 µl in 384-well polypropylene plates (384PP). 
The transfer protocol should thus be designed carefully to ensure that the full working 
volume range of the source plate is exploited. If the stability of the sample is high enough, 
the dead volume might even be reused after transfer. The drawback of requiring a dead 
volume is outweighed by the advantages of the liquid handler, which include its high 
accuracy (see chapter 3.1). As a further benefit, the contact-free nl-transfer exempts from 
washing steps and minimizes cross contaminations. After transfer, the sample does not touch 
the well surface, but forms a surfactant surrounded droplet inside the oil. This should 
significantly reduce unspecific surface adhesion of biomolecules (“sticking”), an often 
encountered challenge in capillary thermophoresis. The elimination of sticking represents a 
major benefit, even if surfactant and oil might have to be optimized for different sample 
types. 
Aptamer analysis is likely to gain in importance, now that the comprehensive aptamer patent 
portfolio is starting to expire.46 This might well facilitate commercial aptamer applications. 
Additionally, nl-thermophoresis is a highly attractive analysis tool for other types of 
samples. Sample preparation is unlikely to be limiting, as the liquid handler can be deployed 
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for various solution types. We e.g. produced stable nl-droplets of 50% human blood serum 
(Figure 2A, inset). In the current nl-thermophoresis instrument the lowest detectable 
fluorophore concentration inside droplets is approximately 500 nM. Thus, KDs in the high 
nanomolar range can be determined exactly. To allow for the quantification of higher 
affinities, the sensitivity of the instrument needs to be improved. This should be possible by 
optimizing the optics, e.g. by using a photomultiplier tube (PMT), which is more sensitive 
than the employed CCD camera. In addition, further LED/filter combinations would enable 
measurements of different fluorophores. With these optimizations, a similar versatility as for 
capillary thermophoresis can be expected. This flexibility of capillary measurements is 
demonstrated in the following chapters. 
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4 Thermophoretic Protein Studies 
Proteins are involved in most biomolecular interactions, as they fulfill various cellular 
functions. Due to these diverse roles, proteins have highly variable properties. As a result for 
their analysis, they often require very specific assay adjustments. Moreover, for distinct 
proteins, interactions with very different molecule classes can be of interest. How this need 
for flexibility is met by capillary thermophoresis, will be shown in the following, structured 
according to the protein’s binding partner. 
4.1 Protein-Protein Binding in Cell Lysate: TEM1-BLIP 
The β-lactamase TEM1 is the most widespread bacterial resistance enzyme to β-lactam 
antibiotics like penicillins. The binding of TEM1 to the β-lactamase inhibitory protein BLIP 
is a well characterized model system for protein-protein interaction. For this interaction, the 
contribution of individual amino acids has previously been studied using site-specific 
mutations. 47–50 Three mutations of TEM1 and BLIP that have been reported to significantly 
affect the binding affinity were analyzed with capillary thermophoresis. 
For a first set of experiments, wild-type TEM1 (wt-TEM1) was labeled with the red 
fluorescent dye NT647 via crosslinker reactive groups. Binding of labeled TEM1 to wild-
type BLIP (wt-BLIP) and two BLIP mutants with tryptophan-to-alanine substitutions at 
position 112 or 150 (p.W112A-BLIP, p.W150A-BLIP) was quantified. A fit to equation 10 
revealed KD= (3.8±0.8) nM for the wt-interaction (Figure 7A). Both alanine substitutions 
within BLIP reduced the TEM-affinity to KD= (0.5±0.1) µM for p.W112A-BLIP and KD= 
(1.7±0.4) µM for p.W150A-BLIP (Figure 7B and C). These values agree excellently with the 
literature values determined by SPR (wt: (3.2±0.6) nM, p.W112A: (0.36±0.06) µM, 
p.W150A: (3.8±0.6) µM).47,48 In addition, the thermophoresis signal seems to contain further 
information on the binding event. Upon binding of wt-BLIP and p.W112A-BLIP to TEM1, 
the complex shows an increased depletion compared to unbound TEM1 (negative slope in 
Figure 7A and B). Binding of p.W150A-BLIP has the opposite effect (Figure 7C). This 
p.W150A mutation has been reported to induce a pronounced conformational rearrangement 
of BLIP, defects in geometrical shape complementarity to TEM1 and trapping of additional 
water molecules in the TEM1-BLIP interface.49 This decreases the enthalpic driving force 
for binding and likely causes the differences in thermophoresis. 
For a second set of experiments, wt-BLIP was labeled with the yellow fluorescent fusion 
protein Ypet. Binding of labeled BLIP to wt-TEM1 and a TEM1-mutant with an arginine-to-
alanine substitution (p.R243A-TEM1) was quantified. For the interaction of the wt-proteins 
KD= (4.8±1.7) nM was found (Figure 7D). This reproduces the SPR literature value of 
(3.5±0.5) nM.50 It also agrees with the result measured via the reversed assay design 
(Figure 7A). The p.R243A-TEM1 mutant’s affinity for BLIP was reduced to KD= 
(0.19±0.05) µM, which agrees with literature.51 All TEM-BLIP measurements presented so 
far were conducted in buffer. A buffer, however, does not resemble the highly crowded, 
intracellular environment. Thus, the interaction of Ypet-wt-BLIP and wt-TEM1 was also 
quantified in mammalian cell lysate. Under these close to in vivo conditions, thermophoresis 
revealed KD= (10±4) nM. This demonstrates, that even in cell lysate, thermophoresis 
quantifies protein-protein interactions with high selectivity and sensitivity. 
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Figure 7 Thermophoresis quantifies TEM1-BLIP binding. (A) Wt-BLIP-titration to wt-TEM1-NT647 
yielded KD= (3.8±0.8) nM. (B) The p.W112A-mutation in BLIP reduced its TEM1-affinity to KD= 
(0.5±0.1) µM. (C) p.W150A-BLIP bound TEM1 with an even lower affinity of KD=1.7±0.4 µM. (D) Wt-
TEM1-titration to the fusion protein Ypet-wt-BLIP yielded KD= (4.8±1.7) nM (black circles). Mutated 
p.R243A-TEM1 showed a lower affinity of KD= (0.19±0.05) µM (red triangles). In cell lysate, Ypet-wt-
BLIP and wt-TEM1 bound with KD= (10±4) nM. This demonstrates the applicability of thermophoresis for 
measurements in cell lysate. Notably, the sign of the signal amplitude changed in lysate due to differences 
in pH, ionic strength etc. 
4.2 Protein-Peptide Binding With Two Phases: AMA1-RON2 
The binding of two proteins of the malaria-causing parasite Plasmodium falciparum plays a 
key role during red blood cell invasion: apical membrane antigen 1 (AMA1) and rhoptry 
neck protein 2 (RON2).52 This qualifies the AMA1-RON2 interaction as a potential drug 
target. RON2 contains a highly conserved region with two fully conserved cysteine residues 
which are critical for AMA1-binding.53 This conserved RON2 region was used as a peptide 
(4.3 kDa) to quantify its interaction with AMA1 (66 kDa) via thermophoresis. 
Firstly, the binding of labeled RON2-FITC to titrated AMA1 was assessed 
thermophoretically, yielding KD= (28±2) nM (Figure 8A). Secondly, the assay was reversed 
and the binding of labeled AMA1-NT647 to titrated RON2 was analyzed. This assay 
revealed a biphasic binding event (Figure 8B). The high affinity binding was superimposed 
by an additional low affinity binding. Individual fits of each binding event to equation 10 
yielded KD= (62±16) nM and KD’= (1.4±0.2) µM. In addition, a model for two serial binding 
events with different KDs was used to fit all data points simultaneously: 
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For both binding events, the fit assumes an identical amplitude ܯ but, as the data suggests, 
with an opposite sign. ݐ denotes the binding curve’s y-offset. Fitting to this serial binding 
model revealed KD= (81±21) nM and KD’= (1.2±0.1) µM (Figure 8B, inset). The high 
affinity KD slightly varies for the different assay designs. This is likely due to a limited fit 
accuracy for the biphasic signal, as either less data points (two individual fits) or a more 
complex fit function (serial binding) were used. Despite this limitation, both experiments 
yield high affinity KDs in the double-digit nM range, demonstrating the assay reversibility of 
thermophoresis studies. In addition, this example evidences the importance of performing 
titration assays both ways around: while AMA1-titration precisely quantifies the KD, only 
the RON2-titration revealed the second, low-affinity binding event. 
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Figure 8 AMA1-RON2 binding in thermophoresis and SPR. (A) Thermophoresis: AMA1-titration to 
RON2-FITC yielded KD= (28±3) nM. (B) RON2-titration to AMA1-NT647 revealed a biphasic event. 
Fitting both phases separately revealed KD= (62±16) nM for the high affinity phase (blue) and KD’= 
(1.4±0.2) µM for the low affinity phase (red). Inset: All data points were fit to a serial binding model 
assuming two binding events. This yielded KD= (81±21) nM and KD’= (1.2±0.1) µM. (C) SPR: AMA1-
titration to immobilized RON2 yielded KD= (13±1) nM. (D) RON2-titration to immobilized AMA1 yielded 
KD= (38.3±0.4) nM. A heterogeneous ligand model fit the dissociation phase best, indicating a biphasic 
event as observed in thermophoresis. 1 RU= 1 SPR response unit؆ 1 pg/mm2. 
To evaluate the thermophoresis results, comparative SPR-measurements were conducted. In 
SPR, AMA1-titration against immobilized RON2 yielded KD=(13±1) nM (Figure 8C). 
RON2-titration against immobilized AMA1 revealed KD= (38.3±0.4) nM (Figure 8D). These 
affinities are slightly higher than those found in thermophoresis analysis, which agrees with 
the reported tendency of SPR to overestimate affinities due to surface artifacts.54 In SPR, the 
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dissociation phase of the RON2-titration was best fit by a heterogeneous ligand model. This 
indicates a second low-affinity binding event, just like thermophoresis did (Figure 8B). 
The second binding event was only detected when RON2 was neither labeled 
(thermophoresis) nor immobilized (SPR). Unlabeled, immobilization-free RON2 might not 
only be present in the cyclized form with a closed disulfide bond, but also in a linear from 
with reduced cysteines. While the cyclized form binds with a high affinity, the linear form 
might bind with a lower affinity, resulting in the second binding phase. Labeling or tethering 
seems to prevent RON2 from assuming the linear form. 
  
22 
4.3 Protein-Small Molecule Binding Without Labeling 4 Thermophoretic Protein Studies 
4.3 Protein-Small Molecule Binding Without Labeling 
As demonstrated in the previous and following chapters, attached fluorescent dyes or fused 
fluorescent proteins enable highly sensitive thermophoresis studies. These attached 
fluorophores also provide high selectivity, which allows for measurements in complex 
bioliquids like cell lysate (chapter 4.1) or blood serum (chapter 5.2). However, fluorescent 
tags come along with certain disadvantages. Attaching modifications to a biomolecule can 
significantly alter its properties, with e.g. membrane proteins being particularly sensitive. 
Possible consequences include changes in affinity or even protein precipitation. In addition, 
unspecific binding to the attached fluorophore can lead to false positive results. Apart from 
these influences on the binding event, labeling procedures and the often required purification 
steps are time and sample consuming. 
A solution to this is label free thermophoresis analysis, which is introduced in the following. 
Label free thermophoresis utilizes the intrinsic UV fluorescence of proteins, arising from the 
aromatic amino acids tyrosine, phenylalanine and tryptophan (Trp), with the latter being the 
dominant intrinsic fluorophore.  For these measurements in the UV range, the capillary setup 
(Figure 1B) was equipped with a 285 nm LED, a quartz objective and a photomultiplier tube 
(PMT). Photon counting PMTs are more sensitive than CCD cameras, especially in the 
350 nm emission regime used for label free thermophoresis. Samples were measured in 
fused silica capillaries with low background UV fluorescence. Concerning the sample itself, 
optimal results are obtained, when only one binding partner exhibits UV fluorescence. This 
is the case for most protein-small molecule interactions. Small molecules typically do not 
show UV fluorescence. In contrast, the majority of proteins contains enough Trp residues to 
exhibit a UV fluorescence signal sufficient for label free thermophoresis. 
4.3.1 Glutamate Receptor iGluR2 
In the mammalian central nervous system, ionotropic glutamate receptors (iGluR) play the 
key role in fast excitatory synaptic transmission.55 The binding of the various iGluR subtypes 
to their ligands is in the focus of ongoing research.56  
Via label free thermophoresis, the interaction of the AMPA receptor subunit iGluR2 
(activated by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) was studied. To this 
end, the soluble ligand binding domain (LBD; 29.2 kDa) was used, which was generated by 
fusing iGluR2’s two discontinuous extracellular fragments S1 and S2. The iGluR2-LBD 
contains 4 Trp. A concentration of 2 µM exhibited a sufficient UV fluorescence intensity 
without significant bleaching. Thermophoresis revealed KD= (835±43) nM for the natural 
agonist glutamate (147.13 Da; Figure 9). This reproduces the literature value of 821 nM.57 
Azobenzene glutamate (glu-azo; 367.15 Da), a photoswitchable agonist allowing for remote 
control of neuronal excitability, bound the iGluR2-LBD with KD= (19±5) µM (Figure 9).58 
Thermophoresis confirmed the finding that glu-azo also binds iGluR2, though designed as a 
kainate receptor ligand.59 When the iGluR2-LBD was pre-incubated with a saturating 
glutamate concentration (500 µM), glu-azo titration did not influence thermophoresis. This 
proves the specificity of the glu-azo signal. It also shows that both agonists compete for the 
same binding site. The label free measurement for glu-azo was verified using labeled 
iGluR2-LBD, as shown in the supporting information of the associated publication 3 
(chapter 9). The measured KD of (22±8) µM did not significantly deviate from the label free 
analysis, which demonstrates that the latter was not disturbed by autofluorescence. 
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Figure 9 Label free thermophoresis quantifies ligand binding to membrane receptors. The glutamate 
receptor subunit iGluR2-LBD bound glutamate with KD= (835±43) nM (black circles) and glu-azo with 
KD= (19±5) µM (red squares). Pre-incubation of iGluR2 with a saturating amount of glutamate prevented 
glu-azo binding, which demonstrates that both agonists compete for the same binding site (blue triangles). 
4.3.2 MAP Kinase p38α 
P38 is a mitogen-activated protein kinase (MAP kinase) responding to stress. The isoform 
p38α is considered the key subtype in cytokine synthesis during inflammatory response. 
Thus, potent inhibitors of p38α promote the development of novel treatments for 
inflammatory diseases.60  
Three small molecule inhibitors of p38α (59.5 kDa) were analyzed. The kinase contains 5 
Trp residues, so that a concentration of 100 nM was sufficient for label free thermophoresis. 
Figure 10 shows, that p38α bound the inhibitor SB202190 (331 Da) with KD= (48±21) nM 
reproducing the literature value of 37 nM.61 PD169316 (360 Da) and SB239063 (368 Da) 
showed upper KD limits of 33 nM and 20 nM. This lies in a similar range as reported IC50 
values of 130 nM (PD169316) and 44 nM (SB239063).62,63 Thermally denatured p38α did 
not show binding, thus proving specificity. 
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Figure 10 Label free analysis of small molecule MAP kinase inhibitors. SB202190 bound with KD= 
(48±21) nM (red squares). PD169316 (black circles) and SB239063 (green triangles) showed upper KD 
limits of 33 nM and 20 nM. Thermally denatured p38α did not bind (blue triangles). Corresponding to 
structural differences, the binding of SB202190 and PD169316 had the opposite effect on thermophoresis 
compared to SB239063. 
Remarkably, the thermophoretic signal contained further information on the ligands. Upon 
binding of SB202190 and PD169316 to p38α, the complex showed a reduced thermophoretic 
depletion compared to the unbound kinase, represented by the positive slope of the binding 
curve. Binding of SB239063 had the opposite effect (Figure 10). These differences are likely 
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related to the inhibitors’ structure. Apart from a single functional group SB202190 (4-(4-
Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazol) and PD169316 (4-(4-
Fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole) are identical in structure. In 
contrast, the structure of the second generation inhibitor SB239063 (trans-1-(4-
Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)-imidazole) differs 
significantly. 
4.4 Discussion 
Capillary thermophoresis showed a broad application range for protein analysis. In addition 
to protein-protein interactions, protein binding to peptides and small molecules was readily 
accessible despite the high molecular weight ratio. Such studies are possible, as 
thermophoresis is extremely sensitive to binding induced changes not only in size, but also in 
charge, hydration shell, and conformation (see equation 5). This is a major advantage over 
SPR and fluorescence polarization,64 which rely on size changes alone, or dynamic light 
scattering, which is limited to a maximum twofold difference of the binding partners’ 
hydrodynamic radii.65 The applicability of thermophoresis is further enhanced, as 
measurements can be performed in various liquids. Buffer and additives may be chosen 
freely, which allows to stabilize different protein types in solution. Thermophoresis was even 
measured in crude cell lysate, which resembles close to in vivo conditions. This might even 
exempt from protein isolation, as a fusion construct of a cellular and a fluorescent protein 
like Ypet should directly be measurable in lysate without purification. Alternatively, certain 
peptide sequence tags allow for site-specific dye coupling in lysate. Sample volumes and 
concentrations obtained by such protein purification free approaches should suit the 
requirements of thermophoresis experiments very well. 
On the other hand, binding in buffer was quantified label free utilizing protein intrinsic UV 
fluorescence. As the binding partners were not attached to a label or surface, their molecular 
properties were not altered and mobility was not restricted. Thus, native binding affinities 
were revealed. To get a suitable UV fluorescence signal, proteins with two Trp residues can 
be used in concentrations down to 100 nM, enabling accurate quantification of KDs down to 
50 nM. High affinity interactions with lower KDs are still detected, but not precisely 
quantified. The fit then only yields an upper KD limit (see chapter 4.3.2). To realistically 
evaluate the applicability of Trp based thermophoresis, the average Trp content of proteins 
has to be considered. According to the minimum redundancy protein database Swiss-Prot 
(release statistics of May 2014), the percentage of Trp residues in all sequences (>0.5 M) is 
1.09 and the average number of amino acids in a sequences is 355.66 This yields an average 
of 3.9 Trp per protein. It demonstrates that label free thermophoresis will be utilizable for the 
majority of proteins, and in many cases also for protein subdomains as e.g. the ligand 
binding domain of iGluR2 (see chapter 4.3.1). Ideally, the ligands should not exhibit UV 
fluorescence. As mentioned above, this holds true for most small molecules, which account 
for the majority of today’s pharmaceuticals. If both binding partners show a similar UV 
fluorescence, the contribution of the titrated fluorescent ligand to the thermophoresis signal 
needs to be quantified in control experiments and then subtracted. 
As discussed in chapter 3, the drawbacks of capillary thermophoresis include unspecific 
surface adhesion of biomolecules (“sticking”). Sticking can often be reduced with 
hydrophilic or hydrophobic capillary coatings and with buffer additives like detergents or 
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bovine serum albumin. Possible artefacts through coatings and additives need to be excluded 
in control experiments. Additional disadvantages of capillary analysis are the unnecessarily 
high sample consumption and the difficult handling. Nanoliter-droplet thermophoresis 
analysis in multi-well plates (chapter 3) overcomes these limitations, yet its applicability for 
protein measurements remains to be tested.  
Despite the discussed limitations, the above experiments demonstrate that capillary 
thermophoresis is highly adaptable to the diverse requirements of different proteins. This 
includes antibodies, a protein class with a high medical relevance, whose thermophoretic 
analysis is discussed in the following chapters.  
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5 Thermophoretic Immunoassays 
Immunoassays are bioanalytical tests that are based on the interaction of antibodies and 
antigens. Either of these two binding partners can be the analyte, while the other one serves 
as a tracer. As mentioned in chapter 1.2, the ELISA is a well established immunoassay 
format, but as a biochemical method only allows for semiquantitative analysis. The required 
surface immobilization of the tracer in ELISAs is an additional drawback, which is also 
discussed in chapter 1.2. In contrast, immunoassays based on thermophoresis allow for 
absolute quantification in free solution. These thermophoretic immunoassays were applied 
for antibody characterization and in vitro diagnostics. The latter application introduces an 
autocompetitive assay to simultaneously quantify affinity and concentration in untreated 
human blood serum. 
5.1 Antibody Characterization 
5.1.1 Towards a Therapeutic Antibody For Granulomatosis With 
 Polyangiitis 
Granulomatosis with polyangiitis (GPA) is a rare, chronic form of systemic vasculitis that 
mainly affects small and medium sized blood vessels. The resultant tissue damage can lead 
to lethal organ failure especially of lung and kidney, so that GPA patients require long-term 
immunosuppression. It is widely accepted that GPA represents an autoimmune disease, 
caused by antineutrophil cytoplasmic antibodies (ANCA). 
The major autoimmune target for ANCA in GPA is proteinase 3 (PR3) bound to the plasma 
membrane of a subset of resting neutrophils.67,68 Neutrophils, which represent the most 
abundant type of mammalian white blood cells, play a key role in innate immune response. 
To this end, they express the antimicrobial serine protease PR3. Just like other protease 
enzymes, PR3 degrades proteins and peptides. To prevent tissue damage, protease activity is 
regulated by an initial activation step, in which the enzyme’s conformation is changed from 
an inactive zymogen form into an active mature form. In addition, protease activity is 
controlled by inhibitors, as for example α1-proteinase inhibitor (α1PI).69 PR3 is stored in 
neutrophil granules in an active, mature conformation. A small amount is expressed on 
neutrophil membranes and recognized by ANCAs. It is not yet clear if this membrane-
associated PR3 assumes the active mature conformation (active PR3), the inactive zymogen 
form (pro-PR3) or both. In vitro ANCAs have been reported to activate neutrophils and 
induce their degranulation leading to endothelial damage.70 This would be a possible 
explanation for the extensive blood vessel damage in GPA.71 In addition, GPA has been 
associated with a point-mutation in the α1PI allele (Z-allele), which decreases both, α1PI’s 
blood levels and protease affinity.72,73 
As a starting point for future GPA treatment, the monoclonal antibody (moAB) MCPR3-7 
with specificity close to PR3’s active site was developed. MCPR3-7 binding properties were 
characterized via thermophoresis. 
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5.1.2 MCPR3-7 Affinity and Selectivity 
Thermophoresis revealed a very high binding affinity of NT647-labeled MCPR3-7 to pro-
PR3: KD≤10 nM (Figure 11A). In addition, MCPR3-7’s affinity to mature PR3 was 
measured. To conserve PR3 in a mature conformation, it was pre-treated with the covalent 
inhibitor chloromethylketone AAPF (CMK). This mature PR3-CMK did not show binding to 
MCPR3-7, clearly indicating that the antibody selectively recognizes PR3’s inactive 
conformation. 
For active PR3, however, MCPR3-7 indeed showed binding, yet with KD= (0.4±0.2) µM 
(Figure 11B) corresponding to an approximately 40-fold lower affinity than for pro-PR3. 
This is probably due to a reversible allosteric switch from the active form of PR3 to a more 
zymogen-like conformation, which is recognized by MCPR3-7. As this switch is not 
possible for PR3-CMK, it was not bound by MCPR3-7. 
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Figure 11 MCPR3-7 binding affinity and selectivity. (A) Thermophoresis revealed a high affinity of 
MCPR3-7 to pro-PR3 (KD≤10 nM; blue rectangles). By contrast, MCPR3-7 did not bind the mature 
conformation of PR3-CMK (gray triangles). (B) Active PR3 was bound with a 40-fold weaker affinity than 
pro-PR3: KD= (0.4±0.2) µM (red circles). This is probably due to a reversible allosteric switch from the 
active to a more zymogen-like conformation. 
5.1.3 Interference with PR3-α1PI Complex Formation 
We tested the effect of MCPR3-7 on the canonical complex formation of mature but 
catalytically inactive PR3 (PR3-S195A) with its inhibitor α1PI. In this regard, MCPR3-7 
was compared to the anti-PR3 moAB CLB-12.8 available commercially. The binding of 
α1PI to PR3 was quantified in the presence and absence of moABs. To this end, PR3 and 
moABs or buffer were preincubated for one hour before adding NT647-labeled α1PI at a 
final concentration of 0.88 µM. 
PR3 and α1PI bound with KD= (1.9±1.1) µM in absence of moABs (Figure 12). In the 
competition experiments, it was not possible to use saturating amounts of MCPR3-7 as this 
antibody could not be concentrated to very high levels. Instead, a relatively low final 
MCPR3-7 concentration of 0.57 µM was used. Thus, not only MCPR3-7-PR3 complexes but 
also free PR3 was present in solution. This reduced the putative overall effect of the antibody 
on the binding curve and lead to a more complex binding behavior. The thermophoresis 
signal corresponds to the binding of α1PI to free PR3 and MCPR3-7-bound PR3 which is 
most likely characterized by two different KDs. The data could not be fit to a more complex 
binding model as saturation was not reached in the binding curve. We thus chose the simple 
model according to equation 10, which revealed an apparent KD of (5.6±1.0) µM (Figure 12). 
Taking into account the rather high KD of α1PI and residual free PR3 (1.9 µM), the actual 
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affinity of α1PI to the MCPR3-7-PR3 complex can be expected to be even lower than the 
measured apparent affinity (5.6 µM).  
In contrast to this pronounced impact of MCPR3-7, preincubation of PR3 with CLB-12.8 did 
not affect PR3’s affinity to α1PI. The fitted binding curves overlay and the KD of 
(1.8±0.8) µM does not significantly differ (without moABs: (1.9±1.1) µM). The PR3-affinity 
is expected to be much higher for CLB-12.8 than for MCPR3-7. We, however, added the 
same concentration of both moABs. Thus, a much higher amount of CLB-12.8-PR3 
complexes than MCPR3-7-PR3 complexes were present in our preincubated solutions. 
Nevertheless, CLB-12.8 did not show any effect on the canonical PR3-α1PI complexation. 
This indicates that MCPR3-7 binding changes the conformation of active PR3, which 
interferes with the canonical complex formation with α1PI, whereas CLB-12.8 does not. 
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Figure 12 Interference of moABs with canonical PR3-α1PI complex formation. In absence of moABs, 
catalytically inactive PR3 and α1PI bound with KD= (1.9±1.1) µM (blue rectangles). Preincubation with 
MCPR3-7 shifted the binding curve to the right corresponding to a 3-fold decrease in the apparent affinity 
to α1PI (KD= (5.6±1.0) µM; red circles) By contrast, preincubation with CLB-12.8 did not significantly 
affect the affinity (KD= (1.8±0.8) µM; gray triangles). 
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5.2 Quantitative In Vitro Diagnostics 
5.2.1 Autoantibodies as Biomarkers for Dilated Cardiomyopathy 
Dilated cardiomyopathy (DCM) is a nonischemic heart muscle disease which is 
characterized by dilation and impaired contraction of the left or both ventricles. With a 
prevalence of one in 2500 individuals, DCM belongs to the main causes of severe heart 
defects.74,75 Moreover, it is a major reason for heart transplantations.76 Besides genetic, toxic 
and infectious factors, autoimmune reactions are discussed as a cause of DCM. In a notable 
number of DCM patients, increased concentrations of autoantibodies against several cardiac 
antigens were found, with the β1-adrenergic receptor (β1-AR) representing the major 
autoimmune target (Figure 13A).77–79 Agonist-like antibodies against β1-AR were associated 
with severe ventricular arrhythmia.78,80–82 These autoantibodies were found in 30-95% of 
DCM patients and 0-13% of unaffected controls.83,84 It is widely accepted that in many 
patients suffering from heart failure, a chronic adrenergic overexcitation plays a harmful 
role.85 Permanent β1-AR stimulation due to elevated catecholamine levels in combination 
with autoantibodies could change the Ca2+ homeostasis of cardiomyocytes. This would result 
in metabolic and electrophysiological disturbances which are responsible for 
tachyarrhythmia and sudden death.86 It was also shown that anti-β1-AR-antibodies increase 
the activity of cAMP-dependent protein kinase (PKA).87 
Therefore, anti-β1-AR-antibodies are a highly relevant serological DCM biomarker. Up to 
now, however, DCM serology is routinely done with ELISAs, which do not allow for 
quantitative analysis (see chapter 1.2). We thus developed a fully quantitative 
thermophoretic assay for serological diagnostics of anti-β1-AR-antibodies. The peptide 
COR1 with the sequence ADEAR RCYND PKCSD FVQ (Figure 13B) served as a tracer.88,89 
COR1 mimics the dominant epitope of anti-β1-AR-antibodies (ARRCYND), which is located 
on β1-AR’s second extracellular loop. Thus, the peptide serves as an artificial antigen. It was 
labeled with the red fluorescent dye D2 (Figure 13C), as serum exhibits a very low 
background fluorescence at the red end of the spectrum. 
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Figure 13 Target signaling pathway in DCM. (A) β1-AR activation. An adenylat cyclase produces cAMP, 
which activates PKA to phosphorylate Ca2+ channels. The resultant Ca2+ influx increases the myocard’s 
contractility. (B) The 18-mer peptide COR1 mimics the dominant autoimmune epitope on β1-AR’s second 
extracellular loop. (C) Labeled COR1 was used as a tracer to quantify anti-β1-AR-antibodies via 
thermophoresis. 
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5.2.2 Affinity and Specificity of the Tracer COR1 
Prior to the diagnostic assay, we tested the affinity of D2-labeled COR1 for monoclonal and 
polyclonal antibodies, which were generated against β1-AR’s complete second extracellular 
domain (ARAES DEARR CYNDP KCCDF VTNRQ). Measurements were performed in 
PBS and 50% human serum. We included into the fit to equation 10 that each antibody is 
capable of binding two peptides. For moAB (c= 100 nM) the fit revealed KD= (101±17) nM 
in PBS and KD= (136±32) nM in serum (Figure 14A, B). For poAB (c= 20 nM) we found 
KD= (70±11) nM in PBS and KD= (66±25) nM in serum (Figure 14C, D). All KDs are in a 
similar range of 70-140 nM. COR1 showed a slightly higher affinity for poAB than for 
moAB whereas measurements in buffer and serum did not significantly differ. It should be 
noted that differences in thermophoresis mostly stems from the size increase upon binding of 
the large antibody (150 kDa) to the much smaller COR1 (3 kDa). Binding of another COR1 
to the second antibody arm did not measurably influence thermophoresis, as a two state 
model was sufficient to describe the binding curves. 
An unspecific moAB against E-cadherin served as a control. While the control did not bind, 
binding was reproduced for the specific moAB (KD= (74±10) nM; Figure 14E). The twofold 
KD reduction compared to Figure 14 likely occurred, as different serum stocks were used. To 
exclude unspecific antibody interactions with the dye D2, COR1 was instead labeled with 
fluorescein (Figure 14F). COR1-fluorescein bound specific poAB with KD= (265±25) nM, 
but did not show binding to the E-cadherin antibody. The slightly reduced affinity for COR1-
fluorescein might result from the required fluorescence correction, which is detailed in the 
supporting information of the associated publication 5 (chapter 9). 
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Figure 14 Affinity of labeled COR1 to moAB and poAB in PBS and 50% human serum. (A, B) For moAB 
the fit revealed KD= (101±17) nM in PBS and KD= (136±32) nM in serum. (C, D) For poAB we found KD= 
(70±11) nM in PBS and KD= (66±25) nM in serum. (E) The specificity of the serum measurements was 
confirmed with an unspecific moAB against E-cadherin, for which no binding was detected. 
(F) Measurements with COR1 labeled with fluorescein instead of D2 showed the same specific binding 
signal, yet with a slightly lower affinity. 
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5.2.3 Autocompetition Assay 
In the assays described so far, one binding partner was titrated against a constant 
concentration of the other, fluorescent partner. This is not possible for diagnostic assays in 
serum. The serum contains the first binding partner, here the anti-β1-AR-antibody. However, 
serum dilution would result in artifacts, as it leads to a change in various properties which 
influence thermophoresis (e.g. pH, protein content). Hence, the concentration of the serum 
containing the anti-β1-AR-antibodies was kept constant. On the other hand, diluting the 
labeled COR1 would lead to bleaching artifacts and was thus also kept constant. Instead, 
unlabeled COR1 was titrated. It competes with labeled COR1 for antibody-binding, which 
leads to a decreasing thermophoresis signal along the titration curve. 
In this autocompetition assay, the fraction of occupied COR1 is given by the mass action law 
just as in a simple binding assay. It has to be tested though, if labeled and unlabeled tracers 
differ in affinity. If a more complex model assuming two different KDs does not describe the 
data better, it can be assumed that the two tracer species have the same affinity. This was the 
case for COR1, as shown later in Figure 16 (inset). Hence, the simple model according to 
equation 10 was used. In contrast to the description in chapter 2.3, ܣ now denotes the partner 
whose concentration is kept constant (antibody in serum). ܤ denotes the total tracer 
concentration, which includes the constant concentration of labeled tracer plus the titrated 
concentration of unlabeled tracer (COR1). Figure 15 shows that antibody affinity and 
concentration have a different influence on the binding curve. An increasing antibody 
concentration shifts the curve to the right along the COR1 concentration axis (Figure 15A). 
By contrast, an alteration of the KD changes the curve’s amplitude (Figure 15B). The 
amplitude reports the fraction of bound labeled COR1. A higher fraction of labeled COR1 is 
antibody-bound when the antibody’s KD is lower (higher affinity). Thus, antibody affinity 
and concentration can be fit independently. 
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Figure 15 Antibody concentration and KD inferred independently. The fraction of antibody-bound 
fluorescent COR1 is plotted against the total COR1-concentration according to equation 10. (A) A change 
of the antibody concentration shifts the binding curve along the COR1 concentration axis. (B) A KD change 
modulates the curve’s amplitude. 
5.2.4 Quantification of Affinity and Concentration 
We tested the autocompetition assay by spiking poAB to final concentrations of 2 nM, 
20 nM, 80 nM, and 200 nM into 50% human serum. Using labeled COR1 in a constant 
concentration of 20 nM, a fit to equation 10 reported poAB concentrations of (0.9±1.5) nM, 
(26±3.4) nM, (108±19) nM, and (176±21) nM (Figure 16). This confirms the pipetted 
concentrations within statistical errors. In addition, the fit revealed KD= (74±11) nM, which 
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agrees with the KD measured in the simple binding assay (66 nM, Figure 14D). The KD was 
again considered as per antibody molecule. The thermophoretic depletion amplitude ∆T∆S 
was fit globally, but held constant for all four concentrations. Baselines ∆TSCOR1 were fit 
individually for each curve as they showed a minor variability of 0.5%. We measured poAB 
concentrations down to 2 nM. At such low concentrations, significant errors arise as the 
thermophoretic depletion amplitude approaches the instrument’s error. Apart from this small 
concentration, all poAB affinities and concentrations were measured with errors around 
20%. 
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Figure 16 Autocompetition assay reproduces pipetted poAB concentrations. In 50% human serum with 
poABs, the total COR1 concentration was increased by adding unlabeled COR1 to 20 nM labeled COR1. 
Thermophoresis only reports the depletion of the labeled species. Unlabeled COR1 competes with labeled 
COR1 for poAB binding, thus reducing the thermophoretic depletion signal. Added poAB concentrations of 
2 nM, 20 nM, 80 nM and 200 nM were reproduced, well within the pipetting errors, as (0.9±1.5) nM, 
(26±3.4) nM, (108±19) nM, and (176±21) nM. Independently, KD= (74±11) nM was inferred. Inset: more 
complex binding models (label dependent affinity, polyclonal binding) failed to better describe the data, 
which confirms the simple binding assumption. 
In the inset of Figure 16, the pipetted poAB concentrations are plotted against fit values for 
three different binding models. This includes the simple binding model with one KD 
(equation 10), label dependent affinity with differing KDs for labeled and unlabeled COR1, 
and polyclonal binding assuming two different antibody subpopulations. The latter two 
models are detailed in the supporting information of the associated publication 5 (chapter 9). 
The label dependent model revealed very similar antibody concentrations of (0.9±1.8) nM, 
(27±14) nM, (110±49) nM, and (170±55) nM. Moreover, it reported statistically 
indistinguishable KDs for labeled COR1 (KD= (76±73) nM) and unlabeled COR1 (KD’= 
(74±25) nM). This confirms that both COR1 species had the same affinity. The polyclonal 
model, assuming half more affine (KD) and half less affine (KD’) antibodies, did not 
statistically distinguish between these two affinities (KD= (73±3) nM, KD’= (74±4) nM). 
Determined poAB concentrations were again very similar ((0.9±1.6) nM, (26±5) nM, 
(100±19) nM, and (170±32) nM). Hence, both more complex models failed to better describe 
the data, so that using the simple model is valid. 
To reliably fit both, antibody concentration and affinity without prior knowledge, two 
autocompetition assays were combined, one in 50% serum and one in a mild dilution down 
to 10% (Figure 17). The global fit assumed an identical, unknown KD and a common 
depletion amplitude ∆T∆S, considering the 5-fold poAB dilution. The fit revealed a poAB 
concentration of (187±26) nM and KD= (73±18) nM. This reproduces the pipetted 
33 
5.2 Quantitative In Vitro Diagnostics 5 Thermophoretic Immunoassays 
concentration of 200 nM with an error of 13% and the previously measured KD of 66 nM 
(see Figure 14) with an error of 25%. Figure 17 shows that a 4-fold reduction of poAB 
concentration or KD would lead to a significantly differing response, even though the 
depletion amplitude ∆T∆S was treated as a free fit parameter. 
Taken together, our measurements demonstrate that thermophoresis allows to simultaneously 
quantify both, antibody affinity and concentration under close to in vivo conditions in 50% 
human serum. 
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Figure 17 Combined autocompetition assays in 50% and 10% human serum quantify poAB concentration 
and affinity. The global fit revealed a poAB concentration of (187±26) nM and KD= (73±18) nM. 
Theoretical predictions for a 4-fold reduction of poAB concentration (dotted) or KD (dashed) significantly 
differ from the measurements. 
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Two specific biomedical applications of thermophoresis were introduced. In both cases, 
antibodies were the biomolecules of interest and thus different types of thermophoretic 
immunoassays were performed. 
Firstly, the antibody MCPR3-7 was characterized. It is directed against proteinase 3 (PR3), 
the major autoimmune target in granulomatosis with polyangiitis (GPA). Thermophoresis 
quantified MCPR3-7’s affinity and revealed its selectivity for the inactive pro-PR3 form. In 
addition, thermophoresis elucidated that MCPR3-7-binding impaired PR3 complexation by 
α1-proteinase inhibitor. These experiments added to the understanding of MCPR3-7’s 
allosteric mechanism of action. Antibodies with similar properties and epitope specificity as 
MCPR3-7 but higher affinity are of high therapeutic interest. In GPA patients, they could 
block the binding of PR3 to neutrophil membranes and serve as selective PR3 inhibitors and 
clearers of PR3. This could reduce neutrophil activation by anti-neutrophil cytoplasmic 
antibodies (ANCA) via membrane-bound PR3 and tissue-damaging effects of secreted PR3. 
The development of such therapeutic antibodies is greatly promoted by the introduced 
quantitative thermophoretic immunoassays which complement classical biochemical 
methods. 
Secondly, thermophoresis was applied to serological diagnostics of autoantibodies associated 
with dilated cardiomyopathy (DCM). The peptide COR1 was used as a tracer. It mimics the 
dominant autoimmune epitope on the second extracellular loop of the β1-adrenoceptor. A 
global fit of two autocompetition assays in 50% and 10% serum simultaneously quantified 
antibody affinity and concentration. The relatively low affinity of the tracer COR1 (KD= 
70 nM) limited the sensitivity to an antibody concentration of approximately 5 nM. 
However, autoimmune antibodies in DCM patients are expected in the low nanomolar range. 
Thus, to allow for direct serological screening, the affinity of the tracer has to be enhanced 
by one order of magnitude. This should be possible by replacing the monomeric COR1 with 
a dimeric tracer peptide, to which an antibody binds with both of its arms.90 The introduced 
autocompetition approach and the possibility to measure directly in untreated serum qualify 
thermophoresis a highly promising tool for serological diagnostics. 
Taken together, thermophoretic immunoassays allow for fully quantitative studies of 
antibody-antigen interactions. Absolute quantification of affinity and concentration is 
achieved, as thermophoresis analysis is free of washing or amplification steps, which might 
introduce nonlinear characteristics into the detection signal. This represents a major 
advantage compared to traditionally used ELISAs. 
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This thesis introduces key innovations to thermophoretic bioanalytics, regarding 
measurement device, assay design and specific biomedical applications. An autocompetition 
assay was successfully used to quantify antibody concentration and affinity, directly in 
mildly diluted human serum. This assay reproduced pipetted concentrations and the KD 
measured beforehand. However, the affinity of the tracer COR1 was too low to resolve the 
very small autoimmune antibody concentrations expected in DCM patient sera. This 
demonstrates the central role of the tracer design in thermophoretic serology. Firstly, the 
affinity needs to be high enough to resolve the concentration range of the biomarker of 
interest. Secondly, tracers need to have a high stability, specificity and fluorescence intensity 
in blood serum, as it was the case for COR1. It has to be guaranteed that the tracer neither 
reacts with, nor unspecifically binds to serum components. Red fluorescent labels guarantee 
a specific fluorescence signal in serum, which shows a very low background fluorescence at 
the red end of the spectrum. With the right tracers, thermophoresis should enable the 
detection of several types of antibodies or antigens, even in other bodily fluids than blood. 
The provided fully quantitative picture of the status of disease related biomarkers promotes 
reliable differential diagnostics and precise therapy monitoring, thus helping to pave the way 
for personalized medicine. 
Apart from diagnostics, thermophoretic immunoassays were also used to characterize the 
potentially therapeutic antibody MCPR3-7. Here, quantitative thermophoresis measurements 
and classical biochemical assays complemented each other very well, leading to a 
comprehensive understanding of MCPR3-7’s properties. Such extensive characterizations 
are especially important for antibodies of therapeutic interest. 
Thermophoresis is also applicable for classical drug discovery. It was successfully used to 
analyze proteins, which represent the majority of today’s drug targets. Thermophoretic 
protein analysis was found to be highly flexible and adaptable. The size ratio of protein and 
binding partner, for instance, is not limiting. Even the binding of a small molecule compound 
(below 1 kDa) to a protein (50-150 kDa) was detected with high sensitivity. This is possible 
as thermophoresis does not only depend on molecular size, but also on various other 
properties like charge or conformation. Protein-small molecule interactions are highly 
relevant, as most of today’s drugs are small molecules. When applied to drug discovery, 
thermophoresis could potentially decrease the high failure rates of candidate compounds, as 
it excludes several common artifacts. Surface artifacts are eliminated, as thermophoresis 
measurements are preformed in free solution. Labeling artifacts can be avoided with label 
free thermophoresis, which was validated in this thesis. On the other hand, thermophoresis 
with a fluorescent label was successfully performed in cell lysate and blood serum. Such 
close to in vivo analyses have a much higher predictive value for a compound’s behavior 
inside the body than measurements in simple buffers do. In this context, thermophoretic 
binding analysis inside living cells represents an attractive extension, but to date has not yet 
been established. 
Another interesting extension of bioanalytical thermophoresis assays is the extraction of 
additional binding characteristics, beyond affinity and concentration. In several of the protein 
measurements shown in this thesis, the thermophoresis signal seemed to contain further 
information on the binding event. This includes conformational changes (TEM1-BLIP), a 
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second binding event (AMA1-RON2) or structural differences of small molecule ligands 
(p38α inhibitors). These findings suggest that thermophoresis could e.g. be used to classify 
ligands or to exactly determine their binding mechanism. This does not only require 
extensive comparative thermophoresis studies, but also a detailed theoretical description of 
thermophoresis. As protein-ligand binding is mainly based on specific non-covalent 
interactions at the partners’ interfaces, a better understanding of the non-ionic contributions 
to thermophoresis is of special interest. 
To elucidate the underlying principles of thermophoresis, high throughput screens (HTS) of 
different protein classes under various conditions would be highly beneficial. 
Thermophoretic HTS also promotes applications in fundamental research, diagnostics, or 
drug discovery. These screens are made possible by the novel capillary-free approach, which 
was introduced and evaluated in this thesis. Instead of capillaries, thermophoresis was 
measured in aqueous nl-samples under an optimized oil-surfactant layer in standard 1536 
well plates. The major benefits of this approach are the 50-fold sample volume reduction and 
the easy handling of the multi-well plates. This standard well plate format should allow for 
an efficient implementation into automated platforms. In one plate, 96 binding curves 
consisting of 16 samples each can be measured. This significantly enhances the throughput 
compared to the available capillary instruments, which measure one or six curves at a time. 
As a further benefit, the water-in-oil system should reduce or even prevent unspecific 
biomolecule adhesion to the sample container. This can be expected, as the sample does not 
touch the well surface but forms a surfactant surrounded droplet inside the oil. 
In the droplets, diffusive mixing after the nl-transfer was successful. Hence, an assay design 
in which a stock dilution series of a biomolecule target is tested against a high number of 
binding partners seems very practical e.g. for drug discovery. For diagnostics, it could be 
combined with the autocompetition approach. A stock dilution of an unlabelled tracer for the 
biomarker of interest would then be tested against multiple patient sera, supplemented with a 
constant amount of labeled tracer. 
Preparing the samples with an ECHO 550 liquid handler has several advantages. The highly 
accurate, nanoliter-volume transfer of a wide variety of possible liquids is preformed contact 
free. This eliminates cross contaminations and also leads to dramatic cost savings as no tips 
are consumed. However, if the ECHO 550 is not already part of an existing automation 
platform, the primary costs for the liquid handler are rather high. This could be an obstacle, 
especially for smaller laboratories. Hence, alternative methods for the preparation of the nl-
droplets in oil remain to be explored, e.g. via microfluidics. 
Taken together, thermophoresis measurements are a highly flexible tool for bioanalytics in 
all fields of the life sciences. New application possibilities beyond standard affinity 
determination in fundamental research are opened up by the innovations presented in this 
thesis. This includes quantitative high-throughput screening in serological diagnostics. 
Thermophoretic HTS is also highly attractive for drug discovery, as it can either be 
performed label free or under close to in vivo conditions in bioliquids. Based on the 
presented results, the application spectrum of thermophoresis can be expected to widen 
considerably. 
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Abstract: Biomolecule interactions are central to pharmacol-
ogy and diagnostics. These interactions can be quantified by
thermophoresis, the directed molecule movement along a tem-
perature gradient. It is sensitive to binding induced changes in
size, charge, or conformation. Established capillary measure-
ments require at least 0.5 mL per sample. We cut down sample
consumption by a factor of 50, using 10 nL droplets produced
with acoustic droplet robotics (Labcyte). Droplets were
stabilized in an oil–surfactant mix and locally heated with an
IR laser. Temperature increase, Marangoni flow, and concen-
tration distribution were analyzed by fluorescence microscopy
and numerical simulation. In 10 nL droplets, we quantified
AMP-aptamer affinity, cooperativity, and buffer dependence.
Miniaturization and the 1536-well plate format make the
method high-throughput and automation friendly. This pro-
motes innovative applications for diagnostic assays in human
serum or label-free drug discovery screening.
Molecular recognition is not only central to cell signaling,
but it also represents the functional principle of pharmaceut-
icals and laboratory diagnostics. A variety of opportunities
thus comes along with an in-depth understanding of biological
binding events. From this perspective, it is not surprising to
see an ever-growing interest in quantitative biomolecule
interaction analysis. To this end, the directed movement of
molecules along a temperature gradient, referred to as
thermophoresis,[1] has been successfully utilized in the last
years.[2,3] It is highly sensitive to molecular size, charge, and
conformation. Based on binding induced changes in at least
one of these parameters, affinity and concentration can be
quantified, even in complex bioliquids.[4]
In the well-established microscale thermophoresis (MST)
approach, samples are measured in glass capillaries. Capillary
MST has been applied for ions, small molecules, nucleic acids,
peptides, proteins, crude cell lysate, and untreated human
blood serum.[4–6] With circa 0.5 mL per capillary filling, the
sample consumption is low compared to, for example,
isothermal titration calorimetry.[7] However, the actual mea-
surement volume is significantly smaller: it lies in the range of
2 nL.[2] The additionally consumed volume becomes essential
when working with expensive or rare material such as patient
samples. This is especially true if high-throughput analyses
need to be performed, for instance, in diagnostics or drug
discovery. Throughput and automation of conventional MST
are further limited by the complicated handling of glass
capillaries.
Therefore, we developed a capillary-free approach to
measure thermophoresis in nL droplets under an oil–surfac-
tant layer inside 1536-well plates (Figure 1). The water-in-oil
system was experimentally characterized for temperature
induced effects. The findings agreed with numerical simula-
tions.
The applicability of the system for biomolecule interac-
tion studies was evaluated with a well-described nucleic acid
aptamer. Aptamers were discovered more than 20 years
ago.[8] Owing to their three-dimensional conformation, these
single-stranded oligonucleotides bind to various biomedically
relevant targets, including proteins and small molecules.[9,10]
Just like antibodies, aptamers show high specificity and
affinity. At the same time, these nucleic acid based ligands
are superior to protein based ligands in production costs,
storage conditions, and chemical modifiability.[10] In vivo,
their small size facilitates good delivery to the target tissue,
Figure 1. A) Droplet production. The liquid handler positions a destina-
tion plate above a source plate with a sample stock (purple). A
transducer emits an acoustic pulse focused to the sample surface,
whereby a 2.5 nL droplet travels into the destination well. To prevent
evaporation, droplets are transferred into an oil–surfactant mix
(brown). Inset: Samples were stable for several hours. 5 nL of 1:1
human serum/PBS. B) Inverted microscopic setup. The droplet center
is heated with an IR laser. Thermophoresis is monitored by fluores-
cence (LED: light emitting diode; CCD: charge-coupled device
camera).
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whereas no immunogenicity and low toxicity have been
reported.[10,11] These benefits and the first marketed aptamer
drug demonstrate the high potential of aptamers.[12]
Aptamer binding studies were miniaturized employing
a non-contact liquid handling system available commercially
(Labcyte). The system delivers 2.5 nL portions from multi-
well source plates into destination plates by acoustic droplet
ejection (Figure 1A).[13] The deviation from the target volume
is less than 2% (Supporting Information, Chapter S3a). To
prevent evaporation, droplets were transferred into a protec-
tive layer of standard microbiology mineral oil supplemented
with a surfactant mix according to Tawfik and Griffiths.[14] For
the presented experiments, we transferred four or eight 2.5 nL
portions to yield 10 nL (270 mm) or 20 nL samples (340 mm).
The positional accuracy of the transfer was reduced owing to
deflection by the oil. To coalesce individual portions, desti-
nation plates with funnel-shaped wells were mildly centri-
fuged after transfer ( 500 g to avoid droplet damage). With
our optimized procedure, we reproducibly obtained nL
samples that were stable for several hours (Figure 1A,
inset). This allowed for multiple thermophoretic binding
assays (10 min each).
Droplets were measured on a newly constructed micro-
scopic setup (Figure 1B). Similar to the previously described
capillary instrument,[2,5] thermophoresis was induced and
analyzed all-optically. As an essential modification to the
capillary setup, an inverted configuration was chosen so that
the sample plate stayed upright to avoid oil dripping. While
fixing the plate guaranteed that the droplets stayed in place,
moving the optical parts allowed sequential measurements.
Before studying biomolecule affinity, we characterized the
effects of local heating on aqueous nL droplets under oil. If
asymmetrically applied, heating occasionally led to convec-
tive flows strong enough to move an entire droplet away from
the laser spot. This was prevented by using plates with a small
well floor area (r= 0.45 mm). Utilizing the temperature
dependence of the fluorescent dye Alexa 647, the radial
temperature profile in the central horizontal plane of a 20 nL
droplet was obtained 0.2 s after the IR laser had been turned
on (Figure 2A). For a temperature increase of DTc= 11 K in
the heat spot center, the droplet periphery warmed up by
DTp= 4 K. A Lorentz fit revealed an FWHM of 120 mm. In
the following, DT denotes the average temperature increase
of the central (30  30) mm area.
Convective flows inside 20 nL samples were visualized
with fluorescent polystyrene beads. Figure 2B is integrated
over 7 s of heating. The beads moved toward the central heat
spot and out of focus, with peak velocities of 5–10 mms1 for
DT= 6 K and 15 mms1 for DT= 15 K. To elucidate these
flows, we performed full numerical simulations considering
diffusion, convection, thermophoresis, and the temperature
dependence of the dye. Simulations of 20 nL (Figure 3) and
10 nL droplets (Supporting Information, Figure S1) verified
that the observed inward flow can be explained byMarangoni
convection. This type of convection is caused by temperature-
induced differences in interfacial tension. In our case, local
heating decreased the interfacial tension between water and
oil at the top and bottom of the droplet, triggering Marangoni
fluid flow along the interface. Owing to the cylindrical
symmetry, toroidal vortices arose in the upper and lower
droplet hemisphere. Figure 3 shows the cross-sections of the
tori in a vertical cut. The dashed line indicates the horizontal
plane. Here, the flow is directed inward in the upper and
lower vortex, which agrees with the experimental observation
in this plane (Figure 2).
After flow field analysis, we recorded fluorescence time
traces, the basis for our binding measurements, in 20 nLAlexa
647 samples (Figure 4A). The experimental curves were
highly reproducible and confirmed by simulation. A series of
different events was identified in agreement with standard
capillary measurements. When the heating laser was turned
on, the fluorescence decreased owing to the temperature
response (DTR) of the dye and thermophoretic molecule
depletion. Thermophoresis and back-diffusion equilibrated
within seconds. Subsequent slow warming of the entire
sample slightly reduced the dye fluorescence intensity, but
did not affect the measurement. When heating was turned off,
fluorescence recovered owing to DTR and back-diffusion. A
larger DT enhanced DTR and thermophoresis in experiment
Figure 2. Local heating of 20 nL droplets. A) Radial temperature profile
in the central horizontal plane (red). The temperature increased by
DTc=11 K in the center and by DTp=4 K in the droplet periphery. A
Lorentz fit (black) revealed FWHM=120 mm. B) Flow profile of
fluorescent polystyrene beads (d=1.0 mm) integrated over 7 s during
heating (DT=15 K). The beads moved toward the heat spot and out
of focus with a peak velocity of 15 mms1.
Figure 3. Numerical simulation of temperature and flow fields in
a vertical cut through a 20 nL droplet after 0.2 s of heating. Left:
Isotherms indicate the temperature increase. Right: The central
horizontal plane (dashed) comprises the boundary of two toroidal flow
vortices. The vortices are driven by Marangoni convection at the
water–oil interface and have already reached the steady state.
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and simulation (Figure 4A). To assess the contribution of
Marangoni convection and thermophoresis, simulations
excluding either effect were performed (Figure 4B; imple-
mentation details are given in the Supporting Information,
Chapter S2a). When neglecting Marangoni convection, the
flow fields differed considerably, but the fluorescence signal
was only slightly altered. Upon removal of thermophoresis
from the simulation, the time traces changed significantly.
This demonstrates that thermophoresis prevailed against the
convective flows.
Having characterized thermophoresis in nL droplets
under oil, we evaluated its applicability for biomolecule
interaction studies. We analyzed a 25 mer DNA aptamer that
binds adenosine and its phosphorylated analogues.[15] This
aptamer has previously been studied extensively.[2,16] For nL-
scale interaction studies, a constant concentration of fluo-
rescently labeled aptamer (c= 2 mm) was added to a serial
dilution of adenosine-5’-monophosphate (AMP). As men-
tioned above, mild centrifugation in the funnel-shaped wells
reliably coalesced individual AMP and aptamer portions.
After coalescence, the concentration of AMP and aptamer
equilibrated by diffusion. The short diffusion times through
the small 10 nL or 20 nL samples guaranteed complete mixing
within minutes. We found diffusive mixing to be as effective as
manual premixing.
The mixed samples were locally heated by DT= 6 K. The
resultant thermophoretic depletion of free aptamer signifi-
cantly differed from its bound complex with AMP (Support-
ing Information, Figure S2). Furthermore, the temperature
response of the aptamer dye (DTR) changed upon AMP
binding.
The fluorescence after DTR and thermophoresis was
divided by the fluorescence before heating as described in the
Supporting Information, Figure S2 and previously.[6] As this
relative fluorescence can be approximated as linear to the
bound aptamer fraction, it was directly fit to the Hill equation
(Supporting Information, Chapter S3c).
Using the original selection buffer according to Huizenga
and Szostak,[15] we found EC50= (116 14) mm in 10 nL
samples and EC50= (104 10) mm in 20 nL samples (Fig-
ure 5A). Both values agree with each other and the literature
value of (87 5) mm from capillary thermophoresis.[2] The
determined Hill coefficients of n= 1.2 0.1 (10 nL) and n=
1.9 0.3 (20 nL) indicate cooperative binding of more than
one AMP, which is consistent with the previously reported
tertiary structure of the complex (Figure 5, inset).[17] More-
over, the Hill coefficients only slightly deviate from each
other and confirm the literature value (n= 1.4).[2] As a control,
we measured a DNA oligonucleotide with the same length as
the aptamer but two point mutations. The dinucleotide
Figure 4. Fluorescence time traces from 20 nL droplets. A) Measure-
ments of three Alexa 647 samples (gray, blue, red) overlap with minor
deviations demonstrating the low batch-to-batch variation. Experi-
ments and simulation (black) agree well. After the IR laser is turned
on (t=10 s), the fluorescence decreases due to the temperature
response (DTR) of the dye and thermophoresis. Thermophoresis and
back-diffusion equilibrate within seconds. After heating (t=50 s), Fnorm
recovers due to DTR and isothermal back-diffusion. A larger DT
enhances DTR and thermophoresis. B) Simulated contributions to the
decrease in Fnorm. Omitting Marangoni convection led to a negligible
change of 0.008 (dotted); omitting thermophoresis changed the signal
by 0.06 (dashed).
Figure 5. The specific signal change in DTR and thermophoresis upon
AMP titration to labeled aptamer was fit to the Hill equation. Mean
values of at least two individual nL samples; error bars: standard
deviation. A) Selection buffer. The fit revealed EC50= (11614) mm and
n=1.90.3 in 10 nL (red squares) and EC50= (10410) mm and
n=1.20.1 in 20 nL (black circles). A dinucleotide mutant showed
a 200-fold increased EC50 value of about 20 mm (blue triangles).
(B) PBS. EC50= (0.900.13) mm was found (black circles), confirming
the buffer dependence of the aptamer (n=1.60.4). The mutant
showed a 130-fold increased EC50 value of about 0.12m (blue
triangles). Inset: Determined Hill coefficients agree with the reported
tertiary structure (NDB code 1AW4): an aptamer (gray) binds two
AMP molecules (red).[17]
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mutant showed a 200-fold reduced AMP-affinity (EC50
 20 mm). This demonstrates the specificity of the binding
signal.
To quantify the reported buffer dependence of the AMP-
aptamer,[2] binding was measured in PBS (Figure 5B). An
EC50 of (0.90 0.13) mm was found, corresponding to a 10-
fold affinity reduction compared to selection buffer. This
reduction is not surprising, as the aptamer has originally been
evolved in and thus optimized for its selection buffer.[15,18] A
dominant effect can most likely be ascribed to magnesium
ions: while the selection buffer contained 5 mm MgCl2, we
used PBS without Mg2+. Mg2+ do not only stabilize DNA, but
can also neutralize AMP phosphate group and thus reduce
repulsion to phosphates in the aptamer backbone.[19] A
reduction of the MgCl2 concentration from 5 to 0 mm has
been reported to significantly reduce AMP-aptamer retention
in affinity chromatography.[16] This is in accordance with the
EC50 differences that we found in nL-thermophoresis. The
Hill coefficient was not significantly affected by the buffer; it
was n= 1.6 0.4 in PBS. The affinity of the mutant control
was reduced 130-fold compared to the aptamer (EC50
 0.12m).
The successful quantification of affinity, cooperativity, and
buffer dependence confirms the applicability of the presented
method for aptamer analysis. This type of study is most likely
to gain in importance now that the comprehensive aptamer
patent portfolio, which presumably has suppressed many
commercial applications, is starting to expire.[20] Furthermore,
nL-thermophoresis is a highly attractive analytical method for
other biomolecules including peptides or proteins, and for
complex bioliquids such as blood. The suitability for these
studies remains to be tested, but can be expected judging from
the application depth of capillary thermophoresis.[4–6] Sample
preparation is unlikely to be limiting, as the liquid handler can
be deployed for various solution types. We, for example,
produced stable nL droplets of 50% human blood serum
(Figure 1A, inset) as required for thermophoretic diagnostics.
Diffusive mixing after nL transfer was successful. Therefore,
an assay design in which a stock dilution series of a biomol-
ecule target is tested against a high number of binding
partners seems very practical, for example, for drug discovery.
It could also be combined with our previously published
diagnostic autocompetition approach.[4] A stock dilution of an
unlabeled tracer for the biomarker of interest would then be
tested against multiple patient sera, supplemented with
a constant amount of labeled tracer.
Compared to conventional capillary thermophoresis, the
volume was reduced 50-fold. This leads to an enormous
potential for high-throughput screens, even more so, as the
easy-to-handle multi-well plates promote automation.
As a further advantage, the nL transfer is contact-free,
which exempts from washing steps and minimizes cross-
contaminations. After transfer, the sample is not in direct
contact with the well surface, but forms a surfactant sur-
rounded droplet inside the oil. This should significantly
reduce unspecific surface adhesion of biomolecules (“stick-
ing”), an often encountered challenge in capillary thermo-
phoresis.[6] The elimination of sticking represents a major
benefit, even if surfactant and oil might have to be optimized
for different sample types.
Considering these advantages, the miniaturization, and
the extensive characterization in experiment and simulation,
nL droplet thermophoresis promises diverse applications
throughout the life sciences.
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1. Experimental section 
Nanoliter samples were prepared on an Echo 550 liquid handler 
(Labcyte Inc, USA). Echo qualified 384-well low dead volume 
source plates (Labcyte Inc) were filled manually. Air bubbles 
were avoided via reverse pipetting and centrifugation (2 min, 
1000×g) of the source plate. Destination plates (1536-well 
imp@ct plates, flat bottom; Greiner Bio-One GmbH, Germany) 
were manually filled with 0.5 µl/ well microbiology mineral oil 
(Carl Roth GmbH, Germany) with 4.5% (v/v) Span 80, 0.5% 
(v/v) Tween 80 (Sigma Aldrich Chemie GmbH, Germany). To 
remove air bubbles, destination plates were centrifuged (2 min, 
1000×g). Taking into account oil properties and destination well 
dimensions, the oil layer was chosen to be thin enough to prevent 
dripping from the upside-down plate during transfer, but also 
thick enough to fully incorporate droplets with diameters of 
approximately 270 or 340 µm (10 or 20 nl). Due to deflection by 
the oil, droplets tended to not reach the well floor. To sink the 
droplets, plates were shortly centrifuged (one pulse up to 
≤500×g). Typically, two or more individually transferred nl-
portions had to be coalesced, which required 5-10 min of centrif-
ugation. To avoid droplet damage, 500×g should not be exceeded. 
The nl-thermophoresis setup was built from optomechanical 
components ordered from Thorlabs GmbH, Germany. A red LED 
(625 nm, 1600 mA) with an aspheric condenser lens (Thorlabs 
GmbH) was used for fluorescence excitation. An Ag-coated 
mirror (AHF Analysentechnik AG, Germany), an infinity-
corrected tube lens (Thorlabs GmbH) and a CCD-camera (Sting-
ray F-145B; Allied Vision Technologies GmbH, Germany) were 
employed for imaging. Cy5-fluorescence filters were ordered 
from Laser Components GmbH, Germany. Temperature gradi-
ents were created with an infrared laser diode (l=1480 nm, 
P<500 mW; Fibotec Fiberoptics GmbH, Germany) coupled into 
the fluorescence light path with a heat-reflecting mirror 
(NanoTemper Technologies GmbH, Germany) and focused into 
the fluid with a 20x plan-apochromat objective (NA=0.8; Carl 
Zeiss AG, Germany). The optical components were mounted 
onto three orthogonal precision translation stages (Physik 
Instrumente GmbH, Germany; Edmund Optics Inc., USA). 
All measurements were performed at room temperature. The 
temperature increase was measured utilizing the temperature 
dependence of the fluorescent dye Alexa 647 (Life Technologies). 
Flows were visualized with 0.05% (m/v) crimson fluorescent 
microspheres (d=1.0 µm; Life Technologies, USA) in MilliQ 
water with 3.25 µM Alexa 647. 
Binding assays were performed in selection buffer (20 mM 
Tris-Cl, 300 mM NaCl, 5 mM MgCl2, pH 7.6) and in PBS 
(10 mM Na2HPO4, 1 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, 
pH 7.0). AMP sodium salt (Sigma Aldrich Chemie GmbH) was 
diluted starting at maximum final concentrations of 10 mM (se-
lection buffer) or 0.1 M (PBS). DNA oligonucleotides 
(biomers.net GmbH, Germany) with the sequences 5’-Cy5-CCT 
GGG GGA GTA TTG CGG AGG AAG G-3 (aptamer) or 5’-
Cy5-CCT tGG GGA GTA TTG CGG AtG AAG G-3’ (mutant) 
were added to the AMP-dilution steps manually prior to (PBS) or 
during nl-droplet transfer (selection buffer) to yield final oligo-
nucleotide concentrations of 2 µM and final droplet volumes of 
10 or 20 nl. Fluorescence after thermophoresis was averaged over 
a (30x30) µm area in the heat spot and normalized to the cold 
fluorescence. Mean Fnorm-values of at least two nl-samples from 
identical stocks were fit to the Hill equation. Error bars represent 
the standard deviation. 
Finite element simulations were done using COMSOL 
Multiphysics (COMSOL Inc., USA). Flows in the aqueous drop-
let and the oil were described by cylindrically symmetric incom-
pressible Navier-Stokes equations, combined with equations for 
thermal convection and conduction, laser absorption, and 
Marangoni convection at the interface. Molecules inside the 
droplet are subject to diffusion, convection and thermophoresis. 
The temperature dependence of the interfacial tension was ad-
justed to reproduce experimentally measured flow velocities. For 
the time traces in Fig. 4b, the fluorescence was averaged over a 
cylindrical volume (d=30 µm) in the droplet center. 
2. Numerical simulation of locally heated nl-droplets 
a. Excluding Marangoni convection or thermophoresis 
The physics in the aqueous droplet are described by a set of 
coupled partial differential equations. In addition to the incom-
pressible Navier-Stokes equations, equations for thermal convec-
tion and conduction, and laser absorption, two more equations 
are required. For Marangoni convection, this is 
ߟሺ௜ሻ ൤ݎ࢔ · ׏ ൬
࢚ · ࢜
ݎ
൰൨ ൌ ߛ்࢚ · ׏ܶ , 
nit vectors
en
n, ߟሺ௜  the viscosity of water or 
oil 
ection-diffusion equation, extended by a thermophore-
sis-term: 
߲ܿ
which must hold at the oil-water interface.[1] ࢔  and ࢚  are the 
normal and tangential u , ࢜ is the fluid velocity and ݎ 
the radial coordinate. ߛ் ൌ ߲ߛ/߲ܶ  d otes the temperature de-
pendence of the interfacial tensio ሻ
on each side of the interface. 
The distribution of the solute inside the droplet is described 
by a conv
߲ݐ
൅ ׏ሾሺെܦ׏ െ ܦ்׏ܶ ൅ ࢜ሻܿሿ ൌ 0 . 
ܦ is the diffusion coefficient and ܦ் the thermodiffusion co-
efficient. Their ratio is the Soret coefficient  ்ܵ ൌ ܦ் ܦ⁄ . 
To quantify the respective contributions of Marangoni con-
vection and thermophoresis to the observed fluorescence de-
crease, two control simulations were performed. In these controls, 
eith ient ܵer the Soret coeffic ் or the temperature dependence of 
the interfacial tension ߛ் has been set to zero. 
In the latter case (ߛ் ൌ 0, “no Marangoni”), the flow fields in 
the droplet are very different from those in the full simulation. 
However, the fluorescence time traces are not altered signifi-
cantly. On the other hand, setting ܦ் ൌ 0  (hence ்ܵ ൌ 0 , “no 
thermophoresis”) strongly reduces the magnitude of the fluores-
cence decrease. Therefore, the Soret coefficient of the solute 
trongly affects the observed fluorescence time tras ces. Moreover, 
nvective flows. this signal is not masked by the co
 
b. Influences from droplet size 
To assess the influence of the droplet size on the thermophoresis 
measurements, we simulated droplets of two different sizes, 20 nl 
(340 µm) and 10 nl (270 µm) (Fig. 3 and Fig. S1). The resulting 
flow fields and temperature distributions were highly similar. 
The mean flow velocity was 12 µm/s in the 20 nl-droplet and 
14 µm/s in the 10 nl droplet. The average temperature increase in 
the measurement volume (d=30 µm) was 10 K in the 20 nl-
droplet and 11.5 K in the 10 nl-droplet (for the same heating 
power). These minor differences illustrate that the measurement 
principle is independent of the droplet size in the relevant range. 
Therefore, small deviations from the target volumes will not have 
any considerable effect on the thermophoresis measurements. 
he differences could even be fully avoided by decreasing the 
heating power in 10 nl. 
 
10 nl-droplet after 0.2 s of heating. This figure is completely 
analogous to Fig. 3. In particular, the laser power is the same as for the 
20 nl droplet. 
racy is achieved, as the liquid handler 
me
10°
s for binding studies. However, a concen-
trat
 size e.g. due to inaccurate source well filling or oil layer 
reparation can easily be identified with the optical measurement 
s of various molecular properties. The thermophoretic 
dep
d aptamer. Thus, the titration steps 
howed a stepwise change in the dye’s temperature response and 
the thermophoretic depletion. 
 
thermophoresis (hot, red) was divided 
by the fluorescence before heating (cold, blue). This relative fluorescence 
was analyzed further (see below). 
to show cooperative binding, we fit 
, the bound fraction was plotted 
on a linear y-axis against the AMP concentration on a log10 x-
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Figure S1. Numerical simulation of temperature and flow fields in a vertical 
cut through a 
3. Thermophoresis measurements in nl-droplets 
a. Accuracy of the acoustic droplet production 
The accuracy of the Labcyte ECHO 550 liquid handler for aque-
ous buffers was previously analyzed by Harris et al.[2] In this 
systematic analysis, deviations from the expected volume lay 
below 2% for PBS or TRIS buffer with MgCl2 for all tested 
volumes. This high accu
asures fluid height and properties before transfer and then 
calibrates automatically. 
The transfer volume deviations of <2% does not affect the nl-
thermophoresis measurements, as experiments in both, 20 nl and 
10 nl droplets gave consistent results. This corresponds to a 
volume difference of 50%. In addition, simulations in 20 nl and 
nl were almost identical in terms of convective flows, temper-
ature distribution, and fluorescence time traces (2b with Fig. S1). 
Volume deviations correspond to concentration errors, when 
mixing two compound
ion error <2% is very small compared to e.g. manual pipetting 
of small µl-volumes. 
Taken together, the inaccuracy of the transfer is so small, that 
it is not critical for our technique. Furthermore, rare outliers in 
droplet
p
setup. 
 
b. Raw fluorescence time traces of a binding study 
Fig. 2 shows fluorescence time traces of labeled aptamer with 
and without AMP during a thermophoresis experiment in 20 nl-
selection buffer droplets. The heating laser was turned on after 
10 s, which led to a fluorescence decrease because of two events. 
Firstly, the intensity of the fluorophore decreased due to the 
temperature increase. Secondly, thermophoretic molecule move-
ment away from the heat spot led to depletion and thus lowered 
the fluorescence. Both events were influenced, when AMP bound 
to the aptamer. The temperature response of the fluorophore is 
sensitive to its local environment. This temperature response is 
thus influenced by binding in close proximity to the dye or by 
conformational changes of the aptamer during the binding event. 
In case of the AMP-aptamer binding, the dye’s temperature 
response was smaller for the unbound aptamer than for the bound 
complex. Thermophoresis is highly sensitive to binding induced 
change
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0
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letion was weaker for free aptamer than for its complex with 
AMP. 
Titration of AMP two a constant aptamer amount changed 
the ratio of bound and unboun
s
 
Figure S2. Raw fluorescence time traces of aptamer without and with 
different concentrations of AMP (20 nl, selection buffer). Unbound aptamer 
(top, black) shows a smaller temperature response of its fluorophore and a 
weaker thermophoretic depletion than the bound complex with AMP (bottom, 
orange). To quantify binding, AMP was titrated against a constant aptamer 
concentration. This led to a changing ratio of unbound and bound aptamer 
and thus to a stepwise change of the time traces (middle, brown). The 
fluorescence after dye response and 
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c. Data analysis in binding studies 
Fig. S2 illustrates the first analysis step of the fluorescence time 
traces: The thermophoresis before heating (cold, blue) was aver-
aged between 8.4 s and 9.5 s, and the fluorescence after heating 
(hot, red) between 22.4 s and 23.5 s. Afterward, the hot fluores-
cence was divided by the cold fluorescence, to yield the strength 
of dye temperature response and thermophoretic depletion. This 
signal can be approximated as linear to the bound aptamer frac-
tion. It can thus directly be fit to the binding model. As AMP and 
aptamer have been reported 
the data to the Hill equation. The Hill equation revealed the EC50 
and the Hill coefficient.  
To obtain the bound fraction, we subtracted Fhot/Fcold of the un-
bound aptamer as a baseline and normalized the curve to a fully 
bound plateau of 100%. Finally
axis (see Fig. 5).  
[1 F. M. Weinert, D. Braun, Phys. Rev. Lett. 20
[2] D. Harris, M. Mutz, M. Sonntag, R. Stearns, J. Shieh, S. Picket, R. 
 Ellson, J Olechno, JALA 2008, 13, 97–102. 
 
Methods 59 (2013) 301–315Contents lists available at SciVerse ScienceDirect
Methods
journal homepage: www.elsevier .com/locate /ymethMicroscale thermophoresis quantiﬁes biomolecular interactions under
previously challenging conditions
Susanne A.I. Seidel a, Patricia M. Dijkman b, Wendy A. Lea c, Geert van den Bogaart e,
Moran Jerabek-Willemsen j, Ana Lazic i, Jeremiah S. Joseph f, Prakash Srinivasan d, Philipp Baaske j,
Anton Simeonov c, Ilia Katritch f, Fernando A. Melo g, John E. Ladbury g, Gideon Schreiber h,
Anthony Watts b, Dieter Braun a, Stefan Duhr j,⇑
a Systems Biophysics and Functional Nanosystems, Ludwig-Maximilians-Universität München, Amalienstrasse 54, 80799 Munich, Germany
bBiomembrane Structure Unit, Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK
cDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
d Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
eDepartment of Tumor Immunology, Radboud University Nijmegen Medical Centre, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands
f The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
gDepartment of Biochemistry and Molecular Biology and Center for Biomolecular Structure and Function, University of Texas MD Anderson Cancer Center,
Unit 1000, 1515 Holcombe Boulevard, Houston, TX 77030, USA
hDepartment of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel
iNanoTemper Technologies, Inc., One Embarcadero Center, Suite 1060, San Francisco, CA 94111, USA
jNanoTemper Technologies GmbH, Flößergasse 4, 81369 Munich, Germanya r t i c l e i n f o
Article history:
Available online 24 December 2012
Communicated by Peter Schuck
Keywords:
Microscale thermophoresis
Binding afﬁnity
Label-free
Bioliquids
Dimerization
Cooperativity1046-2023/$ - see front matter  2013 Elsevier Inc. A
http://dx.doi.org/10.1016/j.ymeth.2012.12.005
⇑ Corresponding author. Fax: +49 89 4522895 60.
E-mail addresses: Stefan.duhr@physik.uni-muenchen.
(S. Duhr).
URL: http://www.nanotemper-technologies.com (a b s t r a c t
Microscale thermophoresis (MST) allows for quantitative analysis of protein interactions in free solution
and with low sample consumption. The technique is based on thermophoresis, the directed motion of
molecules in temperature gradients. Thermophoresis is highly sensitive to all types of binding-induced
changes of molecular properties, be it in size, charge, hydration shell or conformation. In an all-optical
approach, an infrared laser is used for local heating, and molecule mobility in the temperature gradient
is analyzed via ﬂuorescence. In standard MST one binding partner is ﬂuorescently labeled. However, MST
can also be performed label-free by exploiting intrinsic protein UV-ﬂuorescence.
Despite the high molecular weight ratio, the interaction of small molecules and peptides with proteins
is readily accessible by MST. Furthermore, MST assays are highly adaptable to ﬁt to the diverse require-
ments of different biomolecules, such as membrane proteins to be stabilized in solution. The type of buf-
fer and additives can be chosen freely. Measuring is even possible in complex bioliquids like cell lysate
allowing close to in vivo conditions without sample puriﬁcation. Binding modes that are quantiﬁable
via MST include dimerization, cooperativity and competition. Thus, its ﬂexibility in assay design qualiﬁes
MST for analysis of biomolecular interactions in complex experimental settings, which we herein demon-
strate by addressing typically challenging types of binding events from various ﬁelds of life science.
 2013 Elsevier Inc. All rights reserved.1. Introduction
1.1. The importance of biomolecular afﬁnity quantiﬁcation
Binding events involving proteins and other biomolecules play a
central role in all ﬁelds of life science, from molecular physiology
and pathology to diagnostics and pharmacology. Therefore, biomo-
lecular interaction analysis does not only give fundamental in-ll rights reserved.
de, Stefan.duhr@nanotemper.de
S. Duhr).sights into the molecular biology of the cell but also paves the
way towards improved disease treatment.
Cellular networks for signal transduction are mainly based on
the direct interaction of biomolecules. A typical example is the li-
gand binding-induced activation of cell membrane receptors. It
has recently been shown for the ﬁbroblast growth factor receptor
(FGFR), that not only interaction with the ligand, but also with a
negative regulator is required for proper receptor function: binding
of growth factor receptor-bound protein 2 (Grb2) dimers inhibits
FGFR activation in absence of extracellular stimuli [1]. Pathological
alterations of these signal transduction networks have to be eluci-
dated to understand disease etiology. In infectious diseases, host
cell invasion is a critical step that involves speciﬁc protein–protein
302 S.A.I. Seidel et al. /Methods 59 (2013) 301–315interactions. For instance, the malaria-causing microorganism Plas-
modium falciparum invades red blood cells through multiple recep-
tor-ligand interactions. One of the key steps requires injecting
parasite rhoptry neck proteins (RONs) [2]. RON2 then functions
as a receptor for apical membrane antigen 1 (AMA1) present on
the parasite’s surface. The interaction of RON2 and AMA1 is there-
fore of major interest as a potential drug target [3].
In these examples, qualitative binding studies alone would
hardly be sufﬁcient. Instead, quantitative analysis not only allows
obtaining biologically relevant information but also evaluating it
in the context of the corresponding system. Microscale themopho-
resis (MST) quantiﬁes biomolecular interactions based on the un-
ique physical principle of thermophoresis not utilized by any
other technique. As thermophoresis is inﬂuenced by binding-in-
duced changes of various molecular properties, MST distinguishes
itself from other biophysical techniques relying on measurable
changes in one single parameter. In addition, MST beneﬁts from
very low sample consumption and short measurement times. Its
highly ﬂexible assay design makes MST a widely applicable ap-
proach, even when the system of interest poses challenging condi-
tions. In this work, we place MST in the context of other well-
established biochemical and biophysical methods and illustrate
how it can be used to quantify interactions that are difﬁcult to
quantify by other means. Measurements in cell lysate or in com-
plex buffers as are needed to stabilize GPCRs are shown. In addition
to small molecule interactions, homodimerization, binding events
comprising multiple constituents and cooperativity are discussed.
We furthermore give detailed information on the background of
MST and on its experimental implementation.
1.2. Tools for biomolecular binding analysis
The optimal approach to determine binding constants for a gi-
ven biological system can be selected by considering the speciﬁc
strengths and weaknesses of the currently available techniques.
Biochemical methods are straightforward to perform and compa-
rably low in cost and effort. They include electrophoretic mobility
shift assays (EMSA) for the study of protein-nucleic acid interac-
tions and antibody-based techniques such as enzyme linked
immunosorbent assays (ELISA) [4,5]. Despite their popularity and
application depth, classical biochemical methods are typically lim-
ited to semi quantitative interaction analysis [6].
A number of biophysical approaches, including isothermal titra-
tion calorimetry, dynamic light scattering, ﬂuorescence polariza-
tion and surface plasmon resonance, do allow quantitative
binding studies. Isothermal titration calorimetry (ITC) has the
advantage of not requiring labeling or tethering. In this calorimet-
ric approach, the heat change upon binding is measured by titrat-
ing one binding partner into an adiabatic sample cell, which
contains a constant amount of the other binding partner. ITC gives
direct access to afﬁnity, stoichiometry and thermodynamic param-
eters. However, sensitivity is low, requiring relatively high
amounts of sample to generate a sufﬁciently strong heat signal,
which can be difﬁcult to achieve for biological samples. Binding
afﬁnities from nM to sub-mM can be resolved with low throughput
[7–9]. Label-free, free solution binding analysis is also possible via
dynamic light scattering (DLS). DLS utilizes the autocorrelation of
time-dependent ﬂuctuations in light scattered by biomolecules in
solution. The translational diffusion coefﬁcient and thus the hydro-
dynamic radius (rH) of the biomolecules are inferred. A binding-in-
duced change in the average particle size can thus be detected. In
high-density plate formats, DLS allows for high-throughput mea-
surements of afﬁnities in the low to high micromolar range. The
technique, however, relies on a signiﬁcant difference in the rH of
the unbound partners relative to the complex and is thus limited
to binding partners that maximally differ by a factor of two in theirrH. It has to be taken into account that rH scales with the cube root
of the molecular weight. The sensitivity is thus lower for the bind-
ing of two larger proteins compared to the binding of two smaller
ones [10,11]. Another free solution method is ﬂuorescence polari-
zation (FP; or ﬂuorescence anisotropy). FP requires ﬂuorescent
labeling of one of the binding partners, usually a small molecule li-
gand, which is then excited with polarized light. Fast rotation of
the small ligand causes the emitted light to be depolarized. Binding
of a larger protein leads to an increase in size and thus slower rota-
tion. As a result, the emitted light remains polarized to a greater
extent. FP allows for fully automated high-throughput analysis.
Applicability and sensitivity are limited by the relation of ﬂuores-
cence lifetime of the dye, the size of the ﬂuoroligand and the
molecular weight change upon binding. Fluorescein, a dye fre-
quently used for FP, has a lifetime of 4 ns and is thus only applica-
ble in FP assays in which a ligand of less than several thousand
daltons in size is labeled [12,13]. Considering that ﬂuorescein itself
has a molecular weight of >300 Da, it seems quite conceivable that
labeling alters the ligand’s binding behavior.
In contrast to the aforementioned methods, surface plasmon
resonance (SPR) is not performed in free solution. Instead, it relies
on immobilizing one of the binding partners to a thin noble metal
ﬁlm. Light at the resonance wavelength is used to induce surface
plasmons. When a binding partner binds to the immobilized bio-
molecule layer, the refractive index increases and therefore the
resonance frequency changes. The technique allows for real-time
determination of on- and off-rates and covers afﬁnities from sub
nM to low mM with an intermediate throughput rate. Mass trans-
port as well as rebinding are well-described complications for ki-
netic measurements [14,15]. Establishing new assays for surface-
bound techniques like SPR can be time-consuming. Furthermore,
surface immobilization may affect the bound molecules’ dynamics
and thus alter the binding event [16].
As a solution-based method, microscale thermophoresis avoids
such surface artifacts and immobilization procedures. In standard
MST, one binding partner is ﬂuorescently labeled [17]. However,
protein interactions can also be analyzed using label-free MST
which utilizes the intrinsic UV-ﬂuorescence of proteins [18]. MST
relies on binding-induced changes in thermophoretic mobility,
which depends on several molecular properties, including not only
size, but also charge and solvation entropy [19]. Therefore, MST
does not require a change in size or mass like FP and SPR and is
not limited by the molecular weight ratio of the binding partners
like DLS. This does not only lead to a wider applicability but also
to a greater ﬂexibility in assay design. Applicability and ﬂexibility
are further enhanced by the fact that virtually any type of buffer
as well as complex bioliquid can be used.2. The concept of microscale thermophoresis
2.1. Experimental approach
2.1.1. The MST instrument
Microscale thermophoresis is an all-optical approach to charac-
terize the properties of biomolecules. Visible light is used for ﬂuo-
rescence excitation in the Monolith NT.115 MST instrument, for
which three types of LED-ﬁlter combinations are available: blue
(excitation 460–480 nm, emission 515–530 nm), green (excitation
515–525 nm, emission 560–585 nm) and red (excitation 605–
645 nm, emission 680–685 nm). In the Monolith NT.LabelFree
instrument an excitation wavelength of 280 nm and an emission
of 360 nm are used to, respectively excite and detect the intrinsic
UV-ﬂuorescence of proteins. As illustrated in Fig. 1A, an infrared
(IR) laser with a wavelength of 1480 nm is coupled into the light
path of ﬂuorescence excitation and emission. The IR radiation is
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Fig. 1. Microscale thermophoresis. (A) MST setup. The sample solution inside a
capillary placed on a temperature-controlled sample tray (TC) is locally heated with
an IR-laser (IR), which is coupled into the path of ﬂuorescence excitation and
emission with an IR reﬂecting ‘‘hot’’-mirror (HM). FO: ﬂuorescence observation;
OBJ: objective. (B) Schematic representation of the ﬂuorescence time trace recorded
by the MST instrument. A series of processes can be separated from each other: The
initial ﬂuorescence (I) drops fast as soon as the heating IR-laser is turned on (t = 5 s).
This T-jump (II) on a 100 ms timescale depicts the ﬂuorophore’s temperature
sensitivity. It can easily be separated from the following diffusion-limited thermo-
phoresis (III) lasting several seconds. Both T-jump and thermophoresis can be
inﬂuenced by a binding event. Turning off the IR-laser (t = 35 s) leads to the inverse
T-jump (IV) and the backdiffusion (V). The ﬂuorescence after thermodiffusion (F1) is
normalized to the ﬂuorescence F0 which is either the initial ﬂuorescence (depicted
here) or the ﬂuorescence after the T-jump. In the former case shown here,
thermophoresis and T-jump are both included in the signal analysis whereas in the
latter, only thermophoresis is captured.
S.A.I. Seidel et al. /Methods 59 (2013) 301–315 303focused onto the sample to exactly the spot where ﬂuorescence
intensity is measured. The IR radiation is absorbed by the water
molecules of the sample buffer to create a temperature gradient.
As the coherent laser radiation can be easily focused, the tempera-
ture gradient is localized and strong while the overall temperature
remains low. The temperature increase has a 1/e extension of
25 lm, and a total volume of 2 nl of the sample is heated by typi-
cally 1–6 K, depending on IR-laser power and sample capillary
type. The height of the capillaries is tightly regulated to guarantee
highly reproducible temperature gradients. The capillaries have a
constant inner and outer diameter and are made from highly pure
glass. This ensures that a constant amount of laser power is ab-
sorbed, that the conductive heat transport through the glass is con-
stant and that no diffraction of laser radiation occurs. Other
important capillary properties are discussed separately in
Section 2.1.4.2.1.2. Fluorescent labels
The thermophorectic movement is detected through ﬂuores-
cence of one of the binding partners, originating either from an
attached ﬂuorescent label or ﬂuorescent fusion protein or from
protein intrinsic UV-ﬂuorescence.
Crosslinker reactive groups are commonly used for protein
labeling. The ﬂuorescent dye is coupled to the crosslinker, which
covalently binds to speciﬁc functional groups of the protein. For in-
stance, N-hydroxysuccinimide (NHS) esters react with primary
amines of lysine side chains or at the protein’s N-terminus. Cou-
pling to arginine’s guanidino group is possible as well. Alterna-
tively, maleimide dyes can be used to label sulfhydryl groups
present in reduced cysteine residues. In both cases, unreacted
dye needs to be removed prior to the binding analysis. Biomole-
cules typically contain more than one of these potential labeling
sites. However, the exact position of the ﬂuorescent label is not
important for thermophoretic analysis. Furthermore, the presence
of labels at random positions adds to MST’s robustness, as it min-
imizes possible local effects of a label on the binding behavior.
Coupling reactions often require a speciﬁc pH, but the conditions
are normally well-tolerated by most proteins. Besides proteins,other types of molecules can be ﬂuorescently labeled to study
binding interactions (e.g. nucleic acids, sugars, lipids, etc.).
Alternative ﬂuorescent labeling approaches can be used to spe-
ciﬁcally label the target protein without the need for prior puriﬁca-
tion. In vitro translation systems allow for the linkage of
ﬂuorophore-puromycin conjugates to the C-terminus [20] or the
incorporation of ‘‘non-natural amino acids’’. These amino acids
can already carry a ﬂuorescent dye [21] or can be speciﬁcally mod-
iﬁed after incorporation [22]. In addition, recombinant proteins can
be used directly in cell lysate. Either fusions to a ﬂuorescent pro-
tein, such as the green ﬂuorescent protein (GFP), can be used or
speciﬁc peptide sequence tags allowing for site-speciﬁc dye cou-
pling. Sample volumes and concentrations obtained by such pro-
tein puriﬁcation-free approaches typically suit the requirements
of MST experiments very well.
Fluorescent labels provide high sensitivity such that sub-nM
concentrations can be used. They also ensure selectivity for mea-
surements in complex ﬂuids or mixtures of molecules carrying dif-
ferent labels. It is however possible that ﬂuorescent labels
inﬂuence certain binding interactions. Some biomolecules, such
as most membrane proteins (e.g. G protein-coupled receptors),
are particularly sensitive to modiﬁcations. A solution to this is la-
bel-free MST which utilizes intrinsic protein ﬂuorescence in the
UV-range, arising from the aromatic amino acids tyrosine, phenyl-
alanine and tryptophan (Trp) with the latter being the dominant
intrinsic ﬂuorophore. To get a measurable UV-ﬂuorescence signal
in label-free MST, proteins of average Trp-content (2 or more
Trp) can typically be used in concentrations as low as 100 nM. A
protein concentration of 100 nM allows to precisely quantify
KDsP 50 nM, whereas smaller KDs can still be detected but not
accurately quantiﬁed [18].
The choice of source of ﬂuorescence should take into account
the nature of the liquid in which the MST analysis will be per-
formed. Background ﬂuorescence of the buffer at the ﬂuorophore
wavelength should be avoided to obtain a good signal to noise ra-
tio. Therefore, label-free measurements cannot be conducted in
complex bioliquids such as concentrated cell lysate or blood serum
since these show a high background UV-ﬂuorescence due to their
high protein content. Red ﬂuorescent labels are the best choice
for measuring in serum as its background ﬂuorescence is very
low at the red end of the spectrum. The ﬂuorescence intensity
should be high enough to keep the concentration of the non-ti-
trated ﬂuorescent binding partner in the order of the expected KD
or below. This ensures maximum resolution and highest precision
when determining dissociation constants.
2.1.3. The serial dilution
MSTmeasures equilibriumbinding events. For this, the non-ﬂuo-
rescent partner is titrated against a ﬁxed concentration of the ﬂuo-
rescent partner. The initial ﬂuorescence intensity should be
constant throughout the serial dilution unless the ﬂuorophore is
close to the binding sites or there are problems with aggregation
or surface adsorption. To clarify this, the inﬂuence of detergents or
BSA and a negative control of the protein should be tested. Changes
in the ﬂuorescence intensity in label-free MST should be treated
carefully, as the non-negligible background ﬂuorescence in the
UV-range makes the measurements more susceptible to false-
positive signals arising merely from ﬂuorescence changes. Thus,
background subtraction and negative controls are very important.
The available monolith series instruments accept up to 16 cap-
illaries for one experiment. The minimal concentration of titrated
partner needs to be sufﬁciently low to measure the thermophoretic
movement of the unbound state. The maximal concentration has to
be higher than the expected dissociation constant to reach satura-
tion of the fully bound complex. As a rule of thumb this is about
20-fold above the dissociation constant.
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Having prepared the serial dilution, the samples are ﬁlled into
capillaries through capillary action. Sample volumes of less than
4 ll are sufﬁcient resulting in low sample consumption. MST cap-
illaries have precisely deﬁned dimensions with inner diameter
variations of less than 1 lm guaranteeing highly reproducible tem-
perature gradients. The temperature gradient and the overall tem-
perature increase also depends on the thickness of the outer layer
of glass since its heat conductivity determines the efﬁciency of
heat transport away from the focal IR-laser area. The inner capil-
lary surface greatly inﬂuences the quality of the measurement.
Standard MST capillaries (NanoTemper Technologies) are physi-
cally treated to obtain a highly homogeneous surface and thus a
low background signal. Unspeciﬁc adsorption of one of the binding
partners to the capillary surface is readily detected by the MST de-
vice. It can be avoided by using capillaries coated with hydrophilic
or hydrophobic polymers or by using buffer additives like deter-
gents or proteins (e.g. BSA). When using BSA for small molecule
measurements, control experiments are recommended to rule
out unspeciﬁc binding of the small molecule to BSA.
2.2. Theoretical background
2.2.1. Thermophoresis
The directed movement of particles in a temperature gradient,
thermophoresis, was already described by Carl Ludwig in 1856
[23]. Thermophoresis can be depicted as a molecular ﬂow, which
is directly proportional to the temperature gradient with the pro-
portionality constant DT, the thermal diffusion coefﬁcient:
j ¼ cDT grad T
j: molecular ﬂow; c: molecule concentration; DT: thermal diffusion
coefﬁcient; T: temperature.
In steady state this thermophoretic ﬂow is counterbalanced by
mass diffusion:
j ¼ D grad c
D: diffusion coefﬁcient.
The thermophoretically induced change in concentration is
then determined by the ratio of D and DT which is referred to as
the Soret coefﬁcient ST:
ST ¼ DDT
For a given spatial temperature difference DT the steady state
concentration change is therefore given by:
chot
ccold
¼ expðSTDTÞ
chot: molecule concentration in the hot area; ccold: molecule concen-
tration in the cold area.
This thermophoretic depletion depends on the interface be-
tween molecule and solvent. Under constant buffer conditions,
thermophoresis probes size, charge, solvation entropy and confor-
mation of the molecules. As biomolecular binding events typically
affect at least one these parameters, thermophoresis can be used as
a ﬂexible tool for biomolecular afﬁnity quantiﬁcation [19].
2.2.2. MST signal analysis
The MST instrument excites and records ﬂuorescence of the
focal IR-laser area within the sample before, during and after the
laser is turned on. As thermophoresis is diffusion limited, the spa-
tial restriction of the temperature gradient, achieved by using an
IR-laser for heating, allows for short measurement times well be-
low 30 s per sample. The ﬂuorescence time trace, schematically
represented in Fig. 1B, displays a series of deﬁned and separableprocesses, each of them containing different information on the
binding event.
Before heating, the initial ﬂuorescence (region I in Fig. 1B) is
recorded. It should be constant for all samples. Minor random
variations due to pipetting errors do not inﬂuence the result, as a
relative ﬂuorescence signal is used. Occasionally, changes of the
initial ﬂuorescence occur due to binding close to the ﬂuorophore.
Having carefully ruled out artifacts as a possible reason (see Sec-
tion 2.1.3.), the KD may already be inferred from these changes in
some cases by plotting the initial ﬂuorescence against the concen-
tration of the titrant and ﬁtting to a binding model (see below).
Turning on the IR-laser leads to an abrupt change in ﬂuorescence
intensity. This so-called temperature jump (T-jump, region II in
Fig. 1B) corresponds to the temperature-dependent change of ﬂuo-
rescence, an inherent property of the ﬂuorophore [24]. This tem-
perature dependence is sensitive to the ﬂuorophore’s local
environment. Thus the T-jump can be inﬂuenced by conforma-
tional changes or binding in close proximity to the ﬂuorophore
[25] which may provide spatial information on the binding site.
The T-jump occurs on the same short timescale of several 100 ms
as the fast heating by the IR-laser. It can thus easily be separated
from the following relatively slow thermophoresis (region III in
Fig. 1B) which, as a diffusion-limited process, lasts several seconds.
The thermophoretic motion creates a concentration gradient of the
ﬂuorescent molecules. Fluorescence intensity reaches a plateau
representing the steady state in which thermodiffusion is counter-
balanced by mass diffusion. Immediately after the heating laser is
turned off, the ﬂuorescence recovery due to the ﬂuorophore’s tem-
perature dependence, the inverse T-jump (region IV in Fig. B), indi-
cates cooling of the sample. Finally, backdiffusion (region V in
Fig. 1B), driven by pure mass diffusion, leads to the compensating
of the concentration gradient.
As mentioned above, relative ﬂuorescence is used to quantify
binding via MST:
Fnorm ¼ F1F0
Fnorm: normalized ﬂuorescence; F1: ﬂuorescence after thermodiffu-
sion; F0: initial ﬂuorescence or ﬂuorescence after T-jump.
F1 refers to the ﬂuorescence measured several seconds after the
IR-laser has been turned on, when the traces of unbound and
bound state can be discriminated. The steady state does not neces-
sarily have to be reached within the time of the experiment [17]. F0
refers to either the initial ﬂuorescence or the ﬂuorescence after the
T-jump which is approximately 1 s after the laser has been turned
on. In the former case depicted in Fig. 1B, thermophoresis and T-
jump are both included in the signal analysis whereas in the latter,
only thermophoresis is captured. When the T-jump is inﬂuenced
by the binding event, including it leads to a better signal to noise
ratio in the resulting binding curve. Analysis of thermophoresis
with and without T-jump typically yields the same result. Both
processes should, however, not be used for a combined analysis
when their binding-induced changes show amplitudes with an
opposite sign and would thus cancel each other out.
For small relative temperature and concentration changes as is
the case in MST experiments, the above mentioned equation
describing the concentration change due to thermophoresis can
be approximated by linearization:
chot
ccold
¼ expðSTDTÞ  1 STDT
Fnorm corresponds to ST, plus where applicable the additional
contribution of the ﬂuorescence change due to the ﬂuorophore’s
temperature dependence dF/dT:
Fnorm ¼ 1þ dFdT  ST
 
DT
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tion of the concentration of the titrated binding partner. As the
thermophoretic movement of bound and unbound state superpose
linearly, the fraction bound (FB) is described by:
Fnorm ¼ ð1 FBÞFnorm; unbound þ ðFBÞFnorm; bound
FB: fraction bound; Fnorm, unbound: normalized ﬂuorescence of
the unbound state; Fnorm, bound: normalized ﬂuorescence of the
bound state.
In many cases the binding event can be described by a simple
model according to the law of mass action. More complex binding
modes require different models, e.g. the Hill equation for coopera-
tivity. It would be beyond the scope of this review to discuss differ-
ent binding models in detail. Thus the often applicable model
according to the law of mass action will be described in the follow-
ing. The binding process of a partner A and a partner B leading to
the formation of a complex AB is characterized by:
Aþ B¡ AB
A: binding partner A; B: binding partner B; AB: bound complex
of A and B.
The equilibrium dissociation constant KD which quantiﬁes the
binding afﬁnity is deﬁned as:
KD ¼ ½Afree½Bfree½AB
KD: equilibrium dissociation constant; [A]free: concentration of free
partner A; [B]free: concentration of free partner B; [AB]: concentra-
tion of bound complex of A and B.
As the free concentrations are not known, total concentrations
are used instead. The total concentration of A and B are deﬁned as:
½A ¼ ½Afree þ ½AB and ½B ¼ ½Bfree þ ½AB
Thus
KD ¼ ½Afree½Bfree½AB ¼
ð½A  ½ABÞð½B  ½ABÞ
½AB
In the following, Awill represent the titrated partner, B the part-
ner, whose concentration is kept constant and whose ﬂuorescence
is read out. To obtain the KD from the MST data, we solve for the
fraction bound of B, FB:
FB ¼ ½AB½B ¼
½A þ ½B þ KD 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½A þ ½B þ KDÞ2  4½AB
q
2½B
FB is now expressed as a function of the total concentration of A
and B with the KD being the single free parameter. Fnorm from the
MST measurement linearly reports FB and can thus directly be ﬁt-
ted to this equation.
Fnorm is plotted on a linear y-axis in per mil (‰) against the total
concentration of the titrated partner on a log10 x-axis. The advan-
tage of this semi-log plot is, that the binding data can be easily in-
spected by eye: the curve shows a characteristic s-shape (or
mirrored-s-shape) in which the unbound and saturated state build
a lower and upper plateau. Fnorm of the unbound state is revealed
by the ﬁt and can be subtracted as a baseline value to yield DFnorm,
as depicted in the ﬁgures in this manuscript.
The plots showmeanDFnorm-values resulting from independent
repeats of the MST experiment. The error bars on individual data
points represent the standard deviation between these repeats.
The means are ﬁtted and the resultant KD-values are given together
with an error estimation from the ﬁt. The ﬁtting procedure as-
sumes a Gaussian, symmetric error distribution. Thus the error
can reach negative values, if the sensitivity limit determined by
the lowest detectable concentration of ﬂuorescent partner isreached. In these cases, the KD-values are presented as an upper
limit and can also be lower.
2.3. Summary: assay optimization
MST experiments can easily be optimized as any potential prob-
lems are immediately revealed during assay design and speciﬁc
troubleshooting steps are available. Although some points have al-
ready been mentioned in the last paragraphs, this section summa-
rizes and details the information on optimization. The list is
certainly not exhaustive but can serve as a practical guide for users.
Surface adsorption to reaction tubes, pipette tips or glass capillar-
ies (‘‘Sticking’’):
Indications:
 If the capillary scan in the MST-instrument shows asymmetric
peaks, peaks with shoulders or double peaks, the labeled
material is most likely sticking to the capillary walls. Some-
times it takes several minutes before this is observed, some-
times it is not observable at all even though it is taking place.
 The ﬂuorescence strongly drops along the titration curve as one
of the partners or the complex sticks.
 The ﬂuorescence of the sample is much lower than expected
when compared to a calibration curve of the dye in the mea-
surement buffer.
 The ﬂuorescence of the same sample decreases much faster
over time than would be explained by bleaching.
 The raw data curves of multiple measurements of an identical
sample strongly deviate.
Optimization:
 Use low-binding reaction tubes and pipette tips.
 Use capillaries coated with hydrophilic or hydrophobic
polymers.
 Use buffer additives like detergents or proteins, e.g. BSA. When
testing small molecules, binding to BSA has to be excluded
experimentally.
Aggregation:
Indications:
 The raw data curves show bumps or waves.
 The raw data curves of multiple measurements of an identical
sample strongly deviate.
Optimization: improve sample stability, quality and homogeneity
by
 spinning down the sample before the experiment (e.g. 5 min at
15000  g) and only using the supernatant;
 using buffer additives like detergents or proteins;
 optimizing the buffer in general (ionic strength, pH, etc.)
Suboptimal ﬂuorescence intensity:
Indications:
 Low signal to noise ratio in ﬂuorescence intensity during the
capillary scan and in the raw data curves.
 The upper parts of the peaks in the capillary scan are cut-off or
there is no raw data curve but a ﬂat line as the upper limit of the
dynamic range of the ﬂuorescence detection is exceeded (2500
counts on the current model of NT.115, see manual).
 The ﬂuorescence of the sample is much higher or lower than
expected.
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 Test for free dye (high ﬂuorescence intensity) or low labeling
efﬁciency and loss of material (low ﬂuorescence intensity)
during the labeling process e.g. by photometrically determin-
ing the dye and protein concentration.
 Adjust the LED-power or concentration of the ﬂuorescent bind-
ing partner to yield a ﬂuorescence intensity between 200 and
1500 counts. The optimal concentration and LED-setting can
be found before the binding measurement by preparing a dilu-
tion series of the ﬂuorescent partner in the measurement buffer.
Suboptimal concentration range in the serial dilution:
Indications:
 No binding is observed.
 The plateau of the unbound state or the saturation of the fully
bound state are not reached.
Optimization:
 Optimize the concentration range of the titration, e.g. by using
the concentration ﬁnder of the Nanotemper-Analysis-Software.
 When the highest possible concentration of one binding
partner is below saturation levels (e.g. due to solubility
problems) reversing the assay design might be helpful.
Low signal to noise ratio in MST signal amplitude:
Indication:
 The binding-induced change in the MST signal can barely or not
at all be discriminated from the background ﬂuctuation.
Optimization:
 Improve the quality of the sample by optimizing the buffer or
spinning down the sample before the experiment (e.g. 5 min
at 15000  g) and only using the supernatant.
 Increase the IR-laser power to use a higher temperature
gradient.
 Reverse the assay design.
 Increase the activity of the ﬂuorescent sample.
3. Material and methods
3.1. TEM1-BLIP
Wt-TEM1 was labeled using the Monolith NT Protein Labeling
Kit RED (NanoTemper Technologies) according to the supplied pro-
tocol. The concentration of labeled TEM1 or Ypet-wt-BLIP was kept
constant at 10 nM. The corresponding unlabeled binding partner
was titrated in 1:1 dilutions, with the highest ﬁnal concentration
chosen about 20-fold above the KD expected from previously pub-
lished SPR results. Thus the highest ﬁnal concentrations were
250 nM wt-BLIP, 6 lM W112A-BLIP and 11 lM W150A-BLIP for
the experiments with wt-TEM-NT647. For the measurements with
Ypet-BLIP, maximum concentrations of 2 lM wt-TEM and 7.5 lM
R243A-TEM were used in buffer, 250 nM TEM in lysate.
A 50 mM Tris–HCl buffer, pH 7.6 containing 150 mM NaCl,
10 mM MgCl2 and 0.05% Tween-20 was used. For the measure-
ments in cell lysate, 20  106 millions 293T cells were lysed in
500 ll RIPA-buffer and centrifuged at 15,000  g for 5 min to re-
move large aggregates and cell debris. Ypet-BLIP was diluted in
200 ll lysate to a ﬁnal concentration of 20 nM and mixed withthe TEM1 dilution series in buffer to yield a ﬁnal Ypet-BLIP concen-
tration of 10 nM in 50% lysate.
Measurements were performed in standard treated capillaries
(NanoTemper Technologies) on a Monolith NT.115 system (Nano-
Temper Technologies) using 50% LED and 80% IR-laser power. Laser
on and off times were set at 30 s and 5 s, respectively.
3.2. RON2-AMA1
MST experiments were performed on a Monolith NT.115 system
(NanoTemper Technologies) using 100% LED and 20% IR-laser
power. Laser on and off times were set at 30 s and 5 s, respectively.
Recombinant His-tagged AMA1 (His-AMA1) was expressed in
Pichia and puriﬁed on a nickel column as previously described
[3]. The protein was labeled with NT647 (NanoTemper Technolo-
gies) and applied at a ﬁnal concentration of 25 nM. Both unlabeled
RON2 peptide and biotinylated RON2 peptide were synthesized by
LifeTein LLC (South Plainﬁeld, NJ). A twofold dilution series was
prepared for the unlabeled RON2 in DMSO. Subsequently, 0.5 ll
of each dilution point was transferred to 9.5 ll labeled AMA1-solu-
tion, with the ﬁnal RON2 concentration ranging from 50 lM to
1.5 nM, thus maintaining the DMSO concentration at 5% constant
sample-to-sample. Samples were ﬁlled into hydrophilic capillaries
(NanoTemper Technologies) for measurement. FITC labeled RON2
peptide was obtained from Peptide 2.0 (Chantilly, VA), further dis-
solved in DMSO to produce a 20 lM stock solution and applied at a
ﬁnal concentration of 10 nM. A twofold dilution series was pre-
pared for unlabeled His-AMA1 in PBS and each dilution point
was similarly transferred to FITC-RON2 solution. The ﬁnal concen-
trations of His-AMA1 ranged from 7.8 lM to 0.24 nM. Samples
were ﬁlled into standard treated capillaries (NanoTemper Technol-
ogies) for measurement.
SPR experiments were performed on a ProteOn XPR36 system
(Bio-Rad, Hercules, CA) at 25 C using PBS with 0.005% Tween-20
as the running buffer. Immobilization of the His-AMA1 protein
was achieved at 30 ll/min on an HTE chip. Samples of the unla-
beled RON2 peptide were prepared at ﬁnal concentration of
500, 167, 55, 18.5 and 6.2 nM and were injected at 30 ll/min in
each horizontal channel. Association was monitored for 2 min,
dissociation for 10 min. In a separate experiment, immobilization
of the biotinylated RON2 (b-RON2) peptide was achieved on a
NLC chip at 100 ll/min. Samples of the His-AMA1 protein were
prepared at 300, 100, 33, 11 and 3.7 nM and were injected at
30 ll/min in each horizontal channel. Association was monitored
for 2 min, dissociation for 30 min. Kinetic titration data were pro-
cessed in ProteOn Manager by concatenating the responses of all
ﬁve analyte concentrations, and by globally ﬁtting to either a sim-
ple Langmuir binding model without mass transfer or a heteroge-
neous ligand model using both buffer blank and interspot as
references.
FP experiments were performed on a Viewlux™ high-through-
put charge-coupled device (CCD) imager (PerkinElmer, Waltham,
MA) using an excitation ﬁlter of 480 nm and an emission ﬁlter of
540 nm. His-AMA1 was serially diluted in PBS with 0.01% Tween-
20 (ﬁnal concentration: 7.8 lM to 0.24 nM) and mixed with
20 nM FITC-RON2 peptide (ﬁnal concentration) in a 384-well
Greiner (Monroe, NC) solid bottom assay plate. Plates were read
after 5 min incubation at room temperature. For the reverse titra-
tion, biotinylated RON2 peptide was serially diluted in the same
buffer (ﬁnal peptide concentration started at 100 nM) and was
mixed with 25 nM (ﬁnal concentration) NT495-His-AMA1.
3.3. GPCR
A fusion construct of the rat neurotensin receptor 1, NTS1B,
with N- and C-terminal fusion partners, maltose binding protein
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scribed by Attrill et al. [40], with the modiﬁcation that the ligand
afﬁnity column eluate was concentrated using a 1 mL HisTrap
Ni2+-column (GE Healthcare), and the eluate thereof was diluted
in imidazole- and salt-free buffer (50 mM Tris pH 7.4, 0.1% dodecyl
maltoside (w/v), 0.01% cholesteryl hemisuccinate (w/v), 10% glyc-
erol (v/v)) to lower the imidazole concentration to 85 mM and
the sodium chloride concentration to 50 mM in the ﬁnal sample
to allow salt-sensitive ligand binding, giving a ﬁnal receptor con-
centration of 2.5 lM as determined from A280 and gel electro-
phoresis against BSA standards. SR48692 was obtained from
Sanoﬁ-Aventis and neurotensin was purchased from Sigma Al-
drich. A N-terminal cysteine derivative of neurotensin (Alta Biosci-
ence, Birmingham) was labeled with AlexaFluor488 (Sigma
Aldrich) by mixing the dye with a threefold excess of the peptide,
adjusting the pH to 7 and incubating for 1 h at room temperature.
The labeled compound was puriﬁed by HPLC using a 20–60% ace-
tonitrile gradient on a semi-preparative C18 column. Labeling
and purity were veriﬁed by mass spectrometry. Neurotensin-
A488 was lyophilised and subsequently stored in 50 mM Tris pH
7.4.
Twofold dilution series starting at 375 nM NTS1B in the stan-
dard MST experiments and 2.5 lM neurotensin as well as 25 lM
SR48692 in the label-free MST experiments were prepared in the
following buffer: 50 mM Tris pH 7.4, 0.1% dodecyl maltoside
(w/v), 0.01% cholesteryl hemisuccinate (w/v), 10% glycerol (v/v),
imidazole 85 mM and sodium chloride 50 mM. Neurotensin-
Alexa488 was used at 25 nM, while NTS1B was used at 150 nM.
As a control, the SR48692-dilution was tested against a constant
concentration of 150 nM thermally denatured NTS1. Due to the
fact that concentrations of the receptor in label-free MST experi-
ments were above the KD, the determined KD is a lower limit and
afﬁnity can be higher. Lowering receptor concentration will in-
crease resolution. Please note, in label-free experiments the detec-
tion limit (i.e. minimum concentration of the ﬂuorescent molecule)
depends not only on the number of tryptophanes, but also on their
respective position in the protein. Typically, concentrations as low
as 100 nM can be used [18]. The ﬁt to the quadratic solution of the
law of mass action allows to determine even higher afﬁnities than
that with high precision.
In the competition experiment, a constant neurotensin concen-
tration of 1 lM was used and SR48692 was diluted 1:1 starting at
50 lM. Label-free experiments were performed at 20% LED and
40% IR-laser power, standard MST experiments at 90% LED power
and 20% IR-laser power. Laser on and off times were set at 30
and 5 s, respectively.
The A2aR was stored and measured in 50 mM K-HEPES pH 7.5
buffer containing 800 mM KCl, 10% glycerol, 0.05% dodecyl malto-
side (w/v) and 0.01% cholesterol hemisuccinate (w/v). The concen-
tration of A2aR was determined by measuring protein peak area in
an analytical size exclusion chromatogram, and comparing it with
protein standards. For the label-free MST experiments, A2aR was
used at a constant concentration of 250 nM when testing
theophylline-binding and 500 nM in all other experiments. The
ligands were added to the buffers in the required concentrations
from a 100 mM stock in DMSO. Twofold dilution series of the
ligands were prepared, starting at the following concentrations
and resultant maximum DMSO concentrations: 250 lM for amilo-
ride (2.5‰ DMSO), 100 lM for theophylline (0.1% DMSO), 1 mM
for caffeine (1% DMSO) and 5 lM for ZM241385 (0.05‰ DMSO).
For the competition experiments in presence of 250 lM amiloride,
twofold dilution series of caffeine starting at 2 mM and theophyl-
line (2% DMSO) starting at 1 mM (1% DMSO) were used. Prior to
measurement, ligands were incubated with protein for 10 min on
ice. Experiments were performed at 20% LED and 20% IR-laser
power with laser on and off times set at 30 and 5 s, respectively.3.4. G9a
G9a was labeled with NT495 or NT647 dye (NanoTemper Tech-
nologies) and applied at a ﬁnal concentration of 50 nM in 50 mM
Tris–HCl, pH 7.5, with 150 mM NaCl and 0.05% Tween-20.
BIX-01294 was obtained from Sigma–Aldrich (St. Louis, MO) and
further dissolved in dH2O to produce a 30 mM stock. A 16-point
twofold dilution series (in dH2O) of BIX-01294 was mixed with
G9a solutions to generate a ﬁnal compound concentration ranging
from 500 lM to 15.3 nM. Peptides corresponding to the ﬁrst 21N-
terminal amino acids of histone H3 followed by a GG linker and a
biotinylated lysine (b-H3(1–21)) were purchased from AnaSpec
(Fremont, CA). b-H3(1–21) was similarly diluted in dH2O and
mixed with labeled G9a to generate a ﬁnal concentration ranging
from 183.6 lM to 5.6 nM. After 15-min incubation at room tem-
perature, samples were ﬁlled into standard treated capillaries
(NanoTemper Technologies) and MST measurements were per-
formed on a Monolith NT.115 (NanoTemper Technologies) using
100% LED (50% LED for NT647-G9a) and 20% or 40% IR-laser power.
Laser on and off times were respectively set at 30 and 5 s. For com-
petition experiments, labeled G9a was pre-mixed with a constant
concentration of b-H3(1–21) or S-adenosylmethionine (SAM) and
incubated at room temperature for 15-min. Either compound
was added at a concentration near its respective KD (determined
using MST for the peptide substrate or based on literature value
for SAM [67,69,70]): 2 lM b-H3(1–21) or 20 lM SAM. In a separate
experiment, either compound was added at a saturating level (15–
50-fold above its KD): 100 lM b-H3(1–21) or 300 lM SAM. The
same dilution series of BIX-01294 was added to the pre-formed
G9a-b-H3(1–21) or G9a-SAM complex, and MST was measured
after 15-min incubation at room temperature.
The interaction between G9a and BIX-01294 was also evaluated
using a label-free approach. Speciﬁcally, a 16-point serial dilution
of BIX-01294 was mixed with G9a (ﬁnal concentration: 2 lM) with
BIX-01294 ﬁnal concentration ranging from 200 lM to 6.1 nM.
Samples were ﬁlled into LabelFree standard treated capillaries
(NanoTemper Technologies) and measured on a Monolith
NT.LabelFree (NanoTemper Technologies) using 30% LED and 25%
IR-laser power. Laser on and off times were also set at 30 and
5 s, respectively.4. Results and discussion
Studying protein interactions can be challenging in certain
cases. Problems arise from high mass ratios of the binding partners
as in the case of protein-small molecule interactions. Membrane
proteins are experimentally demanding, as they are hard to stabi-
lize in solution. Measuring cooperative and competitive binding
modes as well as working in biological liquids instead of simpliﬁed
buffers can be difﬁcult. In the following we demonstrate that MST
is applicable under all mentioned challenging conditions by show-
ing previously unpublished data and highlighting relevant exam-
ples from literature.4.1. Protein–protein interactions
4.1.1. b-Lactamase TEM1 binds its inhibitor BLIP
Protein–protein binding is mainly based on speciﬁc non-cova-
lent interactions at the binding partners’ interfaces. The contribu-
tion of different amino acid residues can be elucidated by
quantifying the inﬂuence of site-speciﬁc mutations. An in this
respect well-characterized system is the binding of b-lactamase
TEM1 to the b-lactamase inhibitory protein BLIP. Herein, we inves-
tigated the binding of TEM1 b-lactamase to BLIP using MST.
-80
-60
-40
-20
0
F n
o
rm
 [‰
]
1 10 100
Concentration wtBLIP [nM]
wt-TEM1-NT647 binds
 wtBLIP
 
-15
-10
-5
0
5
F n
o
rm
 [‰
]
100 101 102 103
Concentration W112A-BLIP [nM]
wt-TEM1-NT647 binds
 W112A-BLIP
200
150
100
50
0
F n
o
rm
 [‰
]
102 103 104
Concentration W150A-BLIP [nM]
wt-TEM1-NT647
 W150A-BLIP
A B
C D
20
10
0
-10
F n
o
rm
 [‰
]
10-1 100 101 102 103
Concentration ligand [nM]
Ypet-wt-BLIP binds
 wtTEM
 R243A-TEM
 wtTEM in lysate
Fig. 2. MST quantiﬁes the TEM1-BLIP interaction in agreement with SPR literature values. (A) By ﬁtting the change in thermophoretic depletion upon titration of wt-BLIP to a
constant amount of wt-TEM1 labeled with the ﬂuorescent dye NT647 to the quadratic solution of the mass action law, a binding constant of KD = 3.8 ± 0.8 nM was
determined. (B) TheW112A-mutation in BLIP reduces the afﬁnity to TEM1 to 0.5 ± 0.1 lM. (C) W150A-BLIP binds TEM1 with an even lower afﬁnity of KD = 1.7 ± 0.4 lM. (D) In
a reversed assay design, the concentration of the fusion protein Ypet-wt-BLIP was kept constant while titrating in wt-TEM1. In concordance with the binding curve shown in
A, a KD of 4.8 ± 1.7 nMwas determined (black circles). Mutated R243A-TEM1 showed a lower afﬁnity of KD = 0.19 ± 0.05 lM (red triangles). In cell lysate, the KD between Ypet-
wt-BLIP and wt-TEM1 was quantiﬁed as 10 ± 4 nM, thus demonstrating the applicability of MST for measurements in complex bioliquids. Notably, the sign of the MST signal
amplitude is changed in lysate compared to buffer due to differences in pH, ionic strength etc.
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of NT647-labeled wild-type TEM1 (wt-TEM1). Binding to wild-type
BLIP (wt-BLIP) as well as to two BLIP mutants with substitutions of
a tryptophan residue at position 112 or 150 by alanine (W112A-
BLIP, W150A-BLIP) was quantiﬁed. MST yielded a KD of
3.8 ± 0.8 nM for the interaction of the wt-proteins (Fig. 2A). As ex-
pected, the alanine substitutions within BLIP resulted in reduced
afﬁnities for TEM with a KD of 0.5 ± 0.1 lM in the case of
W112A-BLIP and a KD of 1.7 ± 0.4 lM in the case of W150A-BLIP
(Fig. 2B and C). Due to limited sample amounts W150A-BLIP satu-
ration was not fully reached which affects the precision of the ﬁt.
Nonetheless, both results are in excellent agreement with the liter-
ature values of 3.2 ± 0.6 nM (wt) [26], 0.36 ± 0.06 lM (W112A) and
3.8 ± 0.6 lM (W150A) [27] determined by SPR. Remarkably, the
thermophoretic signal seems to contain further information on
the binding event. Upon binding of wt-BLIP and W112A-BLIP to
TEM1, the complex shows an increased depletion compared to
the unbound TEM1, represented by the negative slope of the bind-
ing curve (Fig. 2A and B). Binding of W150A-BLIP has the opposite
effect (Fig. 2C). As described by Wang et al., the W150A mutation
in BLIP leads to a pronounced conformational rearrangement, thus
to defects in geometrical shape complementarity to TEM1 and
trapping of additional water molecules in the TEM1-BLIP interface.
Therefore, the enthalpic driving force for binding decreases [28].
This conformational change likely causes the reversal in sign of
the MST-amplitude.
We also used an alternative labeling approach in combination
with the reversed titration protocol. The ﬂuorescent fusion protein
Ypet-wt-BLIP was kept constant while wt-TEM1 and R243A-TEM1
(substitution of arginine at position 243 to alanine) were titrated
(Fig. 2D). For the interaction of the wt-proteins a KD of 5 ± 2 nM
was determined which does not only reproduce the literature va-
lue (3.5 ± 0.5 nM, SPR) [29] but also the result measured via the re-
versed assay design. The R243A-TEM1 mutant showed a reducedafﬁnity for BLIP (KD = 0.19 ± 0.05 lM) which is consistent with lit-
erature [30]. As measurements in buffer do not resemble the highly
crowded, intracellular environment, we also performed MST in
mammalian cell lysate. Under these close to in vivo conditions, a
KD of 10 ± 4 nM was determined for the binding of Ypet-wt-BLIP
to wt-TEM1. This demonstrates the applicability of MST for afﬁnity
quantiﬁcation of protein–protein interactions, not only in buffer,
but also in cell lysate.
4.1.2. Grb2 dimerization
Grb2 is known as an adaptor protein involved in several signal
transduction pathways [31]. An additional function has been re-
cently suggested: Grb2 dimers seem to control the activity of the
receptor tyrosine kinase FGFR2 in the absence of extracellular
stimuli by growth factors [1].
The dimerization of Grb2 was analyzed via MST. Fluorescently
labeled Grb2 at a constant concentration of 100 nM was added to
a serial dilution of unlabeled Grb2 ranging from 55 nM to
100 lM. A KD of 0.65 ± 0.08 lMwas determined for Grb2 dimeriza-
tion (Fig. 3). DLS experiments indicate that the dimer is the pre-
dominant form from 40 down to 0.4 lM, whereas below that
concentration, the monomer was present [1]. The MST result is
consistent with DLS, which as discussed in Section 1.2. is most reli-
able when studying the interaction of small, equally sized mole-
cules as it merely detects changes in the hydrodynamic radius.
Also, when measuring dimerization, MST is comparable to DLS in
that the twofold size increase is likely to be the major cause of
the decrease in thermophoretic mobility. In general, quantiﬁcation
of a dimerization process is not trivial. Although dimerization
can also be quantiﬁed via a dilution approach in ITC for KDs in
the lM-range [32], the technique is not feasible for higher dimer-
ization afﬁnities. ITC requires minimal protein concentrations in
the lM-range to get a measurable heat change [8]. If the dimeriza-
tion KD lies in the sub-lM range as for Grb2, nearly all of the
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Fig. 3. Grb2 dimerization quantiﬁed thermophoretically. Unlabeled Grb2 is titrated
to a constant amount of ﬂuorescently labeled Grb2-NT647. Dimerization causes a
change in thermophoresis from which a KD of 0.65 ± 0.08 lM was derived. MST
allows the usage of protein concentrations far below this KD-an obligatory
prerequisite for dimerization quantiﬁcation. Figure adapted with permission from
Lin et al. [1].
S.A.I. Seidel et al. /Methods 59 (2013) 301–315 309protein is present as dimers at this lowest detectable concentration
(Fig. 3). Thus the monomeric state and the monomer–dimer-tran-
sition are not captured and the KD is not measurable via ITC.25
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Fig. 4. The AMA1-RON2 binding analyzed via MST, SPR and FP. (A) Titration of the AMA
signal change (KD = 28 ± 2 nM). (B) Titrating the peptide (4.3 kDa) to a constant AMA1-NT
The signal indicated a biphasic event. Fitting the high afﬁnity phase (blue) reveals a KD
phase (red) yields a KD of 1.4 ± 0.2 lM, which putatively results from the binding of a non-
one ﬁt function assuming two binding events is used. This yields similar KDs of 81 ± 21 nM
of AMA1 yields KD = 13 ± 1 nM conﬁrming MST. (D) Via the reversed SPR assay design,
dissociation phase best, thus also indicating a biphasic event as observed in MST. (E)
48 ± 11 nM). (F) Titrating the small peptide instead reduces the FP signal amplitude sign
points were omitted because they appeared to represent the onset of a second phase in4.2. Protein-peptide interaction: AMA1 and RON2
The invasion of red blood cells by the malaria-causing parasite
Plasmodium falciparum is critically dependent on the interaction
of two parasite proteins, RON2 and AMA1 [3,33,34]. To quantify this
interaction, the binding between a short RON2 peptide and AMA1
was extensively characterized using MST, SPR and FP. The RON2
peptide represents a conserved region among all P. falciparum
isolates with known sequence; in this region, two completely con-
served cysteine residues forming a disulﬁde bridge have been
determined to be essential for binding to AMA1, as mutation or
alkylation abolished binding [3].
We used two MST-assay designs for the AMA1-RON2 interac-
tion: titration of AMA1 to a constant concentration of RON2-FITC
and titration of RON2 to a constant concentration of AMA1-
NT647. When titrating AMA1, the MST signal shows a single
binding event with a KD of 28 ± 2 nM. In contrast, the titration of
RON2 yielded an MST signal in which the high afﬁnity binding is
superimposed by a second binding event at higher RON2 concen-
trations. When quantifying the high-afﬁnity binding from these
data, we restricted the ﬁt to the ﬁrst half of data points yielding-15
-10
-5
0
5
F n
o
rm
 [‰
]
101 102 103 104
Concentration RON2 [nM] 
100
80
60
40
20
0
R
es
po
ns
e 
[R
U]
6004002000-200
Time [s]
RON2
 500 nM
 167 nM
 55 nM
 18.5 nM
 6.2 nM
MST:
AMA1-NT647 binds
         RON2
SPR:
250
245
240
235
FP
 [m
P]
0.1 1 10 100
Concentration RON2 [nM]
FP:
AMA1-NT495 binds
         RON2
1 protein to a constant amount of RON2-FITC peptide induces a pronounced MST
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cyclized RON2 population. Inset: Instead of two independent ﬁts for the two phases,
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Fig. 5. Label-free MST for quantiﬁcation of GPCR NTS1B ligand binding. (A) Homology model of neurotensin receptor 1 (NTS1; Satita Tapaneeyakorn, Biomembrane structure
unit, University of Oxford) based on rhodopsin for the transmembrane regions and the b-adrenergic receptors for the loop regions viewed from the side (left) and top (right).
Residues involved in binding of neurotensin (W339, F344 and Y347, cyan), inverse agonist SR48692 (Y324, Y351, T354, F358 and Y359, green) or both (M208, F331 and R327,
magenta), as determined from mutagenesis studies [71], are highlighted. (B) Label-free MST utilizes NTS1B’s intrinsic Trp ﬂuorescence to quantify the binding to neurotensin
(KD 6 20 nM). (C) In agreement with other biophysical techniques, MST using ﬂuorescently labeled neurotensin yields a lower afﬁnity (KD = 21 ± 20 nM). (D) Using label-free
MST, a KD of 15 ± 11 nM for the inverse agonist SR48692 was determined (black circles). Pre-saturating NTS1 with neurotensin right-shifts the KD for SR48692 to 640 ± 50 nM
(red squares). Denatured NTS1B did not show binding to SR48692 thus proving speciﬁcity (blue triangles).
310 S.A.I. Seidel et al. /Methods 59 (2013) 301–315a KD of 62 ± 16 nM. Fitting the low-afﬁnity binding yielded
KD = 1.4 ± 0.2 lM. We also analyzed all data points with a ﬁt
assuming two independent binding events with different KDs,
where we used the simpliﬁcation that both binding events have
the same signal amplitude. This ﬁt yielded KDs of 81 ± 21 nM and
1.2 ± 0.1 lM.
The KD determined for the high-afﬁnity AMA1-RON2 interac-
tion varies for the different MST designs. This is because in case
of the biphasic signal, the high-afﬁnity KD is either determined
by ﬁtting less data points or by using a ﬁt function with an addi-
tional parameter, the second low-afﬁnity KD. Despite this limita-
tion, the KDs for the high-afﬁnity binding lie in the double-digit
nanomolar range for both assay designs, which demonstrates the
method’s reversibility. However, the example also shows theA
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Fig. 6. Label-free MST for quantiﬁcation of GPCR A2aR ligand binding. (A) Binding of
(KD = 5 ± 2 lM; red squares) and ZM241385 (KD 6 43 nM; blue triangles) to A2aR induce
binding (KD = 52 ± 7 lM; green inverted triangles) leads to a much larger MST signal am
amplitudes were obtained for the binding of caffeine and theophylline in presence of sa
84 ± 10 lM for caffeine and 27 ± 6 lM for theophylline.importance of performing the assay in both ways: while AMA1-
titration is needed to precisely quantify the KD, only the titration
of RON2 gave additional information on a second, low-afﬁnity
binding event.
In SPR, when AMA1 was titrated against a constant level of
immobilized RON2, a KD of 13 ± 1 nM (Fig. 4C) was found. The
reversed assay design of titrating the same RON2 species as used
in MST experiments yielded a KD of 38.3 ± 0.4 nM (Fig. 4D). The dis-
sociation phase in the SPR data was best ﬁt by a heterogeneous
ligand model, indicative of the same second, low-afﬁnity binding
phase captured in (Fig. 4B and D).
This second binding event could be explained by the fact that
the unlabeled RON2 peptide might be present in two forms in solu-
tion: one with and one without a disulﬁde bond, i.e. a cyclized andB
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s a comparably small change in thermophoretic mobility. (B) In contrast, amiloride-
plitude, thus indicating conformational changes upon binding. Comparable signal
turating amiloride concentrations, where the apparent afﬁnities were decreased to
S.A.I. Seidel et al. /Methods 59 (2013) 301–315 311a linear from. As the second binding phase is not present in the
reversed assay design (Fig. 4A), the labeled RON2 seems to be
homogeneously cyclized.
An EC50 of 0.05 ± 0.01 lM was obtained by FP experiments
where AMA1 titration was performed against a constant concen-
tration of labeled RON2 as illustrated in Fig. 4E. As expected, the re-
versed assay design, in which biotinylated RON2 was titrated
against a constant level of labeled AMA1, yielded a much smaller
FP signal amplitude (Fig. 4F). This is because the FP signal ampli-
tude is largely based on the degree of binding-induced size change.
Nevertheless, the observed EC50 also lies in the double-digit nano-
molar range (77.1 ± 0.2 nM).
This AMA1-RON2 case study shows, ﬁrstly, that MST can yield
KD data very comparable to that obtained by other well-established
biophysical methods, including FP as a solution-based and SPR as a
solid-phase technique. All KDs lie in the double digit nM-range. SPR
yielded slightly higher afﬁnities than MST. However, it has previ-
ously been described, that due to surface artifacts SPR tends to
overestimate the afﬁnity compared to other techniques [35]. Sec-
ondly, the experiments also exhibited the ability of MST to detect
binding even when the assay was set up in a relatively less favor-
able manner in terms of size change upon binding: when the larger
molecule AMA1 (66 kDa) was labeled and was held constant, titra-
tion of the smaller peptide (4.3 kDa) yielded a similar high-afﬁnity
binding phase as that obtained in the reverse titration. Thirdly, for
this particular system, ﬂuorescent labeling of either binding part-120
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Fig. 7. Lipid and Ca2+-binding to synaptotagmin-1 by MST. (A) Scheme of the binding inte
(grey). Note the two possible binding pathways A1–A2 and B1–B2. (B) Membrane binding
concentration). The apparent binding constants were 50 ± 10 and 13 ± 3 lMPIP2 in the ab
for details). (C) Cooperative Ca2+ and PIP2 binding to synaptotagmin-1. Ca2+ and PIP2 b
dimensional MST curve, respectively. In the presence of saturating concentrations of
Accordingly, in the presence of saturating Ca2+ concentrations, the apparent PIP2 bind
from [56].ner did not adversely affect the binding event, i.e. did not give
rise to a signiﬁcant change in the KD or assay artifacts such as
non-speciﬁc binding to the ﬂuorescent label. An interesting and
more speciﬁc aspect of this system is the observation of a second
binding phase that most likely reﬂects the prescence of both, a
cyclized and an linear form of the unlabeled RON2 peptide. How-
ever, difﬁculties associated with the production and handling of a
fully-reduced/linear peptide precluded us from performing care-
fully controlled experiments comparing MST and SPR responses
derived from fully-cyclized and fully- linear peptide counterparts;
thus, the proposed explanation for the observed biphasic behavior
remains speculative at this point. Overall, the AMA1-RON2 case
study illustrates that MST is a sensitive and versatile biophysical
technique for protein-peptide interaction studies. We note that
while the RON2 peptide represents a good model system to study
the interaction by a range of biophysical techniques without the
added encumbrance brought about by the need to produce a sec-
ond protein, these initial ﬁndings need to be further validated
through a study using the intact protein pair.
4.3. Analyzing GPCR membrane proteins NTS1 and A2aR
Membrane proteins make up a third of the proteome and con-
stitute the majority of drug targets. Their biological importance
notwithstanding, they are extremely challenging to work with. G
protein-coupled receptors (GPCR) are the largest class of mem-103 104 105
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312 S.A.I. Seidel et al. /Methods 59 (2013) 301–315brane proteins encoded in the human genome [36] and share a
common architecture (Fig. 5A): a bundle of seven transmembrane
(7TM) helices connected by ﬂexible loop regions. Even though
structural data is still scarce it has become apparent that while
the 7TM fold is conserved, there is remarkable structural diversity
particularly at the extracellular ligand binding side of the proteins
[37]. Clearly, a combination of structural knowledge, ligand dock-
ing [38,39] and fast and reliable technologies for measurement of
ligand binding afﬁnities are necessary and indispensable tools for
next generation drug discovery efforts. Typically, ligand binding
of GPCRs is studied by radioligand binding assays. However, the
availability of radioligands is frequently a limiting factor. MST
could provide a good alternative to determining the afﬁnities of li-
gands without the need for radioligands.
Neurotensin receptor 1 (NTS1) is one of the few class A GPCRs
that can be expressed in E. coli and puriﬁed in a functional, li-
gand-binding form [40]. Using MST we determined the binding
afﬁnity of the tridecapeptide ligand neurotensin for a fusion con-
struct of NTS1, NTS1B [41]. Titrating NTS1B to AlexaFluor488-
labeled neurotensin gave a KD of 21 ± 20 nM (Fig. 5C). Due to
limited amounts of NTS1B protein, saturation could not be reached,
which affects the precision of the ﬁt. Thus, we also used the re-
versed protocol yielding KD 6 20 nM (Fig. 5B). The intrinsic UV-
ﬂuorescence of NTS1B was exploited and the ligand was titrated,
so that saturation was reached. The MST results are in good agree-
ment with previous SPR data showing a dissociation constant of
1–2 nM for the binding of neurotensin to an NTS1 fusion construct,
[42] while slightly lower afﬁnities have previously been found for a
ﬂuorescently labeled (TAMRA) neurotensin derivative by ﬂuores-
cence correlation spectroscopy (KD = 7 ± 3 nM, Harding, unpub-
lished results), although other ﬂuorophores did not affect the
afﬁnity (KD = 1.4 nM for Cy5-neurotensin) [43]. KD dependence on
the choice of ﬂuorophores has previously been observed for other1.2
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Fig. 8. MST analysis of small molecule binding to G9a. (A) The speciﬁc interaction of the
well as standard MST with a NT495-label (black circles), where the results were in excelle
reported ITC measurements. (B) The afﬁnity of the peptide b-H3(1-21) to both G9a-NT
identical KDs (1.5 ± 0.4 lM for G9a-NT495 and 1.5 ± 0.2 lM for G9a-NT647). (C) Pre-in
4 ± 1 lM in presence of 2 lM (red squares) and to 37 ± 7 lM in presence of 100 lM of th
contrast, addition of SAM in concentrations of 20 lM (KD = 1.4 ± 0.3 lM, red squares) and
KD of BIX-01294 to G9a.ﬂuorescent ligand derivatives as well [44]. We also studied binding
of a known inverse agonist, SR48692, to NTS1B and obtained a KD
of 15 ± 11 nM using label-free MST (Fig. 5D). This value is in good
agreement with the afﬁnities reported in literature obtained for
NTS1 in membrane extracts (KD  3-10 nM [45,46]). A competition
assay in which we added SR48692 to receptor pre-saturated with
neurotensin (1 lM) shifted the dissociation constant more than
an order of magnitude (KD = 0.64 ± 0.05 lM; Fig. 5D), conﬁrming
speciﬁcity of binding and that both compounds compete for the
same binding pocket (Fig. 5A). Non-speciﬁc binding was further
excluded by performing a control experiment with denatured
receptor. Interestingly, binding of the agonist neurotensin has an
opposite effect on the thermophoretic depletion compared to bind-
ing of the inverse agonist SR48692. This could be due to the differ-
ent structures of the binding partners, however, considering the
small size of both ligands (<2 kDa) compared to the receptor
(100 kDa), it could even reﬂect the different structural effects the
agonist and the inverse agonist have on the receptor, with neuro-
tensin promoting conformational changes, while SR48692 locks
the receptor in an inactive conformation, giving rise to differences
in the hydration shell and thus in the thermophoretic properties of
the complex.
As a second type of GPCR, we tested the adenosine A2A receptor
(A2aR) expressed and puriﬁed as a fusion with apocytochrome
b562RIL as previously described [47]. We used label-free MST to
analyze the binding of three orthosteric antagonists, caffeine, theo-
phylline and ZM241385, and one allosteric ligand, amiloride. The
afﬁnities for these ligands have been previously determined as
Ki = 18 lM for caffeine, [48] Ki = 14 lM for theophylline, [49,50]
Ki = 1.2 nM for ZM241385, [51] and Ki = 12 lM for amiloride (Kat-
ritch et al., manuscript in preparation). These Ki values are based
on heterologous competition of radioligands and inhibition of bio-
logical function and can thus only give an approximate indication1.0
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S.A.I. Seidel et al. /Methods 59 (2013) 301–315 313of the KD determined via a direct, biophysical measurement like
MST. However, we obtained KDs that were in good accordance:
40 ± 17 lM for caffeine, 5 ± 2 lM for theophylline, 643 nM for
ZM241385 and 52 ± 7 lM (Fig. 6A) for amiloride (Fig. 6B). Amilo-
ride was not used at concentrations above 250 lM due to solubility
problems. This affects the precision of the ﬁt. The signal amplitude
for the three orthosteric ligands was low. In contrast amiloride, an
allosteric ligand that binds to a different site from caffeine and the-
ophylline [51], induced a strong change in thermophoretic mobil-
ity, shown in Fig. 6B. Allosteric ligands are known to alter
receptor activity by inducing conformational changes [52]. As
amiloride is similar in size to the other tested ligands, the much
stronger change in thermophoretic mobility upon binding is likely
to be caused by this signiﬁcant conformational change leading to a
reorientation of the receptor’s hydration shell. Addition of caffeine
and theophylline in presence of saturating amounts of amiloride
also had a strong but opposite effect on thermophoresis, indicating
non-competitive binding that also produced signiﬁcant conforma-
tional change. Apparent KDs of 84 ± 10 lM for caffeine and
27 ± 6 lM for theophylline were derived. Hence, label-free MST
can also be used to investigate allosteric binding in GPCRs.
This study demonstrates that MST can be used as a quick, sen-
sitive tool to measure binding afﬁnities for difﬁcult systems such
as GPCRs which suffer from low expression yields and protein
instability. In addition to the pharmaceutical importance of know-
ing binding afﬁnities, biophysical studies of membrane proteins of-
ten require truncations or addition of fusion partners to improve
stability and expression, or mutations to facilitate labeling for var-
ious techniques. Being able to easily assess the effect of these mod-
iﬁcations on the ligand binding capacity to verify the validity of the
approach used is invaluable. In comparison to most commonly
used techniques, the low sample requirements and the simplicity
of the mix-and-read protocol make MST more suited for such rou-
tine binding afﬁnity analyses. Compared to alternative techniques
such as SPR, MST suffers less from the need for rigorous buffer con-
trols, which can be problematic for membrane proteins in deter-
gent where the exact protein concentration and especially the
detergent concentration can be difﬁcult to determine.
4.4. Cooperative binding within the ternary complex: synaptotagmin
Synaptotagmin-1 (syt1) is the main Ca2+-sensor for fast
calcium-regulated neurotransmitter release [53]. It binds ﬁve
Ca2+-ions with afﬁnities ranging from 50 lM to 10 mM as mea-
sured by NMR and ITC [54,55]. Ca2+-binding was reproduced by
MST using hydrophobic capillaries and 2.5 mg/ml BSA in order to
overcome association of syt1 with the capillaries. An apparent
binding afﬁnity of 210–230 lM was determined by MST [56,57].
Syt1 also binds to membranes containing anionic phospholipids
such as phosphatidylinositol 4,5-bisphosphate (PIP2) and this
binding is important for its function (Fig. 7A). Binding to PIP2 oc-
curs already in absence of Ca2+ as shown by membrane binding
co-sedimentation assays in density gradients with a cytoplasmic
fragment of syt1 and artiﬁcial liposomes [58]. However, precise
quantiﬁcation of membrane binding is limited because co-
sedimentation assays do not report binding under equilibrium
conditions. This problem was overcome in a recent study where
Förster resonance energy transfer (FRET) was measured from
syt1 labeled with a donor ﬂuorophore to liposomes tagged with
an acceptor ﬂuorophore [59]. Since close proximity between the
two ﬂuorophores is required for FRET (typically well below
5 nm), the results of FRET-based assays fundamentally depend on
the labeling positions and binding orientations of syt1 to the
membrane.
MST does not suffer from these limitations and allows to mea-
sure membrane binding under equilibrium conditions irrespectiveof the precise labeling of syt1 (Fig. 7B). Indeed, binding of the
labeled syt1 to 100 nm-sized PIP2-containing liposomes resulted
in a clear change of the MST signal. As apparent from Fig. 7B, the
binding strength of syt1 to PIP2-containing liposomes was 5-fold
enhanced in the presence of Ca2+ with readily distinguishable
KD-values (50 ± 10 lM in the absence and 13 ± 3 lM in the pres-
cence of Ca2+). The addition of Ca2+ was the only change in an
otherwise identical MST assay design. Therefore, the change in
KD most likely reﬂects the inﬂuence of Ca2+ on the KD. Similar coop-
erative Ca2+ and PIP2 binding was previously observed with co-
sedimentation assays and FRET [55,58]. However, all these assays
(including the MST assay shown in Fig. 7B) suffer from the limita-
tion that Ca2+-binding is not directly measured, but only inferred
from binding to the liposomes. Thus, in these assays, Ca2+ and
PIP2 binding cooperativity can only be measured in case syt1 ﬁrst
binds to (sufﬁcient) Ca2+ prior to membrane binding (pathway
A2–A2 in Fig. 7A) and cannot be distinguished in case syt1 already
binds to PIP2 in absence of Ca2+ (pathway B1–B2).
In order to measure binding of Ca2+ to syt1 under saturating
conditions of PIP2, we adapted our MST assay and added PIP2
not incorporated into liposomes but directly to the capillaries.
Due to the high charge of PIP2 (between 3 and 5) [59] even
brain-isolated PIP2 (i.e. with long acyl chains) is water soluble up
to several mM [60] and short chain fatty acid analogs (such as
C8-PIP2) have even higher solubilities and micelle concentrations.
By direct addition of PIP2 to the capillaries, the full multidimen-
sional binding spectrum of Ca2+ and PIP2 could be determined with
a single set of MST experiments (Fig. 7C). In the presence of satu-
rating concentrations of PIP2 (>10 lM), the apparent binding afﬁn-
ity for Ca2+ was increased more than 40-fold [56]. This interplay
between Ca2+, PIP2 and syt1 has profound implications for the
mechanisms of neurotransmitter release.
4.5. Competitive small molecule binding to histone methyltransferase
G9a
The histone methyltransferase (HMT) G9a plays a crucial role in
epigenetic regulation and has been implicated in cancer [61]. Thus,
G9a inhibitors are expected to exert synergistic effects in epige-
netic cancer therapy. A potent new G9a modulator is UNC0321,
[62] a BIX-01294 analog. The latter was originally identiﬁed as a
G9a inhibitor with an IC50 ranging from sub-lM (Thioglo assay
and AlphaScreen assay) [63] to low lM (DELFIA format) [64].
Through an antibody-based time-resolved ﬂuorescence assay,
BIX-01294 was found to be the ﬁrst non-peptidomimetic com-
pound that inhibited G9a in a non-competitive mode versus the
methyl donor, S-adenosyl-L-methionine (SAM) [64]. Furthermore,
it was conﬁrmed by co-crystallization with G9a-like protein that
BIX-01294 acted as a competitive inhibitor for the peptide sub-
strate [65]. Despite the availability of several different assay for-
mats to measure HMT activity [66], direct or competition binding
assays for HMTs and their potential inhibitors have been largely
limited to FP, ITC or differential scanning ﬂuorimetry (DSF) exper-
iments [63]. Thus, MST could provide further information on the
G9a system by assessing the direct interaction between the protein
and BIX-01294, the protein and its cognate substrate peptide, and
the mode of action of BIX-01294 versus both the peptide and the
cofactor.
We ﬁrstly evaluated the afﬁnity of BIX-01294 for G9a via MST.
We obtained a KD of 0.7 ± 0.2 lM in both the label-free approach
and using NT495-labeled G9a (Fig. 8A), which demonstrates, that
the label did not have an inﬂuence on the binding. The values are
in the same general range established by the enzymatic IC50 values
for the compound (reported in multiple papers and summarized in
Liu et al. 2009 [63] to be between 1.7 and 1.9 lM) and the ITC-
derived KD of 0.13 lM (reported in Liu et al. 2009 [63]). This further
314 S.A.I. Seidel et al. /Methods 59 (2013) 301–315validates both of our MST assays and showcases the ability of MST
to detect binding interactions between proteins (G9a; 32.6 kDa)
and small molecules (BIX-01294; 490.6 Da) in spite of the extreme
size ratio. We subsequently studied the binding of G9a, labeled
with either NT495 or NT647, to its cognate peptide substrate, a bio-
tinylated histone peptide (b-H3(1–21)). Both labeled G9a versions
yielded identical KDs, with the former giving a KD of 1.5 ± 0.4 lM
and the latter a KD of 1.5 ± 0.2 lM (Fig. 8B). These values are in
close agreement with the KMs reported for similar peptide sub-
strates against mammalian G9a [67]. Next, we investigated the
mode of inhibitory action of BIX-01294 with respect to either the
peptide substrate b-H3(1–21) or the SAM cofactor. Prior to BIX-
01294 titration, each component was pre-incubated with NT495-
G9a at either a concentration near its respective KD or at saturating
amounts. The results were compared to BIX-01294-G9a binding in
absence of the components. As expected, the apparent KD for BIX-
01294 against G9a was reduced upon increasing concentrations of
b-H3(1–21), suggesting that the compound was competing with
the peptide for binding to the histone binding site (Fig. 8C). In con-
trast, the addition of increasing concentrations of SAM had little
effect on the compound’s afﬁnity for G9a (Fig. 8D), indicating that
the compound was not competing with SAM. These results are in
good agreement with previous enzyme kinetic [64] and co-crystal-
lization studies [65] aimed at elucidating the ligands’ mode of
action. In summary, the G9a case study demonstrates that MST
not only provides enough sensitivity to quantify protein-small
molecule interactions but also yields binding afﬁnities that are
comparable with those obtained from well-established methods,
such as ITC. Moreover, MST has clearly been shown to be able to
offer insight on the mode of action of small molecules versus the
target protein’s native substrate or cofactor.5. Conclusion
We successfully used MST to quantify the interaction of differ-
ent proteins with a variety of binding partners. In all cases, the
determined KDs were in agreement with results obtained by other,
well-established biophysical techniques for protein interaction
analysis. As MST is a capillary based format and binding-induced
changes in thermophoretic mobility are detected via ﬂuorescence,
ll–volumes and low nM–concentrations are sufﬁcient. This results
in small sample consumption and allows direct quantiﬁcation of
high afﬁnity protein dimerization as in the case of Grb2. The
measured KD of 0.7 lM lies well below the minimally usable,
lM-concentrations for ITC [8]. The monomeric state and mono-
mer–dimer-transition of Grb2 would not be captured and quantiﬁ-
cation via ITC would not be possible.
The free solution approach of MST avoids immobilization proce-
dures and possible surface artifacts. Labeling artifacts can be
excluded entirely by using label-free MST, which only requires a
sufﬁcient intrinsic UV-ﬂuorescence of the protein binding partner.
In standard MST, the use of different ﬂuorescent labels provides a
means of excluding labeling effects as demonstrated for G9a-bind-
ing to b-H3(1-21). Additionally, the ﬂuorescent label can be at-
tached to either of the binding partners to test for possible label-
dependent changes of the binding behavior as shown in the
AMA1-RON2 experiment. This reversibility in assay design results
from the fact that thermophoresis is sensitive to various molecular
properties and thus, MST, in contrast to DLS, FP and SPR, does not
rely on size changes alone and is not limited by the molecular
weight ratio of the binding partners. The strongly preferred assay
design for SPR and FP, on the other hand, is to measure interactions
by titrating the larger binding partner to a constant amount of the
smaller one. However, labeling or immobilizing the smaller ligand
bears a higher risk of changing its properties, as the label or anchoris large compared to the ligand. For MST, the reversed assay design
of measuring the binding of an unlabeled small molecule to a much
bigger, ﬂuorescent protein works equally well, as illustrated by the
G9a-BIX-01294 interaction analysis and the label-free GPCR bind-
ing studies.
The solution, in which the MST experiment is performed, can be
chosen freely to meet the sample’s speciﬁc buffer requirements.
This is invaluable when working with membrane proteins like
GPCRs, which typically require strictly optimized buffer conditions
and detergents to be stabilized in solution. In addition to buffers
with all kinds of additives, proteins embedded in liposomes can
be analyzed via MST as well, as demonstrated by the syt1-mea-
surement. MST can also be performed in complex bioliquids such
as cell lysate. When combined with the use of ﬂuorescent fusion
proteins, as illustrated in the TEM1-BLIP analysis, the fusion pro-
tein does not even have to be puriﬁed prior to the measurement,
but the crude cell extract can directly be used. For the TEM1-BLIP
system, the afﬁnities in buffer and lysate were in good agreement.
Discrepancies can, however, appear between simple buffers and
complex ﬂuids [17]. This demonstrates the importance of analyz-
ing protein interaction in its natural, crowded environment. Apart
from cell lysate, MST can also be performed in untreated human
blood serum, allowing direct quantiﬁcation of afﬁnity and concen-
tration of antibodies as disease related biomarkers [68].
In addition, complex binding modes are readily accessible via
MST, e.g. competition in the binding of BIX-01294 and b-H3(1-
21) to G9a. Furthermore, the cooperative binding of PIP2 and
Ca2+ to syt1 was quantiﬁed via MST. In previous assays, cooperativ-
ity had been inferred from Ca2+ binding to membranes. Thus, lipo-
somes with low PIP2 content were used, to which syt1 only binds
in presence of Ca2+. MST with soluble PIP2 allowed to measure un-
der saturating PIP2 conditions. As a result, PIP2 binding in absence
of Ca2+ was captured as well, revealing a much higher cooperativ-
ity. Due to the low solubility and micelle concentration of PIP2, it
would not be possible to perform a comparable assay with a tech-
nique requiring higher sample concentrations than MST.
MST provides reliable quantitative information on protein inter-
action based on a simple protocol, making measurements fast and
efﬁcient with low sample consumption. It is sensitive to binding-
induced changes in several molecular properties and ﬂexible in as-
say design. Taken together, this makes MST a highly applicable tool
for protein interaction analysis, even for challenging biological
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The analysis of protein binding to small molecules, nucleic
acids, and ions not only gives fundamental insights into
cellular processes but also paves the way towards improved
disease diagnosis and treatment. Herein, we report on a novel
label- and preparation-free method to quantify biomolecular
interactions and gather additional information on the binding
event. The technique is based on the recently developed
microscale thermophoresis (MST).
Several approaches to explore biomolecule binding
require fluorescent or radioactive labeling.[1] Other methods,
such as surface plasmon resonance (SPR) and quartz crystal
microbalance (QCM), rely on surface immobilization.[2] But
the coupling of a protein to a tag or surface may alter or even
inhibit the binding event.[3] Furthermore, the coupling reac-
tions and associated clean-up steps are time consuming and,
for some biomolecules, difficult to optimize. This is partic-
ularly true for those protein preparations that are typically
low in yield or less stable in solution, like membrane receptor
systems. A recent solution-based label-free method is the
kinetic capillary electrophoresis with mass spectrometry
(KCE-MS), which only requires that the binding partners be
separable by electrophoresis.[4] Another method is back-
scattering interferometry (BSI), which is limited to proteins
displaying detectable changes in the refractive index (RI)
upon binding and displays remarkable sensitivity for high-
affinity interactions.[5] So far, most genuinely label-free
studies of protein–ligand interactions have been performed
using isothermal titration calorimetry (ITC). ITC provides
direct access to the thermodynamic parameters of a binding
event but requires considerably high protein concentrations
to gain a measurable signal.[6]
In contrast MST is characterized by low sample con-
sumption. As the name already implies, it is based on
thermophoresis, the directed movement of particles in
a temperature gradient.[8,9] A temperature difference DT in
space leads to a depletion of the solvated biomolecules in the
region of elevated temperature, quantified by the Soret
coefficient ST: chot/ccold= exp(STDT).
This thermophoretic depletion depends on the interface
between the molecules and the solvent.[9] Under constant
buffer conditions, thermophoresis probes the size, charge, and
solvation entropy of the molecules. The thermophoresis of
a protein typically differs significantly from the thermopho-
resis of a protein–ligand complex as a result of binding-
induced changes in size, charge, and solvation energy.[10,11]
Even if a binding event does not significantly change the size
or charge of a protein, MST can still detect the binding owing
to binding- induced changes in the molecules solvation
entropy. Glutamate binding to ionotropic glutamate receptors
(iGluRs), for instance, causes a conformational change
observable byMST. Binding leads to a closure of the proteins
clamshell-like ligand-binding domain (LBD), inducing recep-
tor activation (Figure 1B).[12,13]
The MST setup consists of a fluorescence microscope with
a 1480 nm infrared laser coupled into its optical path (Fig-
ure 1A). The laser is focused into the capillaries containing
the sample, where it creates a temperature gradient. Up to
now the thermophoretic movement has been detected using
a fluorescent tag attached to one of the binding partners
(standard MST). To avoid the possible drawbacks of labeling
we propose the use of intrinsic protein fluorescence. It is
mostly caused by the aromatic amino acids phenylalanine,
tyrosine, and tryptophan (Trp), with the latter being the
dominant intrinsic fluorophore. We used an UV-light-emit-
ting diode for fluorescence excitation and a photomultiplier
tube (PMT) to record emission. Especially in the short-
wavelength regime around 350 nm used for label-free MST,
photon-counting PMTs are more sensitive than the CCD
cameras employed for standard MST.
Examples of measured fluorescence signals from label-
free MST are shown in Figure 1B. After the temperature has
increased, the fluorescence initially changes rapidly as an
inherent property of the fluorophore. This “temperature
jump”, which occurs on a timescale of 100 ms, can easily be
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distinguished from the subsequent rather slow thermodiffu-
sion lasting several seconds.[11] To infer binding affinity,
a titration series is prepared in which the concentration of
the ligand is varied while the concentration of the protein is
kept constant. For each dilution step, the temperature
perturbation is applied and the fluorescence response is
recorded. The thermophoretic signal changes stepwise with
increasing ligand concentration. This corresponds to the
changing ratio of unbound protein to bound complex and
reflects the alteration of molecular properties upon binding
(Figure 1B). To derive the dissociation constant KD from the
raw data, the fluorescence signals are normalized to the
undisturbed situation before heating. Working with these
relative signals avoids the difficulties of analyzing absolute
fluorescence levels or small alterations in absorption and
emission spectra upon binding. As known from standard
protein fluorescence spectroscopy, such signals can be com-
plex to interpret, mostly because of the presence of multiple
Trp residues or energy transfer between amino acids.[14] In the
following examples, we prove that label-freeMST is a valuable
tool to study the binding of numerous types of ligands to
different protein classes.
In the mammalian central nervous system iGluRs play
a key role in fast excitatory synaptic transmission.[15] The
investigation of ligand binding to the various iGluR subtypes
is in the focus of ongoing research.[12] Using label-freeMSTwe
analyzed the interaction of the non-NMDA receptor subunits
iGluR2 and iGluR6 with different agonists. We used soluble
LBD versions generated by fusing the two discontinuous
extracellular fragments S1 and S2.
The LBD of the AMPA receptor subunit iGluR2
(29.2 kDa; Figure 1B) contains four tryptophan residues. A
solution with a concentration of 2 mm exhibited sufficient UV
fluorescence intensity without significant bleaching. Analyz-
ing the change in thermophoretic mobility, we found a KD
value of (835 43) nm for the natural agonist glutamate
(147.13 Da; Figure 2). This accurately reproduces the liter-
ature value of 821 nm.[16] Azobenzene glutamate (glu-azo;
367.15 Da), a photoswitchable agonist allowing for remote
control of neuronal excitability, binds to the iGluR2-LBD
with a KD value of (19 5) mm (Figure 2).[17] MST confirms
the finding that glu-azo, designed as a kainate receptor ligand,
also binds iGluR2.[18] Adding glu-azo to iGluR2-LBD pre-
incubated with a saturating amount of glutamate (500 mm) did
not influence thermophoresis. The result proves the specific-
ity of the glu-azo signal and indicates that both agonists
compete for the same binding site. We verified results of the
label-free measurement for glu-azo by performing standard
MST with labeled iGluR2-LBD (see the Supporting Infor-
mation, Figure S-1). The measured KD value of (22 8) mm
does not deviate significantly from the value determined by
the label-free analysis. This demonstrates that label-free MST
was not disturbed by autofluorescence and that the label did
not affect the interaction. We additionally quantified ligand
binding to the kainite receptor subunit iGluR6. We used the
iGluR6-LBD (4 Trp; 29.3 kDa) in a concentration of 2 mm.
The determined upper limit of 359 nm for the affinity to
glutamate is in agreement with the reportedKi value of (355
74) nm (see Figure S-2).[19] The iGluR6-LBD binds glu-azo
with a KD value of (3.2 0.4) mm (see Figure S-3).
Label-free MST is sensitive enough to measure the
binding of small molecules. Three selective small-molecule
inhibitors of p38a (59.5 kDa) were tested. P38 is a mitogen-
activated protein kinase (MAP kinase) responding to stress.
The isoform p38a is considered the key subtype involved in
cytokine synthesis during inflammatory response. Thus,
potent inhibitors of p38a might lead to the development of
effective novel approaches for the treatment of inflammatory
diseases.[20]
The kinase contains five Trp residues, so that a concen-
tration of 100 nm was sufficient. As shown in Figure 3 p38a
binds the inhibitor SB202190 (331 Da) with a KD value of
Figure 1. Label-free microscale thermophoresis. A) A capillary contain-
ing a protein sample with intrinsic tryptophan fluorescence is placed
on a thermoelectric cooler (TC) providing a constant basis temper-
ature. Fluorescence is excited with an UV LED and recorded with
a photomultiplier tube (PMT). The solution inside the capillary is
locally heated with an IR laser, which is coupled into the fluorescence
microscope using an IR-reflecting “hot” mirror. B) The fluorescence of
the heated spot is recorded, normalized, and plotted against time.
After the IR laser is switched on at t=5 s, the fluorescence decreases
as the temperature increases, and the fluorescent protein molecules
move away from the heated spot because of thermophoresis. The
unbound iGluR2 ligand-binding domain (yellow; PDB code 1FTO)
shows stronger thermophoretic depletion than the complex with
glutamate (blue; PDB code 1FTJ).[7] This reflects the conformational
change of the protein upon binding.
Figure 2. Ligand binding to membrane receptors. Binding curves are
derived from the specific change in the thermophoretic mobility upon
ligand titration to a constant iGluR2-LBD concentration of 2 mm. The
curves show binding affinities of (83543) nm for glutamate and
(195) mm for glu-azo. The two agonists compete for the same
binding site, as preincubation of iGluR2 with a saturating amount of
glutamate prevents glu-azo binding (control).
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(48 21) nm, reproducing the literature value of 37 nm.[21] The
upper limits of affinity for PD169316 (360 Da) and SB239063
(368 Da) were determined to be 33 nm and 20 nm, respec-
tively. This is in good agreement with reported IC50 values of
130 nm (PD169316) and 44 nm (SB239063).[22,23] Nonspecific
interactions can be excluded as thermally denatured kinase
p38a did not show binding.
Remarkably, the thermophoretic signal contains further
information on the ligands. The complexes formed from
SB202190 (and PD169316) to p38a show less thermal
depletion than the unbound kinase, which is represented by
the positive slope of the binding curve. The binding of
SB239063 has the opposite effect (Figure 3). Apart from
a single functional group, the compounds 4-(4-fluorophenyl)-
2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB202190)
and 4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-
imidazole (PD169316) are identical in structure. The structure
of the second-generation inhibitor SB239063 (trans-1-(4-
hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridi-
midin-4-yl)imidazole), however, differs significantly. These
differences are likely to be the cause of the opposite effect on
thermophoretic depletion.
Using label-free microscale thermophoresis, we success-
fully quantified different types of biomolecular binding events
which are summarized in Table 1. Affinities reported in the
literature were confirmed for all groups of interactions. For
the LBD of the membrane receptor iGluR2, we observed that
glu-azo binds to the same site as glutamate, yet with a much
lower affinity. The affinity of small-molecule binding to the
kinase p38a was measured and we found that structurally
different inhibitors had an opposite influence on the thermo-
phoretic depletion. This interesting finding suggests that
thermophoresis could be used to not only determine binding
strength but also gather additional information on the binding
event. Comparative label-free MST studies would be neces-
sary and might be a putative tool to classify novel ligands. The
use of label-free MST is, however, not restricted to small-
molecule testing. We also demonstrated the applicability for
aptamer and ion binding (see the Supporting Information).
Label-free MST is particularly suitable for screening
approaches as a typical interaction measurement requires
only about 50 mL of a protein solution at a concentration of
0.1–2.0 mm. Furthermore, the measurement only takes about
5–10 min. This is made possible by the simple “mix-and-read”
protocol without laborious sample preparations like surface
immobilization or labeling. As the binding partners are not
attached to a label or surface, molecular properties are not
altered and mobility is not restricted. Thus native binding
affinities are measured.
Label-free MSTrequires a sufficient intrinsic fluorescence
signal of the protein, whereas difficulties arise from the UV
fluorescence of the ligand and buffer. The UV fluorescence of
the buffer, for example, caused by a Trp-containing spectator
protein adds to background fluorescence leading to increased
noise and a constant offset in the thermophoretic signal, but
not to a change in the affinity specified by the binding. If both
binding partners show a similar Trp fluorescence, direct
quantification with label-free MST is not possible. The
contribution of the titrated fluorescent ligand to the measured
thermophoresis signal needs to be quantified by control
experiments and then subtracted. This corrected thermopho-
resis signal should make it possible to infer the thermopho-
retic binding signal. However, most ligands, including the
group of small molecules accounting for the majority of
todays pharmaceuticals do not exhibit UV fluorescence.
A protein of average Trp content ( 2 Trps) can be used in
concentrations down to 100 nm, making it possible to
accurately quantify KD 50 nm. Interactions with higher
affinities can still be detected qualitatively, but not precisely
quantified. If insufficient Trp residues are incorporated, it is
possible to introduce Trp by mutation. A conservative
exchange of another aromatic amino acid for Trp often does
Figure 3. Screening of small-molecule kinase inhibitors. Three selective
inhibitors were successfully tested for binding to the nonactivated
form of MAP kinase p38a (c=100 nm). Corresponding to structural
differences, the binding of SB202190 and PD169316 has the opposite
effect on the thermophoretic movement compared to SB239063.
SB202190 binds with a KD value of (4821) nm. The upper limits of
affinity for PD169316 and SB239063 were determined as 33 nm and
20 nm, respectively. These results are in good agreement with pre-
viously reported values. Thermally denatured p38a did not show
binding (control).
Table 1: Protein binding studied by label-free MST.[a]
Binding event KD values from label-free MST Literature values
iGluR2
glutamate (83543) nm 821 nm[16]
glu-azo (195) mm –
iGluR6
glutamate 359 nm[b] (35574) nm (Ki)[19]
glu-azo (3.20.4) mm –
p38a
SB202190 (4821) nm 37 nm[21]
PD169316 33 nm[b] 130 nm (IC50)[22]
SB239063 20 nm[b] 44 nm (IC50)[23]
thrombin[c]
15 mer (3215) nm 25 to 100 nm[25, 26]
29 mer (13342) nm 0.5 or 100 nm[26, 27]
Syt1[c]
Ca2+ (32626) mm 50 mm to 3 mm[28]
[a] For all types of biomolecular binding events the measured affinities
were in agreement with reported literature values. [b] These affinities
represent upper limits. The exact error estimations can be found in the
Supporting Information. [c] See the Supporting Information for
descriptions, figures, and experimental details.
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not affect the molecular properties and protein function.[24]
Alternatively, labeling and standard MST can be chosen,
which typically can be used for lower protein concentrations
and thus for the exact determination of affinities in the region
ofKD< 1 nm.
[9] Considering its practicability and applicability
described above, label-free MST should be a promising novel
tool to enhance knowledge on protein binding in all fields of
life science.
Experimental Section
The setup is based on a Zeiss Axiotech Vario microscope with a 40
quartz objective, numerical aperture 0.8 (Partek GmbH, Muenster,
Germany). An UVTOP LED with a center wavelength of 285 nm
(Thorlabs GmbH, Dachau, Germany) was used for excitation,
a photomultiplier tube (P10PC, ET Enterprises Ltd, Uxbridge, UK)
for detection. Fluorescence filters for tryptophan (F36-300) were
purchased from AHF-Analysentechnik (Tuebingen, Germany).
Fused-silica capillaries from Polymicro Technologies (Phoenix,
USA) with different inner diameters and volumes of approximately
500 nL were used. Prior to the measurement, the polyimide coating
was removed with an open flame and the capillaries were cleaned
with ethanol on the outside. The temperature gradients were created
with an IR laser diode (Furukawa FOL1405-RTV-617-1480, l=
1480 nm, k= 320 mm for water, 320 mWmaximum power) purchased
from AMS Technologies AG (Munich, Germany). The IR laser beam
was coupled into the path of fluorescence light with an IR-reflecting
“hot” mirror (NT46-386; Edmund Optics, Barrington, USA) and
focused into the fluid with the microscope objective. As measured
using the temperature-dependent fluorescence of TAMRA dye, the
temperature in the solution was increased by 6 K in the beam center
with a 1/e2 diameter of 25 mm. All measurements were performed at
a capillary basis temperature of 20 8C. The capillary basis temperature
was controlled with a thermoelectric cooler.
The expression vectors for iGluR2- and iGluR6-LBDs were
kindly provided by Mark Mayer. P38a was provided by Krishna
Saxena; PD169316, SB202190, and SB239063 were purchased from
Sigma Aldrich (Munich, Germany). For the standard MST control,
iGluR2-LBD was labeled using the Monolith NT Protein Labeling
Kit RED according to the supplied protocol.
Measurements were conducted in the following buffers: iGluR2-
and iGluR6-LBD: 10 mm HEPES pH 8.0, 150 mm NaCl, 1 mm
EDTA; p38a : 50 mm Tris pH 7.8, 150 mm NaCl, 10 mm MgCl2,
0.05% TWEEN20. As a control, p38a was incubated at 95 8C for 1 h.
All solutions were incubated at room temperature for 1 h after the
proteins had been mixed with the different target molecules.
The KD values were obtained by fitting the fraction of bound
proteins to the quadratic solution of the binding reaction equilibrium,
derived from the law of mass action, with the KD being the single free
parameter.[29] The fitting function, number of repetitions, and the
explanation of error bars are provided in the Supporting Information.
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1 Fitting function 
To determine the affinity of a ligand L binding to a protein P via 
label free MST, the total concentration of the ligand cL0 is titrated, 
while the total concentration of the protein cP0 is kept constant. For 
the binding event of L to P, the mass action law reads 
( )( )
LP
LPP0LPL0
LP
PL
D c
=
c
=K cccccc −−  
with 
KD : dissociation constant 
cL : free ligand concentration 
cP : free protein concentration 
cLP : concentration of the bound complex 
cL0 : total concentration of the ligand and 
cP0 : total concentration of the protein. 
Solving for the fraction of occupied binder B yields 
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2 Number of repeats and error bars 
The number of independent repeats was at least 3 for all 
measurements except for syt1 and iGluR6 (n=2); error bars show the 
standard deviation between these independent repeats. For iGluR2 
binding glu-azo and the control with the saturated amount of 
glutamate and with the labeled protein n=1. In these cases the error 
was estimated by the noise of the fluorescence detection. 
 
 
3 Exact error estimations for values given as an upper limit 
The fitting procedure assumes a Gaussian, symmetric error 
distribution. Due to this approximation, the distribution reached 
negative values in three cases. The corresponding values are given 
as upper limits of affinity in the manuscript. The exact error 
estimations are listed in Table S-1. 
Table S-1. In three cases an upper limit of affinity is given. The exact 
error estimations are listed below. 
Binding event Upper limit given in 
manuscript 
Exact values derived 
from data fit 
iGluR6   
 glutamate ≤359 nM[a] 153±206 nM 
p38α   
 PD169316 ≤33 nM[a] 18±15  
 SB239063 ≤20 nM[a] 8±12  
 
4 Additional iGluR binding curves 
Figure S-1. Standard MST control for the binding of the iGluR2-LBD 
to glu-azo. The protein was fluorescently labeled and used in a 
concentration of 200 nM. The measured KD of 22±8. µM verifies the 
label free result (19±5 μM) thus excluding disturbances by 
autofluorescence. 
 
Figure S-2. Label free MST measurement of glutamate binding the 
iGluR6-LBD (c=2 μM). An upper limit of affinity of 359 nM was 
derived. 
 1
Figure S-3. Label free MST measurement of glu-azo binding the 
iGluR6-LBD (c=2 μM). The determined KD is 3.2±0.4 µM. 
5 Additional experiments 
 
5.1 Aptamer binding to thrombin 
Despite their much simpler production and higher stability, DNA 
aptamers resemble the binding behavior of antibodies. We 
demonstrate the applicability of label-free MST to monitor the 
binding of these valuable molecular tools using the example of 
human α-thrombin (36.7 kDa; 9 Trp residues). This serine protease 
is part of the human coagulation cascade. In 1992 Bock et al. 
designed a single stranded 15mer DNA aptamer binding to the 
fibrinogen recognition exosite.[1] Five years later Tasset et al. 
reported on a 29mer binding to the heparin exosite.[2] 
For our label-free MST analysis of these aptamers, we used a 
constant thrombin concentration of 200 nM (Fig. S-4). The 
measured KD of 32±15 nM for the 15mer reproduces the previously 
reported standard MST result with 5’-fluorescently labeled 15mer 
(KD=30±19 nM).[3] It is in good agreement with literature values 
specifying the affinity as 25 to 100 nM based on filter binding 
assays.[1,2,4] For the 29mer, label-free MST reported an affinity of 
133±42 nM. This is much higher than the KD of 0.5 nM, reported by 
Tasset et al.[2] However, SPR measurements could not confirm the 
very high affinity of the 29mer either and instead reported a KD in 
the range of 100 nM.[5] Tang et al. even found an affinity lower than 
for the 15mer consistent with our results.[6] Apart from the specific 
aptamers a 15mer dinucleotide mutant was measured. The mutant 
did not show binding, thus proving specificity. 
Figure S-4. Thrombin interaction with aptamers. Specific 15mer and 
29mer DNA aptamers bind to the fibrinogen and heparin exosites of 
human α-thrombin (c=200 nM). We measured a KD of 32±15 nM for 
the 15mer and a KD of 133±42 nM for the 29mer and. A 15mer 
dinucleotide mutant did not bind to thrombin (control). 
5.2 Ca2+ -ion-binding to synaptotagmin 1 
As previously reported protein binding to ions can be measured with 
standard MST.[7] This type of binding events is also accessible via 
label-free MST. We analyzed the interaction of the synaptic vesicle 
protein synaptotagmin 1 (Syt1) with Ca2+. The cytoplasmic C-
terminal part of the protein consists of two C2 domains, C2A and 
C2B. NMR suggests that three and two Ca2+ bind to C2A and C2B, 
respectively. Upon binding, the C2 domains mediate membrane 
translocation. Hence synaptotagmin can act as a neuronal Ca2+ 
sensor triggering exocytosis of neurotransmitters into the synaptic 
cleft.[8] 
We used Syt1's C2AB fragment in a constant concentration of 
1 μM and titrated CaCl2. Label-free MST yielded an overall Ca2+ 
affinity of 326±26 µM (Fig. S-5). A standard MST control with 
fluorescently labeled C2AB confirmed this affinity (see Supporting 
information Fig. S-6). Our results are in good agreement with ITC 
measurements by Radhakrishnan et al.[9] Assuming quintuple 
binding, the group extracted KDs of 48, 142 and 3120 µM for C2A 
and 490 µM for both Ca2+ binding to C2B. To obtain distinct KDs 
for the different binding sites, MST measurements of selective Ca2+ 
binding mutants of C2AB seem to be very suitable.[10] Titrating 
MgCl2 did not result in a change in thermophoresis, demonstrating 
the specificity of the label free MST analysis (Fig. S-5). Standard 
MST experiments on cooperative Ca2+ and phosphatidylinositol 4,5-
bisphosphate binding to Syt1 have already been performed 
successfully, suggesting that label free MST could also be used for 
extensive studies of Syt1 function.[11] 
 
Figure S-5. Synaptotagmin 1 binds Ca2+ ions. Syt1's C2AB fragment 
was used in a constant concentration of 1 μM. CaCl2 titration alters 
the thermophoretic mobility. An overall binding affinity of 326±26 µM 
was derived. In contrast, MgCl2 does not have an influence on 
thermophoresis, documenting specificity. 
 2
 3
 
Figure S-6. Standard MST control for the binding of Syt1-C2AB to 
glu-azo. The protein was fluorescently labeled and used in a 
concentration of 40 nM. The measured KD of 757±299. µM verifies the 
label free result (326±26 μM) thus excluding disturbances by 
autofluorescence. 
5.3 Additional experimental section 
Human α-thrombin was purchased from Haematologic 
Technologies Inc. (Essex Junction, USA). DNA oligonucleotides 
were synthesized by Metabion (Martinsried, Germany). The 
sequences of the oligonucleotides, with mutations as small letters, 
are: 15mer 5’-GGT TGG TGT GGT TGG-3’; 29mer:  5’-AGT CCG 
TGG TAG GGC AGG TTG GGG TGA CT-3’;f 15mer dinucleotide 
mutant: 5’-GGT TGt TGT GGT TtG-3’. The aptamers were 
denatured and re-natured prior to the experiments to ensure that they 
reached their active conformation. The Syt1 C2AB construct from 
R. norvegicus was cloned into a pET28a expression vector. The 
purified protein was kindly provided by Geert van den Boogaart. 
For the standard MST control Syt1-C2AB was labeled using the 
Monolith NT Protein Labeling Kit RED according to the supplied 
protocol. 
Measurements were conducted in the following buffers: 
Thrombin selection buffer: 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 
5 mM KCl, 1 mM CaCl2,1 mM MgCl2, 0.1% TWEEN20;[1] Syt1: 
20 mM HEPES pH 7.4, 150 mM KCl, for the labeled control 
additionally 0.5 mg/ml BSA. All solutions were incubated at RT for 
1h after the proteins had been mixed with the different target 
molecules. 
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Background: Proteinase 3 is an abundant serine protease with high similarity to neutrophil elastase and a major autoim-
mune target in systemic vasculitis.
Results:We identified a monoclonal antibody that inhibits PR3 activity.
Conclusion: PR3-inhibiting antibodies can change its conformation and impair interactions with 1-proteinase inhibitor.
Significance: PR3-inhibiting antibodies may play a role in autoimmune vasculitis and could be exploited as highly selective
inhibitors.
Proteinase 3 (PR3) is an abundant serine protease of neutro-
phil granules and a major target of autoantibodies (PR3 anti-
neutrophil cytoplasmic antibodies) in granulomatosis with
polyangiitis. Some of the PR3 synthesized by promyelocytes in
the bone marrow escapes the targeting to granules and occurs
on the plasmamembrane of naive and primed neutrophils. This
membrane-associated PR3 antigen may represent pro-PR3,
mature PR3, or both forms. To discriminate between mature
PR3 and its inactive zymogen, which have different conforma-
tions, we generated and identified amonoclonal antibody called
MCPR3-7. It bound much better to pro-PR3 than to mature
PR3. This monoclonal antibody greatly reduced the catalytic
activity of mature PR3 toward extended peptide substrates.
Using diverse techniques and multiple recombinant PR3 vari-
ants, we characterized its binding properties and found that
MCPR3-7 preferentially bound to the so-called activation
domain of the zymogen and changed the conformation of
mature PR3, resulting in impaired catalysis and inactivation by
1-proteinase inhibitor (1-antitrypsin). Noncovalent as well as
covalent complexation between PR3 and 1-proteinase inhibi-
tor was delayed in the presence of MCPR3-7, but cleavage of
certain thioester and paranitroanilide substrates with small res-
idues in the P1 position was not inhibited. We conclude that
MCPR3-7 reduces PR3 activity by an allosteric mechanism
affecting the S1 pocket and further prime side interactionswith
substrates. In addition, MCPR3-7 prevents binding of PR3 to
cellular membranes. Inhibitory antibodies targeting the activa-
tion domain of PR3 could be exploited as highly selective inhib-
itors of PR3, scavengers, and clearers of the PR3 autoantigen in
granulomatosis with polyangiitis.
Proteinase 3 (PR33; EC 3.4.21.76) is one of four neutral serine
proteases (elastase, cathepsin G, proteinase 3, and neutrophil
serine protease 4) stored as fully processed mature enzymes in
azurophil granules of human neutrophils (1–4). Small amounts
of PR3 are also expressed on the plasma membrane of resting
neutrophils (5, 6). The degree of this constitutive expression is
genetically determined (7–9), but the surface exposure and
pericellular activity of PR3 around neutrophils is further
increased by priming and activation of neutrophils. Autoanti-
body responses to PR3 have been identified as a central patho-
genic feature in patients suffering from granulomatosis with
polyangiitis (GPA; formerly called Wegener granulomatosis).
PR3-directed autoantibodies are capable of activating cytokine-
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a˜-aminobutyric acid; DAP(CF), diaminopropionyl fluorescein; SBzl, thio-
benzyl ester; nVal or nV, norvaline; For, formyl; Boc, t-butoxycarbonyl;
TAMRA, tetramethylrhodamine; Ahx, aminohexanoic acid; ONp, para-
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primed neutrophils in vitro by binding to surface-exposed PR3
and Fc receptors (10). In its generalized form, a necrotizing
vasculitic process affects and damages the endotheliumof small
vessels in the lungs and kidneys (11).
Although PR3 has been extensively studied for decades, its
biological functions during immune defense responses are
poorly understood. Likewise its interaction with anti-neutro-
phil cytoplasmic antibodies in patients with GPA and their
pathogenic role for this relapsing-remitting disease have not
been clarified. A large genome-wide association study recently
confirmed the genetic association between anti-neutrophil
cytoplasmic antibody formation and the PR3 locus on the one
hand and the presence of the Z-variant of 1-proteinase inhib-
itor (1PI) on the other hand inGPA (12). This finding suggests
that PR3 activity and/or inactivation of PR3by1PI varies in the
human population and contributes to the risk for GPA mani-
festations either at onset, during relapses, or during systemic
progression.
Inhibition of neutrophil elastase and PR3 by 1PI is highly
dependent on the proper conformation of an exposed reactive
center loop, which serves as a pseudosubstrate. Single point
mutations, even at distant sites within 1PI like a lysine substi-
tution of Glu342 in the Z-variant, can affect the conformation
of the reactive center loop and can decrease the association
rates with target proteases (13). Once hydrolyzed after the
methionine in position 358, the new carboxyl terminus of
1PI forms an irreversible covalent acylenzyme complex
that undergoes a sophisticated conformational rearrange-
ment. These enzymeserpin complexes are quickly removed
from neutrophil membranes, the interstitial fluids, and the cir-
culation by a specific receptor-mediated uptake into endolyso-
somes (14). The question as to how antibodies can interfere
with the activity of PR3 and impair its clearance by the natural
plasma inhibitor 1PI, however, has not been addressed and
answered.
Like other serine proteases of neutrophils, PR3 (15, 16) is
synthesized as a proenzyme almost exclusively at the promyelo-
cyte stage. Following cleavage of the signal peptide and trans-
location into the endoplasmic reticulum, the proenzyme (pro-
PR3) egresses from the endoplasmic reticulum and migrates to
the Golgi complex. At this stage, it carries a short amino-termi-
nal extension, the dipeptide Ala-Glu. This dipeptide prevents
the molecule from assuming its active enzyme conformation
prematurely during biosynthesis but is cleaved off by the dipep-
tidyl aminopeptidase I (cathepsin C) just before storage in pri-
mary granules (17–20). After the removal of the amino-termi-
nal dipeptide, the free positively charged amino terminus of
Ile16 (chymotrypsinogen numbering) forms an internal salt
bridge with the side chain carboxylate of Asp194. This rear-
rangement stabilizes the oxyanion hole and renders the active
site cleft fully accessible to substrates. During biosynthesis,
some catalytically inactive pro-PR3 escapes granule targeting
and is transported to the cellular surface for secretion. As pro-
PR3 is a catalytically inactive precursor, it is not cleared by 1PI
and may be more easily accessible for autoantibodies in GPA.
Although the crystal structure ofmature PR3 (without inhib-
itors bound to it) has been reported (21), inferences about the
pro-PR3 structure can be drawn from comparisons with other
closely related zymogen-enzyme pairs for which the structures
are known. The best studied zymogen-enzyme pair, bovine cat-
ionic trypsinogen and its mature counterpart, bovine cationic
trypsin (22), have identical structures for about 85% of the C
chain, but four segments of the main chain are entirely differ-
ent: the amino terminus (Ile16–Gly19), the so-called autolysis
loop (Gly142–Ala152), the Val185–Gly193 loop, and the Val216–
Leu223 loop (22). The latter three loops form the activation
domain in the active enzyme in which the free amino terminus
is inserted into the so-called activation pocket of the zymogen.
All four segments are highly flexible in the zymogen but
ordered in the active enzyme. Allosteric regulation of the two
segments around residues 190 and 220 essentially switches the
molecule from a functionally incompetent zymogen into a cat-
alytically competent state and creates the S1 binding site and
oxyanion hole (22, 23). This conformational switch between the
proenzyme state and the catalytically active state of the mature
enzyme is the well established structural basis for allosteric reg-
ulation of trypsin-/chymotrypsin-like enzyme activity (24).
The goal of our studies was to identify a new class of mono-
clonal antibodies (mAbs) that can discriminate between the
catalytically competent state of the activation domain and the
enzymatically inactive conformation of the zymogen. To
develop such a monoclonal antibody with specificity close to
the active site cleft and activity blocking properties, we immu-
nizedmice with a stable proform of PR3 carrying the tripeptide
Ala-Glu-Pro at the mature amino terminus and selected
hybridomas that showed preferential binding to the proform.
We describe the binding specificity and activity blocking prop-
erties of the newly produced MCPR3-7 in comparison with
the commercially available anti-PR3 mAb CLB-12.8. Besides
the reduction of the PR3 activity, MCPR3-7 also interferes
with the complexation of PR3 and 1PI and switches the active
enzyme into an inactive, zymogen-like state by altering the
autolysis and 190 loops. The antibody can be regarded as a
starting point for the development of antibody-based allosteric
inhibitors of PR3 that block activity and prevent the binding of
neutrophil-activating, pathogenic anti-neutrophil cytoplasmic
antibody.
EXPERIMENTAL PROCEDURES
Cells, Proteases, Antibodies, and Substrates—The human
embryonic kidney (HEK) cell line 293 was purchased from the
American Type Culture Collection (ATCC, Manassas, VA).
The human embryonic kidney cell line 293 EBNAwas received
fromYvesDurocher, National ResearchCouncil Canada,Mon-
treal, Canada. Human neutrophil PR3 purified from neutro-
phils of peripheral blood was obtained from DIARECT AG,
Freiburg, Germany. The anti-PR3 mAb MCPR3-2, which was
used as control inmost experiments, binds pro-PR3 andmature
PR3 equally well and has been described previously (25). The
anti-PR3mAbCLB-12.8was purchased fromSanquin, Amster-
dam,TheNetherlands. The FRET substrateAbz-Tyr-Tyr-Abu-
ANB-NH2 was kindly provided by Adam Lesner, University of
Gdansk, Gdansk, Poland and was described previously (26).
The FRET substrate 5-TAMRA-VADnVADYQ-diaminopro-
pionyl fluorescein (DAP(CF)) was ordered from EMC Micro-
collections, Tu¨bingen, Germany. The thiobenzyl ester sub-
Antibodies Interfering with PR3 Activity and Inactivation
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strates Boc-Ala-Pro-nVal-SBzl and For-Ala-Ala-Pro-Abu-SBzl
were purchased fromBachemAG,Bubendorf, Switzerland, and
the substrate Boc-Ala-ONpwas from Sigma-Aldrich. The sub-
strate Ahx-PYFA-pNA was obtained from Dr. Francis Gau-
thier, Tours, France, and 1PI was from Athens Research and
Technology, Athens, GA.
Expression of Recombinant Pro-PR3 and Mature PR3 Variants—
The different recombinant PR3 variants used for the genera-
tion, selection, and characterization of mAbs with preferential
binding to pro-PR3 are described schematically in Fig. 1A. The
development of the cDNA construct coding for recombinant
wild-type PR3 (pro-PR3ctp) and the cDNA construct of the
active site mutant lacking the codons for the amino-terminal
activation dipeptide (PR3ctp-S195A) as well as their expres-
sion in HEK 293 cells have been described previously (18, 25).
Similarly, the preparation and characterization of the active
site mutant carrying a carboxyl-terminal c-myc-His tag (PR3-
S195A-cmyc) has been described elsewhere (27). When
expressed in HEK 293 cells and secreted into the cell culture
supernatant, pro-PR3ctp and PR3ctp-S195A-cmyc have the
conformation of pro-PR3, whereas PR3ctp-S195A has the
conformation of the mature enzyme (20, 27).
To obtain an immunogen that was not contaminated by
traces of amino-terminally processed PR3 (mature PR3), we
generated a pro-PR3 variant namedproP-PR3ctp,which carries
a three-residue-long propeptide ending with proline. This pro-
peptide cannot be cleaved and removed by cathepsin C. The
cDNA coding for the insertion of a proline residue between the
natural activation dipeptide Ala-Glu and the Ile residue consti-
tuting the amino terminus of themature enzymewas generated
using the QuikChange site-directed mutagenesis kit (Strat-
agene Cloning Systems, La Jolla, CA) with the sense primer
US127-5-GCTGCGGAGCCAATCGTGGGC-3, the anti-
sense primer US128-5-GCCCACGATTGGCTCCGCAGC-
3, and pro-PR3ctp as template. The underlined triplet of nucle-
otides encodes the inserted proline residue.
Stably transfected proP-PR3ctp-expressing HEK 293 cells
were selected and cultured as described previously (20, 27), and
proP-PR3ctp was purified from HEK 293 culture supernatant
by immunoaffinity chromatography using MCPR3-2 coupled
to a cyanogen bromide-activated Sepharose 4B column and 3 M
KSCN in 1% NaHCO3 as elution buffer. ProP-PR3ctp in the
eluted fractions was quantified by capture ELISA as described
(25), pooled, and concentrated after dialysis.
Production of PR3 Variants in Flip-in HEK 293 and HEK 293
EBNA Cells—The constructs as well as the expression of
human pro-PR3 (pro(4DK)-PR3), gibbon pro-PR3, and the two
human/gibbon chimeras were produced as described (28). Fur-
thermore, human pro-PR3was expressed by transient transfec-
tion of HEK 293 EBNA cells as described elsewhere (29). The
catalytically inactive PR3 variant PR3-S195A (Fig. 1A) was
also produced in the HEK 293 EBNA expression system. Puri-
fication of His-tagged proteins from cell supernatants was car-
ried out as described previously (29). The PR3 variants, which
were produced in their proform, were converted into an active
state by enterokinase from calf intestine (Roche Applied Sci-
ence). After dialysis against 20 mM Tris-HCl, 50 mM NaCl, and
2 mM CaCl2, pH 7.4, the proteins were cleaved at an enzyme to
substrate ratio of 1:40 at room temperature overnight.
Generation of Antibodies and Selection of Hybridomas—For
the generation of the mAb MCPR3-7, BALB/c mice were
immunized with immunoaffinity-purified proP-PR3ctp follow-
ing standard immunization protocols. Antibody titers of immu-
nized mice were determined by ELISA. Spleen cells from
immunized mice were fused with a FO myeloma cell line of
BALB/c origin to generate hybridomas. Animal experimenta-
tion for this study was approved by the Institutional Animal
Care andUseCommittee. Handling and care of animals were in
accordance with institutional guidelines.
For the identification and selection of hybridoma antibodies
that bind to pro-PR3 but not to mature PR3, the following cap-
ture ELISA technique was applied. Immulon I strips were
coated with rabbit anti-mouse IgG diluted 1:1000 in 0.5 M
NaHCO3 buffer, pH 9.6 overnight. After blocking with BSA/
immunoradiometric assay buffer (50 mM Tris, 0.1 M NaCl, and
2% BSA, pH 7.4), 0.1g of themonoclonal hybridoma antibod-
ies or control antibody (MCPR3-2) was added and incubated at
room temperature for 30minwhile shaking. Supernatants from
[35S]methionine-labeled proP-PR3ctp- or PR3ctp-S195A-ex-
pressing HEK 293 cells diluted 1:20 in immunoradiometric
assay buffer (50 mM Tris, 0.1 M NaCl, and 0.1% BSA, pH 7.4)
were added and incubated at room temperature for 60 min.
After removal of unbound PR3 by washing, antibody-bound
radioactivity was measured in counts/min for each well. The
hybridomas generating the highest signal difference between
pro-PR3 andmature PR3were chosen for all subsequent exper-
iments (MCPR3-7).
Biosynthetic Labeling and Immunoprecipitation—ProP-PR3ctp-
andPR3ctp-S195A-expressingHEK293 cellswere cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 100Ci/ml [35S]methionine, penicillin, streptomycin, and
10% fetal bovine serum in a 5% CO2 atmosphere at 37 °C over-
night. Unless otherwise stated, all immunoprecipitation steps
were performed at 4 °C. Staphylococcal protein A was incu-
bated with rabbit anti-mouse IgG and then with different con-
centrations of MCPR3-7 (1:100, 1:200, and 1:400 dilutions of a
1.3 mg/ml stock solution) in each case for 1 h. The cell culture
supernatants of biosynthetically labeled cells were precleared
by incubation with staphylococcal protein A for 30 min fol-
lowed by centrifugation at 10,000 g for 2min. The precleared
culture supernatants were then incubated for 10 min with the
staphylococcal protein A/rabbit anti-mouse IgG/MCPR3-7
mixture and washed three times with radioimmune precipita-
tion assay buffer (50 mM Tris, pH 8.0, 0.5% deoxycholate, 1%
Triton X-100, 0.1% SDS, and 50 mM NaF in PBS to which 1
g/ml leupeptin, 2 g/ml aprotinin, and 75 g/ml PMSF were
freshly added prior to use). The precipitate was resuspended in
SDS sample buffer, boiled for 5 min, and centrifuged at
10,000  g for 2 min, and the supernatant was collected and
stored at 20 °C until analysis by SDS-PAGE and Western
blotting.
Bead-based Flow Cytometry—The possible competition
between the two mAbs MCPR3-2 and MCPR3-7 in binding to
pro-PR3 was analyzed by bead-based flow cytometry using the
carboxyl-terminally tagged PR3 variant PR3ctp-S195A-cmyc
Antibodies Interfering with PR3 Activity and Inactivation
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(pro-PR3) (30). Stably transfected HEK 293 cells expressing the
proforms were grown in serum-free medium for 2 days. Cell
culture supernatants were concentrated using an Amicon Cen-
triplus C-10 with a cutoff of 10,000 Da. Imidazole was added to
a final concentration of 20mM, and the concentrate was applied
to a HiTrap chelating high performance column (GE Health-
care) according to the manufacturer’s instructions. Proteins
were eluted with 20 mM phosphate, 500 mMNaCl, and 200 mM
imidazole. Imidazole was removed by centrifugation through a
spin column equilibrated with 50 mM sodium phosphate, 300
mM NaCl, and 0.01% Tween 20, pH 8.0. Proteins were quanti-
fied by Coomassie Plus (Pierce). A total of 2.8  106 beads
coated with PR3 variants were incubated with 0.25 g/100 l
MCPR3-2 or MCPR3-7 as described. After washing with PBS,
0.1% BSA, and 0.01% Tween 20, the beads were incubated with
100 l of a 1:50 dilution of FITC-conjugated MCPR3-2 or
FITC-conjugated MCPR3-7 (prepared in our laboratory) for 5
min, washed, and analyzed by FACScan (setting, fluores-
cence 1 at 682 nm).
FRET-based Activity Assay—The activity of PR3 variants
diluted to 50 nM inTris-HCl buffer (100mMTris, 500mMNaCl,
and 0.01% Brij 39, pH 7.5) was measured over time using the
FRET substrate Abz-Tyr-Tyr-Abu-ANB-NH2 (excitation at
325 nm, emission at 400 nm) at a concentration of 800 nM.
To locate the epitope of MCPR3-7, the activity of human
PR3, gibbon PR3, and two gibbon/human chimeras (after acti-
vation of the respective pro(4DK) precursors) was determined.
The activity of proteases was measured directly after adding a
2-fold molar excess of MCPR3-7. As controls, the emission of
the FRET substrate without the enzyme and the activity of the
enzyme without the antibody were measured. To detect the
inhibitory effect of mAbs, the activity of PR3 was measured in
the presence of increasing concentrations (0–750 nM) of
MCPR3-7, CLB-12.8, andMCPR3-2. The activity was recorded
over time directly after adding the mAbs. The effect of
MCPR3-7 on PR3-mediated cleavage of the FRET substrate
5-TAMRA-VADnVADYQ-DAP(CF) (5 M; excitation at 485
nm, emission at 520 nm) was measured over time. The activity
of a 50 nM PR3 solution in activity buffer (50 mM Tris, 150 mM
NaCl, and 0.01%TritonX-100, pH 7.4) was determined directly
after adding a 3-fold molar excess of the antibody.
Absorbance-based Activity Assay—To search for conforma-
tional changes of PR3 in response to MCPR3-7 binding, the
cleavage of different substrates was investigated. The activity of
50 nM PR3 in activity buffer at a 3-fold molar excess of
MCPR3-7 was comparedwith its activity in the absence of anti-
bodies using Ahx-PYFA-pNA, Boc-Ala-ONp, Boc-Ala-Pro-
nVal-SBzl, and For-Ala-Ala-Pro-Abu-SBzl (1 mM each) as
substrates. For the reaction with the two thiobenzyl ester sub-
strates, 5,5-dithiobis(2-nitrobenzoic acid) was added to the
samples at a concentration of 500 M.
ELISA—To investigate the differential interactions of mAbs
with PR3inhibitor complexes, two covalent and two canonical
complexes were assembled. The covalent complexes were
formed with active PR3 (converted pro(4DK)-PR3) and 1PI or
AAPV-chloromethyl ketone (CMK) (American Peptide Co.,
Sunnyvale, CA), and the canonical complexeswere formedwith
active PR3 and elafin or catalytically inactive PR3-S195A in
association with 1PI (PR3*1PI). The PR3inhibitor com-
plexes were coated on nickel plates via the His tag of the PR3,
and a capture ELISA was performed as described elsewhere
(31). The coating concentration of the PR3 complexes was 2
g/ml. The dilution of the mAb was 1:1000 for CLB-12.8,
1:5000 forMCPR3-2, 1:200 forMCPR3-7, and 1:50 for the IgG1
control antibody (Mouse IgG1Pure, BD Biosciences). As sec-
ondary antibody, goat anti-mouse HRP antibody was used
(dilution, 1:2500), and the reaction was developed with a per-
oxidase substrate. Recognition of PR3 variants was normalized
to the signal obtained with pro(4DK)-PR3, which was set to
100%.
Thermophoresis—MCPR3-7 and 1PI were labeled with the
red fluorescent dye NT647 using the Monolith NT Protein
Labeling kit RED (NanoTemper Technologies, Munich, Ger-
many) according to the supplied protocol. This approach is
based on covalently attaching NT647 N-hydroxysuccinimide
ester to primary amines of lysine residues. Prior to thermopho-
resis experiments, the free dye was removed via dialysis.
To quantify the affinity ofMCPR3-7 to different PR3 confor-
mations, a 1:1 dilution series of pro(4DK)-PR3, PR3-CMK, or
PR3was prepared starting at amaximumconcentration of 5M
each. To guarantee constant buffer conditions throughout the
dilution, the proteinases were diluted in the exact same buffer
as the stock solution: 20 mM sodium phosphate, 300 mM NaCl,
and 0.02% Tween 20, pH 6.2 with (PR3-CMK) or without
(pro(4DK)-PR3 and PR3) 1.75% DMSO. Each point of the dilu-
tion series was mixed 1:1 with MCPR3-7-NT647 in PBS with
0.05% Tween 20 and 2% BSA to yield a constant final antibody
concentration of 50 nM and a maximum proteinase concentra-
tion of 2.5 M.
In addition, thermophoresis was used to test whether the
mAbsMCPR3-7 andCLB-12.8 have an influence on the forma-
tion of canonical 1PIPR3 complexes. Separate 1:1 dilution
series of PR3-S195A in EB buffer (20 mM sodium phosphate
and 500 mM NaCl, pH 7.4) were prepared, starting at a maxi-
mum concentration of 12 M each. 5 l of each dilution step
were mixed with 1 l of either PBS or 1 l of a 4 M stock of
MCPR3-7 or CLB-12.8 in PBS, which results in an antibody
concentration of 670 nM. After incubating the sample for 1 h at
room temperature in the dark, 1 l of a 6.15 M 1PI-NT647
solution in PBS with 0.05% Tween 20 was added, resulting in a
final 1PI concentration of 880 nM. To avoid adsorption to the
capillary walls during the measurement, BSA was added at a
final concentration of 1% (w/v).
Standard treated enhanced gradient capillaries (NanoTemper
Technologies) were filled with the samples. Measurements
were performed on a Monolith NT.115 system (NanoTemper
Technologies) at a constant ambient temperature of 20 °C
using 60% light-emitting diode (experiments with MCPR3-7-
NT647) or 20% light-emitting diode (experiments with 1PI-
NT647) and 20% infrared (IR) laser power with laser on and off
times of 40 and 20 s.
After bleaching correction, the fluorescence after tempera-
ture jump and early thermophoresis was normalized to the fluo-
rescence before laser heating with a LabVIEW routine. Mean
Fnorm values of at least three technical repeats of eachmeasure-
ment were plotted on a linear y axis in permil units (‰) against
Antibodies Interfering with PR3 Activity and Inactivation
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the proteinase concentration on a log10 x axis. The standard
deviation of the repeats was calculated for each point. To get a
better estimate of the error, the mean of all standard deviations
of a binding curve was determined. This mean error is visual-
ized as an error bar on all points of the corresponding graph.
Using IGOR Pro, a weighted fit to the quadratic solution of the
mass action law
FB
AB
B

A B KD  A B KD	2 4AB
2B
(Eq. 1)
where FB is the fraction bound, [A] is the concentration of the
titrated binding partner, [B] is the concentration of the labeled
binding partner, [AB] is the concentration of bound complex of
A and B, and KD is the equilibrium dissociation constant was
performed with KD as the single free fit parameter (32). KD
values are given together with an error estimation from the fit.
The fitting procedure assumes aGaussian, symmetric error dis-
tribution. Thus, the error can reach negative values if the sen-
sitivity limit determined by the lowest detectable concentration
of fluorescent partner is reached. In these cases, the KD values
are presented as an upper limit. Fnorm of the unbound state as
revealed by the fit was subtracted as a base-line value to yield
Fnorm as depicted on the y axis of the figures.
Possible Interference of mAb with PR3 Complexation—The
effect of mAbs on the covalent inactivation reaction of PR3 by
1PI was measured over time. A 3-fold molar excess of mAbs
was added to an 800 nM solution of active PR3 in Tris-HCl
buffer and incubated at room temperature for 1 h. After adding
a 5-fold molar excess of 1PI, the sample was incubated at
37 °C, and 10-l aliquots were taken after different time points.
The reaction was stopped by adding Laemmli buffer and heat-
ing to 95 °C for 10 min. Proteins in the samples were then sep-
arated by SDS-PAGE under reducing conditions and visualized
by silver staining.
Isolation and Priming of Neutrophils—The recognition of
PR3 on the neutrophil membrane from one normal donor was
evaluated without and after stimulation with TNF. The neu-
trophils were isolated from EDTA-anticoagulated blood by
centrifugation on PolymorphprepTM (Accurate Chemical and
Scientific Corp.,Westbury, NY) and hypotonic lysis of erythro-
cytes with distilled water. Cells were washed with cold Hanks’
balanced salt solution without Ca2
/Mg2
 (Mediatech Inc.,
Herndon, VA) and resuspended in Hanks’ balanced salt solu-
tion with Ca2
/Mg2
 (Mediatech Inc.) to obtain 1 107 cells/
ml. One-half of the preparation was primed with 2 ng/ml
recombinant TNF (Roche Applied Science) for 15 min at
37 °C before analysis of membrane expression. Non-primed
neutrophils were analyzed for membrane expression immedi-
ately after isolation.
PR3 on Neutrophil Membranes—The recognition of PR3 on
the membrane was evaluated using flow cytometry. All steps
were performed on ice. Samples containing 1 106 neutrophils
were fixed with 0.5% paraformaldehyde for 10 min, washed
with PBS and 1% BSA by centrifugation at 1200 g at 4 °C for
3 min, and incubated with 0.5 mg/ml heat-aggregated goat
immunoglobulins (IgG; Sigma) for 15 min to saturate Fc
receptors. Next, cells were stained with a saturating dose
of mouse monoclonal IgG1 directed against human PR3
(MCPR3-2 and MCPR3-7) and anti-CD32 (AbD Serotec, UK)
orwith an IgG1 control antibody for 30min. Unbound antibod-
ies were washed off with PBS and 1% BSA, and the cells were
incubated for 30 min with FITC-conjugated goat anti-mouse
antibody. After washing, the fluorescence intensity was ana-
lyzed on a FACScan flow cytometer (BD Biosciences Immuno-
cytometry Systems).
RESULTS
Identification of New mAbs with Preferential Binding to
Pro-PR3—To generate antibodies with preferred specificity for
the inactive conformation of pro-PR3, we produced a pro-PR3
variant that was resistant to cathepsin C cleavage and other
exopeptidases. Non-hematopoietic cells like HEK 293 cells
were found to be devoid of cathepsin C and could not properly
convert recombinant neutrophil serine protease precursors to
mature enzymes.Nevertheless,minimal amounts of amino-ter-
minally processed active recombinant PR3have been noticed in
cell lysates of HEK 293 cells transfected with wild-type PR3
cDNA.4 Therefore, a PR3 variant with an amino terminus that
cannot be trimmed by exo- and endopeptidases was con-
structed and expressed in a stable HEK 293 cell line. The cDNA
construct proP-PR3ctp codes for the insertion of a proline res-
idue between the natural propeptide Ala-Glu and the amino
terminus of mature PR3. The resulting pro-PR3 variant (Fig.
1A) with the amino-terminal sequence Ala-Glu-Pro-Ile-Val-
Gly-Gly cannot be processed by cathepsin C or other exodipep-
tidases. This was verified by radiosequencing of supernatants
and lysates from [3H]isoleucine pulse-labeled HEK 293 cells
expressing proP-PR3ctp (data not shown). ProP-PR3ctp was
purified via immunoaffinity chromatography from cell culture
supernatants of HEK 293 cells.
Splenocytes from BALB/c mice immunized with this pro-
PR3 variant were fused with FO myeloma cells. The resulting
hybridoma cell cloneswere screened for anti-PR3 IgG secretion
via capture ELISA as described under “Experimental Proce-
dures.” Supernatants from 43 cell clones that reacted with pro-
PR3 in the initial capture ELISA were retested in parallel for
reactivity with pro-PR3 and mature PR3. Nineteen of these
showed between 0 and 30% difference in reactivity (group A)
with the two antigens, 13 showed a 31–60% difference (group
B), and 11 displayed a 61–96%difference (groupC). Four clones
from group A, five from group B, and nine from group C were
subjected to another round of dilution subcloning and retested
for differential binding to pro-PR3 and mature PR3. Only six
clones with persistent pro-PR3 reactivity emerged. Four of
these showed similar reactivity with both antigens, and two had
a 75% greater reactivity with pro-PR3 compared with mature
PR3. Clone MCPR3-7, generating the highest signal difference
between pro-PR3 and mature PR3 in the capture ELISA (Fig.
1B), was chosen for further characterization.
To demonstrate the differential binding of MCPR3-7 to pro-
PR3 and mature PR3, rabbit anti-mouse IgG bound to Staphy-
lococcus aureus protein A was incubated with dilutions (rang-
4 U. Specks, unpublished data.
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ing from 1:100 to 1:400 of a 1.3 mg/ml stock solution) of
MCPR3-7 and was used to precipitate 500 ng/ml radiolabeled
pro-PR3 and mature PR3 from stably transfected HEK 293
cell culture supernatants. Immunoprecipitated proteins
were separated by SDS-PAGE (12% gels) under reducing con-
ditions (Fig. 1C). The preferential recognition of pro-PR3 by
MCPR3-7 was observed at all mAb concentrations tested.
These findings confirmed that MCPR3-7 preferentially bound
pro-PR3 but that there was some cross-reactivity with mature
PR3.
Characterization of the MCPR3-7 Binding Site—To deter-
mine whether MCPR3-7 and MCPR3-2, which is known to
bind pro-PR3 and mature PR3 equally well, recognize non-
overlapping PR3 surface structures, we modified the bead-
based capture assay. Pro-PR3 (PR3ctp-S195A-cmyc) was
attached to the beads as an antigen because both mAbs bound
to it with similar affinity. Fig. 2A shows that each unlabeled
mAb inhibited the binding of its FITC-labeled derivative by
more than 90% (upper left and lower right panels). In contrast,
unlabeled MCPR3-7 did not interfere with the binding of
FITC-conjugated MCPR3-2 (lower left panel), and unlabeled
MCPR3-2 inhibited the binding of FITC-conjugated
MCPR3-7 by only 21% (upper right panel). These findings
corroborated previous data (30), clearly indicating that
MCPR3-7 recognized a unique epitope on pro-PR3 that is
different from that of MCPR3-2 and all other mAbs. The
precise binding site of MCPR3-7, however, remained uncer-
tain as the epitope on human PR3 was not lost after replacing
Ala146, Trp218, and Leu223 with the respective residues of
murine PR3.
Tomap the interaction ofMCPR3-7 in closer detail, we stud-
ied its effects on the activity of mature human PR3 in a FRET-
based activity assay. In contrast to CLB-12.8 and MCPR3-2,
MCPR3-7 inhibited the activity of human PR3 (Fig. 2B). This
inhibitory effect was already observed at a 1:1 ratio of PR3 and
MCPR3-7. PR3 was completely inhibited at a 3-fold molar
excess of MCPR3-7, whereas CLB-12.8 and MCPR3-2 did not
show any effect on PR3 activity even at a 15-fold molar excess
over PR3. This inhibitory effect of MCPR3-7 was sequence-de-
pendent as it was much less pronounced for the closely related
PR3 homolog of a gibbon species (Fig. 2C, second panel). The
activity of a chimeric PR3 variant composed of the amino-ter-
minal subdomain of gibbonPR3 and the carboxyl-terminal sub-
domain of human PR3 (gib/hPR3) was also suppressed by
MCPR3-7 (Fig. 2C, right panel). Conversely, MCPR3-7 had a
much smaller effect on the activity of an h/gibPR3 chimerawith
FIGURE 1. Schematic diagram of cDNA constructs and identification of pro-PR3-binding monoclonal antibodies. A, the PR3 variants pro-PR3ctp, proP-
PR3ctp, PR3ctp-S195A-cmyc, and pro(4DK)-PR3 are secreted by HEK 293 cells as an unprocessed zymogen (pro-PR3).PR3ctp-S195A andPR3-S195A do not
contain theamino-terminal activationdipeptideAEandare secretedasmaturebut catalytically inactivePR3. Ile16 andArg243 represent the amino-terminal and
carboxyl-terminal residue, respectively, of mature PR3 and are numbered as in Protein Data Bank code 1FUJ according to chymotrypsinogen. Except proP-
PR3ctp and PR3-S195A, all constructs have been described previously (see references for more details). ProP-PR3ctp carries an additional proline residue
between the natural dipeptide AE (light gray segment) and the amino terminus of mature PR3 (white bar). The resulting amino-terminal amino acid sequence
of proP-PR3ctp is AEPIVGG. The insertion of this proline residue precludes the activation by cathepsin C and prevents any contamination by intracellularly
processed (mature) PR3 in HEK 293 cells. The mutation S195A of the catalytic triad in mature PR3 eliminates the catalytic activity of the molecule, which was
required to avoid autodigestion and damage of HEK 293 cells during biosynthesis of PR3. B, monoclonal antibodies from hybridoma supernatants were
screened by capture ELISA with goat anti-mouse IgG. Subsequently, 0.025 g of radiolabeled pro-PR3 (proP-PR3ctp) or mature PR3 (PR3ctp-S195A) was
added. The captured PR3 is quantified in counts/min (CPM). MCPR3-2 is known to recognize pro-PR3 and mature PR3 equally well and served as a control.
MCPR3-7 displayed the largest difference in the binding to pro-PR3 and mature PR3. All other hybridomas (one example shown) discriminated less well
between the two antigens. C, rabbit anti-mouse IgG bound to S. aureus protein A was incubated with various dilutions of MCPR3-7 (1.3 mg/ml stock solution)
and used to immunoprecipitate radiolabeled pro-PR3 (proP-PR3ctp) or mature PR3 (PR3ctp-S195A) from transfected HEK 293 cell supernatants. Immuno-
precipitated proteins were then separated by SDS-PAGE (lanes 1–3, pro-PR3; lanes 4–6, mature PR3) and visualized by autoradiography (3 days of exposure).
All dilutions of MCPR3-7 showed intense binding of pro-PR3 and weak recognition of mature PR3. Error bars represent S.E.
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a humanized amino terminus and a carboxyl-terminal gibbon
subdomain (Fig. 2C, third panel). As MCPR3-7 completely
inhibited the activity of the gibbon/human PR3 but not that of
the human/gibbon PR3 chimera, we conclude that its major
binding region is located within the carboxyl-terminal sub-
domain (barrel) of human PR3.
Binding Affinity of MCPR3-7 for Different PR3 Con-
formations—To quantify the differences in binding affinities
of MCPR3-7 to either pro(4DK)-PR3, active PR3, or PR3 in a
complex with AAPV-CMK (see below for details), microscale
thermophoresis (MST), the directed movement of molecules
along a microscopic temperature gradient, was utilized. MST
can be used to determine biomolecular binding affinities in free
solution as it probes any binding-induced changes in size,
charge, or conformation (33). In an all-optical, free solution-
based approach, thermophoresis of the samples inside a glass
capillary was induced via IR laser heating and observed via
detection of a red fluorescent label covalently attached to
MCPR3-7. When the IR laser is turned on, the fluorescence
signal drops for two reasons: first, because of an intrinsic
temperature effect on the fluorophore (100-ms time scale), the
so-called temperature jump, and second, because of thermo-
phoretic depletion (several seconds). Pro(4DK)-PR3, CMK-in-
hibited PR3, and PR3 were titrated against a fixed concentra-
tion of labeled MCPR3-7. Binding induced a change in both
temperature jump and thermophoresis. As the thermophoretic
depletion is linear to the bound fraction, the dissociation con-
stant KDwas determined by fitting the data points to the quad-
ratic solution of themass action law.MST revealed a high bind-
ing affinity of MCPR3-7 to the proform with a KD 10 nM. By
contrast, we were not able to detect any binding ofMCPR3-7 to
the active conformation of PR3 stabilized by complexationwith
CMK, an irreversible, mechanism-based small molecule inhib-
itor of PR3 (Fig. 3A). This clearly indicated thatMCPR3-7 selec-
tively recognized the zymogen conformation of PR3. Using
active PR3, however, we noticed thatMCPR3-7was indeed able
to interact with mature PR3 but with a much lower affinity in
comparison with pro(4DK)-PR3 (Fig. 3B). This is probably due
to a reversible allosteric switch from the active form of PR3 to a
more zymogen-like conformation in free solution that is recog-
nized byMCPR3-7. AKD of 0.4 0.2Mcould be inferred from
the data. This means that the affinity of MCPR3-7 for the free
active form is40-fold lower than for its proform.
Interaction of mAbs with Different PR3Inhibitor Complexes—
To test the differential binding capabilities of mAbs to
PR3inhibitor complexes, complexes were formed by adding a
FIGURE 2. Characterization of the MCPR3-7 binding site. A, pairwise competition between the unlabeled PR3-specific mAbs MCPR3-2 and MCPR3-7 and
FITC-conjugatedMCPR3-2 andMCPR3-7 using a bead-based FACS assay. UnlabeledMCPR3-2 andMCPR3-7 (on the left) served as inhibitors for the binding of
the respective FITC-taggedmAbs (on the top) to immobilizedpro-PR3. Pro-PR3was chosenas it binds equallywell tobothmAbs. The continuous lines represent
the binding of FITC-conjugatedmAbs to pro-PR3-coated beads in the absence of a competingmAb; black reference histograms indicate the lack of binding to
uncoated beads; the dashed lines refer to the binding of FITC-conjugated mAbs after preincubation of the pro-PR3-coated beads with unlabeled mAbs. The
degree of inhibition of the FITC-conjugated mAb after preincubation with unlabeled antibodies is expressed in percent. Using the same mAb as unlabeled
competitor, inhibition was 95% for MCPR3-2 (A, upper left panel) and 91% for MCPR3-7 (A, lower right panel). Unlabeled MCPR3-7 did not interfere with the
binding of FITC-conjugatedMCPR3-2 (A, lower left panel), and the binding of FITC-conjugatedMCPR3-7 was only inhibited by 21% due to unlabeledMCPR3-2
(A,upper right panel). These findings indicate that the twomAbs recognizedistinct andnon-overlappingepitopes.B, PR3 activitywasmeasured in thepresence
of three mAbs at different concentrations to study their differential inhibitory capacity (n 3;S.E.). The activity of PR3 (50 nM) was measured with 800 nM
Abz-Tyr-Tyr-Abu-ANB-NH2.MCPR3-2 and CLB-12.8 did not have any effect on the PR3 activity. By contrast, MCPR3-7 completely inhibited PR3 at a 3-foldmolar
excess and above. C, the activity of gibbon PR3, human PR3, and two gibbon/human chimeras was determined in the presence of a 2-fold molar excess of
MCPR3-7. The h/gibPR3 variant consists of the human amino-terminal -barrel and the gibbon carboxyl-terminal -barrel, whereas the gib/hPR3 variant
contains the human carboxyl-terminal -barrel. The activity of PR3 variants in the presence or absence of MCPR3-7 was measured utilizing a highly sensitive
FRET substrate, Abz-Tyr-Tyr-Abu-ANB-NH2, and is shown in relative fluorescence units (RFU) as an example of three technical repeats. MCPR3-7 strongly
inhibited hPR3 and gib/hPR3 but not h/gibPR3. Accordingly, the epitope of MCPR3-7 is located on the carboxyl-terminal -barrel. Error bars represent S.E.
Antibodies Interfering with PR3 Activity and Inactivation
SEPTEMBER 13, 2013•VOLUME 288•NUMBER 37 JOURNAL OF BIOLOGICAL CHEMISTRY 26641
 at U
BM
 Bibliothek G
rosshadern on June 4, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
10-fold molar excess of each inhibitor to PR3 and incubating
these mixtures at 37 °C for 1 h. To generate covalently linked
complexes, natural 1PI or AAPV-CMK was added to active
His-tagged PR3 (activated pro(4DK)-PR3). In the case of 1PI,
the resulting complexes were purified over a nickel column and
checked for complete complexation on a polyacrylamide gel
(data not shown). Free, uncomplexed PR3 was excluded in this
way. The canonical PR3elafin complexes were also made with
active enzyme, whereas the catalytically inactive PR3-S195A
variant was used to assemble the so-called canonical encounter
complex between PR3 and 1PI (PR3*1PI). These PR3 com-
plexes were immobilized on nickel plates. MCPR3-7 (Fig. 4A)
only showed weak binding to active PR3, PR3elafin, CMK-
inhibited PR3, and the encounter complex. By contrast,
MCPR3-7 strongly bound to pro(4DK)-PR3.Most surprisingly,
MCPR3-7 also showed strong binding to the covalent PR31PI
complex although, as mentioned before, not to the PR3AAPV-
CMK complex. The structural background for its differential
binding to serpin-inactivated PR3 and canonical PR3 com-
plexes is the precursor-like conformation of PR3 in the covalent
serpin complex, whereas complexation of active PR3 with
AAPV-CMK and elafin as well as complexation of catalytically
inactive PR3 to 1PI does not alter the mature conformation of
PR3. Conversely, CLB-12.8was able to bind all PR3 variants and
inhibitor complexes except for the covalent PR31PI complex
(Fig. 4B). The epitope of CLB-12.8 lies close to the active site
cleft andmay become inaccessible after binding and rearrange-
ment of 1PI (30). MCPR3-2 was chosen as an appropriate
coating control (Fig. 4C) as it could bind to all PR3 variants.
Thus, equal coating of wells with different variants was ascer-
tained. No interaction between PR3 complexes and an isotype
control antibody was observed.
Inhibitory Effect of mAbs on Serpin Complexation—To assess
the impact of the antibodies on the interaction between PR3
and 1PI, we monitored the covalent complexation in the
presence of a 3-fold molar excess of mAbs after different
incubation times by SDS-PAGE. The reaction of PR3 with
1PI in the absence of antibodies at different time points is
shown in Fig. 5A. The complexes occurred immediately after
mixing the two components, and the reaction was already
completed within 5 s of incubation. In contrast, preincuba-
tion of PR3 with MCPR3-7 led to a delay of complexation
(Fig. 5B). At the early time points until 15 s, hardly any com-
plexes could be detected. Complex formation was only com-
pleted within a time span of 3 min. By comparison, CLB-12.8
(Fig. 5C) and MCPR3-2 (Fig. 5D) did not show any effect on
PR31PI complexation. Under these assay conditions, com-
plexes were formed within the first 5 s as seen without anti-
bodies, and it took only 15 s until all PR3 was covalently
attached to 1PI. These findings clearly indicate that the
binding of MCPR3-7 to PR3 affects the covalent complex-
ation with 1PI and delays the irreversible inhibition of PR3.
FIGURE 3. Thermophoretic quantification of MCPR3-7 binding affinity.
Startingat amaximumconcentrationof 2.5M,pro(4DK)-PR3, activePR3, and
PR3 complexed with AAPV-CMK (PR3.CMK) were titrated against a constant
concentration of fluorescently labeled MCPR3-7 (50 nM). The biophysical
method of MST allows an absolute affinity quantification by fitting the ther-
mophoretic depletion to the quadratic solution of the mass action law with
the dissociation constant KD as the single free fit parameter. Data points rep-
resent themean value of at least three technical repeats; the error bars repre-
sent themeanof theS.D.KDvalues aregivenwith anerror estimation fromthe
fit. A, MST revealed a strong binding affinity of MCPR3-7 to pro-PR3 (KD 10
nM; blue rectangles). In contrast, MCPR3-7 did not showbinding to themature
conformation of the PR3CMK complex (gray triangles). B, active PR3 was
bound with a much lower affinity (KD  0.4  0.2 M) corresponding to a
40-fold weaker binding compared with pro-PR3 (red circles).
FIGURE 4. Interactionofmonoclonal antibodieswithdifferent PR3inhibitor complexes. Inhibitorswere added to PR3 in solution at a 10-foldmolar excess
relative to PR3 and incubated at 37 °C for 1 h. His-tagged pro-PR3 (pro(4DK)-PR3), active PR3 (activated pro(4DK)-PR3), and PR3 complexes were immobilized
on nickel plates. Binding of the monoclonal antibodies was analyzed via ELISA using a secondary anti-mouse HRP-conjugated polyclonal antibody. Recogni-
tion of PR3 variants of three technical repeats was normalized to the signal obtained with pro-PR3, which was set to 100% (n 3;S.E.). A, MCPR3-7 was able
to bind strongly to pro-PR3 and covalent PR31PI complexes but failed to bind to active PR3 or other complexes. B, no binding of CLB-12.8 to the covalent
PR31PI complex was observed, whereas all other variants were bound similarly. C, binding of MCPR3-2 was used as a coating control and showed similar
binding to all complexes. Error bars represent S.E.
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Effects of mAbs on Noncovalent Complex Formation via
Thermophoresis—To find outwhether themAbsMCPR3-7 and
CLB-12.8 interfere with the formation of the canonical
PR31PI complex, thermophoretic competition experiments
were performed. To this end, the binding of NT647-labeled
1PI to PR3-S195A was quantified in the presence or absence
of mAbs (Fig. 6). To form the PR3mAb complexes, the compo-
nents were preincubated for 1 h before adding labeled 1PI and
measuring the binding affinity.
PR3-S195A and1PI boundwith aKD of 1.9 1.1M in the
absence of mAbs. In the competition experiments, we were not
able to use saturating amounts of MCPR3-7 as this antibody
could not be concentrated to very high levels. We instead used
a relatively low MCPR3-7 concentration of 570 nM. Thus, not
only MCPR3-7PR3-S195A complexes but also free PR3-
S195A is present in solution. This reduces the putative overall
effect of the antibody on the binding curve and leads to a more
complex binding behavior. The thermophoresis signal corre-
sponds to the binding of 1PI to free and MCPR3-7-bound
PR3-S195A, which is most likely characterized by two differ-
ent KD constants. The data could not be fitted to a more com-
plex bindingmodel as saturationwas not reached in the binding
curve, and data points for higher MCPR3-7 concentrations
were limited.
We instead chose to fit the data to the simple model accord-
ing to themass action law, which in this case revealed an appar-
ent KD of 5.6 1.0 M. This apparent KD corresponds not only
to the binding of 1PI to MCPR3-7PR3-S195A complexes
FIGURE 5. Interference of monoclonal antibodies with PR3serpin complexation. A, covalent complexation of PR3 (800 nM) with 1PI was measured over
time by adding a 5-fold molar excess of 1PI at 37 °C. B–D, after preincubation of PR3 with a 3-fold molar excess of the different antibodies, the effects of
MCPR3-7 (B), CLB-12.8 (C), andMCPR3-2 (D) on this reactionweremeasured. Examples of three technical repeats are shown. The covalent bindingof1PI to PR3
was delayed by MCPR3-7, whereas CLB-12.8 and MCPR3-2 did not affect this complexation.mAb, monoclonal antibody; IgGH, IgG heavy; IgGL, IgG light.
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but also to 1PI binding to free PR3-S195A still present in
solution. Taking into account the rather high affinity between
1PI and PR3-S195A (1.9 M), the actual binding affinity of
1PI for MCPR3-7PR3-S195A complexes can be expected to
be lower than the measured apparent affinity (KD of 5.6  1.0
M). The competition experiment demonstrates the inhibiting
impact of MCPR3-7 on PR31PI noncovalent complex forma-
tion: preincubation withMCPR3-7 reduced the apparent affin-
ity by a factor of 3. This inhibitory effect was already observed
despite a relatively lowMCPR3-7 concentration. Preincubation
of PR3-S195A with a higher MCPR3-7 concentration can be
expected to lead to a much more pronounced decrease of the
apparent affinity to 1PI. This finding clearly indicates that
binding of MCPR3-7 leads to a conformational change of the
free active PR3 and impairs the canonical interaction of PR3
and 1PI (Fig. 7).
In contrast to this pronounced impact of MCPR3-7, prein-
cubation of PR3-S195A with CLB-12.8 did not have an effect
on its affinity to1PI. The fitted binding curve depicted a nearly
perfect overlay of the curve without mAbs, and the KD of 1.8
0.8 M did not significantly differ from the KD without mAbs
(1.9  1.1 M). The affinity of CLB-12.8 to PR3-S195A is
expected to be much higher than the affinity of MCPR3-7 to
PR3-S195A. Thus, when adding the same concentration of
CLB-12.8 and MCPR3-7, a much higher amount of CLB-
12.8PR31PI complexes is present in solution. Nevertheless,
CLB-12.8 did not have any effect on the canonical PR3-
S195A1PI complexation.
Activity Changes of PR3 Induced by MCPR3-7—To deter-
mine which subsites of PR3 are affected by conformational
changes upon MCPR3-7 binding, the activity of PR3 toward
different substrates was tested in the presence and absence of
MCPR3-7.We used substrates with different amino acids at the
P1 site and different leaving groups at the P1 site. The cleavage
of the substrate Abz-Tyr-Tyr-Abu-ANB-NH2 with the best fit-
ting non-natural residue in P1was strongly inhibited after bind-
ing of MCPR3-7 to PR3 (Fig. 8A). Likewise, the substrates
5-TAMRA-VADnVADYQ-DAP(CF) (Fig. 8B), an optimized
extended peptide substrate, and Ahx-PYFA-pNA (Fig. 8C), a
substrate with a relatively big leaving group in the P1 position,
could no longer be cleaved by PR3-MCPR3-7 complexes. In
contrast, the substrates Boc-Ala-ONp (Fig. 8D) and Boc-Ala-
Pro-nVal-SBzl (Fig. 8E), which carry residues of different sizes
in their P1 position but have relatively small leaving groups in
the P1 position, were efficiently cleaved by PR3 even after
binding of MCPR3-7. The cleavage of For-Ala-Ala-Pro-Abu-
SBzl was partly inhibited by the binding of MCPR3-7 to PR3
(Fig. 8F), but PR3 still showed activity toward this substrate at a
lower rate of about 50%. These findings strongly suggest that
the conformation of the S1 pocket is not changed significantly
after binding of MCPR3-7, but rather the S1 subsite of PR3
is changed. Smaller leaving groups can still interact with
PR3MCPR3-7 complexes, whereas substrates with larger leav-
ing groups could not be cleaved.
Detection of PR3 Expression on Neutrophil Membranes—Af-
ter biochemical characterization of MCPR3-7 and MCPR3-2,
we explored these as potential tools to determine PR3 expres-
sion on the membranes of non-stimulated neutrophils. A
bimodal expression pattern of PR3 representing a large popu-
lation of PR3-positive and a small subpopulation of PR3-nega-
tive neutrophils from peripheral blood was observed using
MCPR3-2 for the recognition of membrane-bound PR3 (Fig.
9A, continuous black line). The majority of cells expressed PR3
on their surface, and a much smaller number of cells had no
detectable membrane PR3 (Fig. 9A). After TNF priming, the
membrane-bound PR3 fraction increased, and essentially all
PMNs expressed PR3 on their surface (Fig. 9B). CD32 staining
served as a positive control and is indicated by the dotted line.
When MCPR3-7 was used for the detection of membrane-
bound PR3 on unstimulated neutrophils, the vast majority of
cells did not display anymembrane PR3, and only a tiny second
population (arrow) with marginal MCPR3-7 reactivity was
observed (Fig. 9C). After TNF stimulation, a strong increase of
membrane-bound PR3 was observed using MCPR3-2, and
again this increase was not discernible with MCPR3-7; in fact,
FIGURE 6. Evaluation of the interference of mAbs with the noncovalent
PR31PI complex formation via thermophoresis. Starting with a maxi-
mum concentration of 12 M, dilution series of PR3-S195A were prepared.
Each sample of the dilutionwasmixed 6:1with either PBS,MCPR3-7 in PBS, or
CLB-12.8 in PBS to yield a mAb concentration of 670 nM. After preincubation
for 1 h at room temperature, 1PI-NT647 was added to yield a final concen-
tration of 880 nM. Thermophoresis revealed a KD of 1.9  1.1 M in the
absence of mAbs (blue rectangles). Preincubation with CLB-12.8 did not have
a significant effect on the affinity (KD  1.8 0.8 M; gray triangles). In con-
trast, preincubation with MCPR3-7 led to a right shift of the binding curve
corresponding to a 3-fold decrease in the apparent affinity to1PI (KD5.6
1.0 M; red circles). Error bars represent S.D.
FIGURE 7. Impact ofMCPR3-7 on PR3 activity and1PI inhibition. Binding
of MCPR3-7 to the proform of PR3 (Z) leads to slight conformational changes
of the zymogen (Z*). The mature form of PR3 occurs in an equilibrium
between a highly favored active (E) and an inactive (E*) conformation. Bind-
ing of the antibody shifts this equilibrium between E and E* toward the inac-
tive E*. The antibody interaction stabilizes an altered conformationof E (mod-
ified substrate binding cleft; left shape) and changes activity and substrate
specificity of PR3 (open substrate binding cleft; right shape). It also has an
inhibitory effect (dotted arrow) on the complexation with 1PI.
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essentially none of the cells displayed PR3 binding toMCPR3-7
(Fig. 9D).
The likely reason for these disparate findings is that human
PR3 is attached to membranes specifically and forms com-
plexes with CD177 and/or lipid bilayers with its active confor-
mation. Under these conditions, it cannot present the
structural determinants recognized byMCPR3-7. These obser-
vations are fully consistent with the idea that MCPR3-7 inter-
actswith hydrophobic patches of the activation domain that are
not accessible in membrane-bound PR3.
DISCUSSION
The initial goal of this study was to identify a mAb that pref-
erentially recognized the inactive proform of human PR3. As
the proform sequence of PR3 is only two residues longer than
the mature enzyme and the amino-terminal sequence of serine
proteases is highly conserved, a unique amino-terminal peptide
as a proform-specific immunogen cannot be designed. We
therefore aimed at identifying a conformation-specific anti-
body that discriminates between the two principal conforma-
tions of mature and catalytically inactive PR3 (23). To prevent
any spurious amino-terminal processing during synthesis of the
recombinant pro-PR3 as well as subsequent in vivo modifica-
tions of the immunogen after injection, we inserted a proline
residue between the natural propeptide and the amino termi-
nus of mature PR3 (Fig. 1A). Most proteases including exo-
aminopeptidases even in combinationwith dipeptidyl aminopep-
tidase I cannot remove this tripeptide after a proline residue
(34, 35). Moreover, endogenous PR3 inhibitors cannot associ-
ate with the proform of PR3, which would restrict the surface-
accessible area for antibody responses.
The challenge of this strategy, however, was the high struc-
tural similarity between the proform (Z) and themature formof
PR3 (E) whose conformations only differ in one subregion, the
so-called activation domain (22). The activation domain of
mature PR3 can adopt a zymogen-like conformation (E*) even
after propeptide removal although with low probability (24).
Binding of an antibody could forcefully induce this zymogen-
like, catalytically inactive state even in mature, amino-termi-
nally processed PR3, resulting in a loss of the S1 binding site and
oxyanion hole. In view of these circumstances, it was not too
FIGURE 8. Binding of MCPR3-7 leads to an alteration in the S1 subsite of PR3. The effect of MCPR3-7 binding on the cleavage of different PR3 substrates
was obtained in three technical repeats (S.E.) with a 50 nM PR3 solution (A–E) or a 100 nM PR3 solution (F). A 3-fold molar excess of MCPR3-7 hindered the
binding and cleavage of 800 nMAbz-Tyr-Tyr-Abu-ANB-NH2 (A), 5M5-TAMRA-VADnVADYQ-DAP(CF) (B), and 1mMAhx-PYFA-pNA (C), whereas the cleavage of
1 mM Boc-Ala-ONp (D) and 1 mM Boc-Ala-Pro-nVal-SBzl (E) was not affected by the binding of MCPR3-7. For-Ala-Ala-Pro-Abu-SBzl (F) at a 1 mM concentration
was still cleaved by PR3MCPR3-7 complexes but at a lower rate of about 50%. The relative activity was determined by normalizing the activity of PR3 in the
absence of antibodies to 1. Error bars represent S.E.
FIGURE9.Differential recognitionofPR3onneutrophilmembrane.Mem-
brane expression of PR3 (continuous black line) in non-stimulated (A and C)
and TNF-primedneutrophils (B andD) was detectedwithMCPR3-2 (A and B)
and MCPR3-7 (C and D). The gray peak represents an isotype control, and
CD32 expression is represented by the dotted line. Non-stimulated neutro-
phils from this individual donor showed a bimodal distribution of PR3 mem-
brane expression (A). PR3 membrane expression increased with priming of
theneutrophils, andessentially all neutrophils expressedPR3detectablewith
MCPR3-2 (B). By contrast, only a small fraction of unprimed neutrophils
(arrow) expressed membrane PR3 using MCPR3-7 (C); PR3 expressed on
primed neutrophils was essentially undetectable by MCPR3-7 (D).
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surprising that most mAbs generated failed to discriminate
these two conformational states and showed very similar bind-
ing to both PR3 preparations.
Therefore, we selected a mAb on the basis of its differential
affinities to both conformational states. To this end, we tested
the direct binding of radioactively labeled pro-PR3 and PR3 to
immobilized hybridoma IgG in an ELISA and to IgGs in solu-
tion followed by a single immunoprecipitation step (Fig. 1, B
and C) and decided to use MCPR3-7, which showed the best
discrimination between the two forms, for further analysis. To
stabilize the activation domain in its active conformation, we
used a mechanism-based small molecule inhibitor, Ala-Ala-
Pro-Val-CMK, which forms a stable covalent complex with the
transition state of PR3 (E) during catalysis, and tested the bind-
ing capability of this antibody to the active conformation.
Indeed, this covalent complex displayed no detectable affinity
toward MCPR3-7 as determined by ELISA (Fig. 4A) and by
thermophoresis in free homogenous solution (Fig. 3A). In con-
trast, free active PR3 in solution showed some affinity for
MCPR3-7 as revealed by thermophoresis, although it was40-
fold lower than that of pro-PR3. This weak interactionwith free
mature PR3 was also detectable by ELISA. Consistent with this
finding, MCPR3-7 showed minimal binding to the so-called
canonical complexes in which PR3 is constrained to adopt its
active conformation (Fig. 4A). Covalently linked complexes
between 1PI and PR3, however, exposed the epitope for
MCPR3-7 (Fig. 4A). Two studies reporting covalent serpin
structures between pancreatic elastase and 1PI (36) and tryp-
sinwith an argininemutant of1-antitrypsin (37) point out that
the P1 residue of the reactive center loop is no longer buried in
the S1 pocket of the protease and that the so-called autolysis
loop 142–149, the 186–190 loop, and the amino-terminal four
residues are disordered.Within this covalent complex, the pro-
tease adopts a zymogen-like conformation (E*) that carries the
target epitope of MCPR3-7 on the accessible surface.
TheMCPR3-7 epitope wasmapped to the carboxyl-terminal
half of PR3 using human/gibbon chimera (Fig. 2C). Non-con-
servative residue substitutions are found on all three loops of
the so-called activation domain: a Lys to Gly change at position
187, a Trp to Arg substitution at 218, and an Ala to Thr switch
at position 146 within the autolysis loop (31). MCPR3-7, which
is able to interact with free active PR3 in solution, showed a
strong inhibitory effect toward human PR3 and most signifi-
cantly inhibited the activity of the chimera with the human
sequence in the carboxyl-terminal half, which makes up the
activation domain. This differential inhibitory effect on the gib-
bon/human versus the human/gibbon chimera (Fig. 2C) clearly
indicates that the major binding site of MCPR3-7 is on the
carboxyl-terminal half of PR3. These functional data are fully
consistent with our previous observation that the epitope of
MCPR3-7 could be reconstructed at least in part by amurine to
human residue swap in the carboxyl-terminal half of murine
PR3 (T146A,R218W,Q223L) (30).
Two other mAbs tested in this study (Fig. 2B) did not show
any effect on the activity of human PR3 and also did not inter-
fere with the inhibitory effect of MCPR3-7, indicating that the
antibody binding site ofMCPR3-7 is unique and does not over-
lap with the epitopes of the other mAbs (Fig. 2A). The strong
inhibitory effect of MCPR3-7 was detected with an internally
quenched substrate that occupies the S3 to S1 subsites of PR3
(Tyr-Tyr-Abu) and interacts with the S4 and S1 pockets by
virtue of its quencher ANB-NH2 and fluorogen Abz, respec-
tively (Fig. 2B).
Substrates with other P1 leaving groups, e.g. 5-amino-2-ni-
trobenozoic acid (ANB-OH), para-nitroaniline (pNA), the
benzylmercaptan from thiobenzyl esters, the para-nitrophenol
from Boc-L-Ala-ONp, do not interact with the S1 subsite of
PR3 as efficiently as ANB-NH2 substrates (26). Indeed, we
found that cleavage of the small ester substrate Boc-L-Ala-ONp
and the thioester substrate Boc-Ala-Pro-nVal-SBzl (Fig. 8, D
and E) was not significantly affected by MCPR3-7, suggesting
that the shape and/or access to the S1 pocket is primarily
altered in theMCPR3-7PR3 enzyme complex. Although the S1
pocket can accept P1 residues like Ala and nor-Val, which are
shorter and longer than Abu, respectively, the S1 pocket
appears to accept only smaller and less polar leaving groups
after MCPR3-7 binding. Extended peptide substrates that have
to be optimally aligned with the S1, S1, and S2 pockets were
most strongly affected by MCPR3-7 binding (Fig. 8B). More-
over, binding of this antibody to active PR3 reduced canonical
interactions with the reactive center loop of 1PI (Fig. 6) and
subsequent covalent complex formation (Fig. 5). Taken
together, all these characteristics qualify MCPR3-7 as a first
prototype of a PR3-directed conformation-specific mAb with
inhibitory properties. Inhibition is most likely due to an allo-
steric effect changing the autolysis and 187–190 loops. Both
loops shape the size and physical character of adjacent subsites
around the cleaved peptide bond, namely S1, S1, and S2. The
autolysis loop (Gly145–Ala152) shows the highest temperature
factor of themain chain and is completely disordered in all four
PR3 molecules of the asymmetric unit (21). A second region
with a high temperature factor maps to the 187–190 loop (21).
Such regions are in general preferred target sites for antibody
interactions and are good targets for allosteric regulation of
enzyme activities. Capture of partially altered loop conforma-
tions of PR3 by MCPR3-7 most likely changes substrate recog-
nition and impairs the interaction of PR3 with the reactive cen-
ter loop of 1PI.
Antibodies that can interfere with the catalytic activity of
serine proteases are classified in two groups according to their
mode of action as reviewed recently (38). Antibodies like
MCPR3-7 induce an allosteric switch in the target antigen. This
first group of antibodies does not directly compete with sub-
strates for the active site cleft but rather interacts with a region
at the periphery of the substrate binding region. Upon binding
to the enzyme, antibodies of this group induce a significant
conformational switch in surface loops that determine the
shape and size of substrate binding pockets. The epitopes of
these antibodies can be regarded as regulatory hot spots that are
connected to mobile surface structures around the active site
cleft. The altered conformation of loops surrounding the sub-
strate binding pockets reduces, alters, or suppresses catalytic
activity.
The second group can bind to the catalytic domain of a serine
protease in a way that substrate access to the catalytic cleft is
partially or fully occluded. Some complementarity-determin-
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ing region loops of these antibodies directly insert into sub-
strate binding pockets and occupy the substrate binding
regions with high affinity. The latter type of antibodies, how-
ever, is rarely found in mammals and is hardly induced by
immunizations as the antigen binding surface of mammalian
antibodiesmostly interacts with convex, protruding surfaces or
a flat surface of an antigen. Directly inhibiting antibodies, how-
ever, have been produced in camelids. These antibodies repre-
sent unusual homodimers of a single heavy chain but are immu-
nogenic in humans. Hence, camelid antibodies so far have
found little application in preclinical (animal) and clinical
studies.
Identification of monoclonal antibodies with similar proper-
ties and epitope specificity asMCPR3-7 but a higher affinity for
mature PR3 should be of medical impact for two reasons. Anti-
bodies of this type would not only block the binding of secreted
soluble PR3 to neutrophils membranes but also could serve as
selective PR3 inhibitors and clearers of PR3. Application of
these antibodies in GPA patients may reduce the extent of neu-
trophil activation by anti-neutrophil cytoplasmic antibody via
membrane-bound PR3 and Fc receptors and other tissue-
damaging effects of secreted PR3.
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ABSTRACT: The direct quantification of both the binding affinity and
absolute concentration of disease-related biomarkers in biological fluids
is particularly beneficial for differential diagnosis and therapy
monitoring. Here, we extend microscale thermophoresis to target
immunological questions. Optically generated thermal gradients were
used to deplete fluorescently marked antigens in 2- and 10-fold-diluted
human serum. We devised and validated an autocompetitive strategy to
independently fit the concentration and dissociation constant of
autoimmune antibodies against the cardiac β1-adrenergic receptor related to dilated cardiomyopathy. As an artificial antigen,
the peptide COR1 was designed to mimic the second extracellular receptor loop. Thermophoresis resolved antibody
concentrations from 2 to 200 nM and measured the dissociation constant as 75 nM. The approach quantifies antibody binding in
its native serum environment within microliter volumes and without any surface attachments. The simplicity of the mix and
probe protocol minimizes systematic errors, making thermophoresis a promising detection method for personalized medicine.
Only a few physical forces are strong enough to inducetranslational motion of molecules in their native
environment. Light fields or magnetic fields, for example, are
not sufficient. Electrophoresis is the dominant technique to
separate biomolecules on the basis of their size and structure.
Unexpectedly, focused temperature fields can move biomole-
cules, an effect termed “thermophoresis”. Temperature cannot
drive molecules over large length scales as electrophoresis does.
Thermophoresis merely leads to a 20% concentration depletion
over tens of micrometers when moderate temperature
differences on the 5 K scale are applied. However, this small
depletion is easily detectable with fluorescence and provides
detailed information on the molecule’s interface.
We devised a strategy to probe both the concentration and
affinity of biomolecules in bulk blood serum applying
microscale temperature gradients. In the recent past,
thermophoresis has been used successfully to detect close to
literature binding constants for nucleotide aptamers as well as
proteins binding to small molecules.1−3
Here, we established a combined dilution and autocompe-
tition protocol to tackle immunological problems in blood
serum as the according native environment. Unlike methods
depending on molecule immobilization to surfaces, microscale
thermophoresis (MST) to measure binding affinity in bulk fluid
requires only a single unspecific fluorescent probe. Fluores-
cence reports a change in thermophoretic depletion upon
binding, thus quantifying the latter within tens of seconds per
sample. We focused on the increasingly important group of
autoimmune diseases which are difficult to classify and treat
using standard immunological methods.
Dilated cardiomyopathy (DCM) is a nonischemic heart
muscle disease characterized by dilation and impaired
contraction of the left or both ventricles. With a prevalence
of 300−400 patients per million, DCM belongs to the main
causes of severe heart defects.4 Moreover, it is the prime reason
for heart transplantations.5 Besides genetic, toxic, and infectious
factors, autoimmune reactions are discussed as a putative
trigger for its appearance. In a notable number of DCM
patients, increased concentrations of autoantibodies against
several cardiac antigens, including membrane proteins such as
cell surface adrenergic receptors, are found.6−8 Some of these
autoantibodies seem to injure the myocardium directly or
indirectly.9 The β1-adrenergic receptor regulating heart activity
represents a major autoimmune target in DCM (Figure 1a).
Agonist-like antibodies found in DCM patients have been
shown to be associated with severe ventricular arryth-
mias.7,12−14 The prevalence of these antibodies varies from
30% to 95% in DCM sera and from 0% to 13% in sera from
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unaffected controls.15,16 It is widely accepted that, in many
patients suffering from heart failure, a chronic adrenergic
overexcitation plays a harmful role.17 Permanent stimulation of
β1-adrenoceptors due to elevated levels of circulating catechol-
amines in combination with autoantibodies could change the
Ca2+ homeostasis of cardiomyocytes, resulting in metabolic and
electrophysiological disturbances which are responsible for
tachyarrhythmia and sudden death.18 It was also shown that
DCM autoantibodies against β1-adrenergic receptors increase
the activity of cyclic adenosine monophosphate (cAMP)-
dependent protein kinase A (PKA).19 Therefore, the detection
of β1-adrenergic receptor autoantibodies in human serum as an
indicator for dilated cardiomyopathy and the development of
specific antigens are important steps toward reliable diagnostics
and treatment of the disease. The autoimmune antibodies’
target, the second extracellular receptor loop,10,11 is mimicked
by the candidate peptide drug COR1 (Figure 1b). Thus, COR1
competes with the binding of autoimmune antibodies to the
receptor. In animal models, COR1 was shown to prevent heart
failure and reverse existing cardiac insufficiency (manuscript in
preparation).
Although quantitative autoantibody analysis is crucial to
characterize and discriminate different autoimmune disease
types and optimize their treatment, it still remains challenging.
Enzyme-linked immunosorbent assays (ELISAs) are widely
used to detect and quantify disease-related biomarkers, but
display several disadvantages. Surface immobilization, initial
strong dilution as well as tedious washing steps, enzymatic
signal amplification, and normalization to a standard curve
often cannot be avoided, resulting in unpredictable influences
on the results. The optimization of surfaces and linkers has
improved the binding protocols of ELISA; however, it is time-
consuming and often depends on the studied binding reaction.
Linking small peptides to surfaces in a way that all binding
epitopes are presented in the same manner as in solution
remains a pertinent obstacle.20,21 The surface density of the
captured proteins is hard to predict.22,23 Additionally, the
nonspecific binding of molecules of interest and plasma/serum
poses a challenge. Thus, absolute biomarker quantification via
ELISA remains difficult. Despite these limitations and pitfalls,
the popularity and application depth of ELISA are enormous.
Only a few solution-phase alternatives to ELISA are being
utilized. As radioimmunoassays (RIAs) fulfilled these principles
very closely, they were popular until the 1970s. However, the
need for radioactive labeling and purification of the analyte−
probe complexes from the free radioactive probe by a
secondary reagent is a significant disadvantage compared to
the later developed ELISA.
A number of recent approaches are based on fluorescence
resonance energy transfer (FRET) between two labeled ligands
to detect binding in biological fluids or inside cells.24 For
example, homogeneous time-resolved fluorescence (HTRF)25
detects binding by proximity in bulk fluids, while in the bead-
based alphascreen26 singlet oxygen is used as a chemical
proximity signal.
In contrast to the above methods, microscale thermophoresis
is much simpler to set up, as only one binder is labeled and the
measurement follows a straightforward mix and read protocol.
It is sample-efficient and immobilization-free and allows
measurements in bulk fluids. As shown here, it can be used
for simultaneous and quantitative analysis of antibody
concentration and affinity, making it a promising alternative
to the commonly used techniques.
■ EXPERIMENTAL SECTION
Setup. A fluorescence microscope (AxioScope Vario, Carl
Zeiss GmbH, Germany) was modified by a 1480 nm infrared
heating laser (Fibotec Fiberoptics, Germany) generating local
temperature gradients in solution (Figure 2a and Supporting
Information).1,2 Most of the laser power is absorbed by the
probe volume. Back-reflected light is absorbed by an IR filter
placed above the fluorescence emission filter, and stray light is
blocked by housing the capillaries. The maximal temperature
increase was measured to be 8 K in the beam center using
BCECF (2′-7′-bis(carboxyethyl)-5(6)-carboxyfluorescein) and
finite element calculations (Figure 2b).27,28 With the initial
temperature jump set at time t = 0 s, the cold fluorescence
signal FI was averaged from −6 to −2 s, while the warm
fluorescence signal FII was between 1.2 and 3.7 s (Figure 2c).
Error bars of fluorescence F are the result of at least four
measurements.
Peptides. The dominant epitope in the second extracellular
domain of the β1-adrenergic receptor is the sequence
ARRCYND forming a disulfide bridge with the cysteine of
the first extracellular loop.11,34 COR1, an 18-mer cyclic peptide
with the sequence ADEARRCYNDPKCSDFVQ and the N-
and C-termini linked via a peptide bond, represents this second
extracellular loop. COR1 was labeled with a red dye, D2
(Figure 1c, Cisbio Bioassays, France).
Sample Preparation. Measurements were conducted in
phosphate-buffered saline (PBS) with 0.1% Tween 20 and
human serum. Serum from unaffected donors was collected in
S-monovettes (Sarstedt, Germany), incubated at room temper-
ature (30 min), and centrifuged (10 min, 12000g). The
supernatant was aliquoted and stored at −20 °C.
Measurement Protocols. For measurements with varying
antibody concentration, titration series of antibodies in PBS
were prepared using Quali-PCR-Tubes (Kisker, Germany). A
serial dilution was set up, starting with a concentration of 2.6
μM polyclonal antibody (pAB), with a 2-fold dilution down to
2.6 nM. Separately, a 40 nM COR1-D2 stock was prepared in
PBS with 0.2% Tween 20 or blood serum. The monoclonal
antibody concentration ranged from 4000 to 1.6 nM with 200
nM COR1-D2. The antibody and COR1 dilution series were
Figure 1. Target pathway. (a) Activation of the β1-adrenergic receptor
via a β-adrenoceptor−adenylyl cyclase protein kinase A cascade. The
cAMP-dependent PKA phosphorylates Ca2+ channels, and the
resulting calcium influx increases the contractility of the myocard.
(b) The extracellular loop of the β1-adrenergic receptor is mimicked
by the peptide sequence COR1. (c) The labeled COR1 variant is used
to detect binding with thermophoresis.
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mixed 1:1 to obtain final measurement samples. For the
autocompetition assay, a serial dilution of unlabeled COR1
from 4000 to 42 nM was set up in PBS. Separately, a stock
solution containing 40 nM labeled COR1-D2 was mixed with
twice the final pAB concentration in human serum at a 1:1
ratio, resulting in a total COR1 concentration (labeled and
unlabeled) from 2000 to 21 nM. For the measurements in 10%
human serum, the stock solutions of COR1-D2 and pAB were
set up in 20% human serum and 80% PBS. After 2 h of
incubation at room temperature, about 5 μL of each sample was
filled into capillaries, which were then closed with sealing wax
(NanoTemper, Germany).
■ RESULTS AND DISCUSSION
Thermophoresis. The movement of molecules in a
temperature gradient27−29 is modeled phenomenologically by
the drift velocity v = −DT,i grad T with temperature gradient
grad T. The proportionality constant DT,i is termed the
“thermal diffusion coefficient” or “thermophoretic mobility”.
The index i distinguishes between the bound and unbound
states of the molecule. The drift is counterbalanced by mass
diffusion:
= − −j c D T D cgrad gradi i i i iT, (1)
with diffusion coefficient Di and molecule concentration ci.
Integration with a temperature-independent DT,i and Di yields a
steady-state concentration of cT,i = ci exp(−ST,iΔT) at the
position where the temperature is increased by ΔT. The Soret
coefficient ST,i is defined by the ratio ST,i = DT,i/Di. A number of
ways to measure thermophoresis have been devised in the
past.30−32 Typically, the depleted concentration is lower, cT,i <
ci; i.e., the Soret coefficient is positive.
Linearity of Detection. In the presented measurements,
the depletion is kept small (∼15%) and changes only slightly
upon binding (2−4%). This is ensured by small applied
temperature differences (ΔT ≈ 5−10 K). As a result, the
linearization cT,i = ci(1 − ST,iΔT) introduces only small
systematic errors:
Δ = − = − Δc c c S c Ti i i i iT, T, (2)
The temperature increase ΔT̃(x,y,z) in the capillary has a rather
complex shape (Figure 2b). Additionally, the efficiency φ(x,y,z)
to detect a photon from position x,y,z by the objective is
nontrivial. Interestingly, due to the above linearization, exact
knowledge of both functions is not required.
The quantum efficiency f T,i of the fluorescent dye attached to
the molecule in binding state i is given by a linear function,
f T,i(ΔT̃) = f i + ΔT̃(∂f i/∂T), for the small temperature range
used (5−10 K). Typical values are ∂f i/∂T ≈ −1%/K.
27 The
molecule concentration in the steady state at position x,y,z is
given by eq 2 with cT,i(ΔT̃) = ci(1 − ST,iΔT̃(x,y,z)). The cold
fluorescence intensity flux FI at ΔT̃ = 0 can be linearly
integrated:
∫
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can be expanded to first order in ΔT̃:
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with the averaged temperature increase ΔT defined by
∫ΔT̃(x,y,z) φ(x,y,z) dx dy dz = ΔT ∫ φ(x,y,z) dx dy dz. As
a result the relative depleted fluorescence signal ΔF/F,
subtracted and normalized to the initial cold fluorescence FI,
is given by
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Δ ∑
∑
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Above, we defined an apparent Soret coefficient by the
combined temperature dependence of the dye and thermopho-
retic depletion into
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Figure 2. Microscale thermophoresis. (a) Experimental setup. An
infrared laser for heating is coupled into the microscope light path
using a dichroic mirror. It is focused into the fluid with the standard
epifluorescence microscope objective. Bright-field illumination is
provided with a high-power light-emitting diode (LED), fluorescence
detection with a charge-coupled device (CCD) camera. (b) Temper-
ature profile based on finite element calculations and temperature-
dependent fluorescence measurements. The inhomogeneous heating
does not affect the analysis in the linear regime, shown in eqs 3−7. (c)
Trace of the COR1 fluorescence intensity in the heated center. The
cold baseline fluorescence before heating (I) drops by outward
thermophoresis and the temperature dependence of the dye (II) and
recovers by back-diffusion after the laser heating is switched off (III).
The measured signal is the fluorescence depletion between the warm
regime (II) and the cold baseline (I). The thermophoretic depletion
shifts depending on the concentration of binder. As an example, we
show the raw data of the measurements presented in Figure 4b, c
which quantify the affinity against COR1 for the monoclonal antibody
in serum and the polyclonal antibody in PBS.
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The fluorescence signal becomes a linear function of the
apparent Soret coefficient Si even for a spatially varying
temperature increase ΔT̃ and fluorescence detection field φ.
Depletion Reports Fraction of Bound Molecules. Let
us consider the chemical binding equilibrium between ligand L
and fluorescently labeled binder B:
+ ⇔B L LBfree free (8)
The binding is reported by the difference in the thermophoretic
depletion of molecule B in the free state Bfree and the bound
state LB with state index i = {Bfree, LB}. The fraction x of
bound concentration against all labeled concentrations x = cLB/
(cB + cLB) is a linear function of the depleted fluorescence ΔF/
F. From eq 6 follows that the fluorescence depletion is given by
Δ = Δ
+
+
F
F
T
c f S c f S
c f c f
B B B LB LB LB
B B LB LB (9)
We will focus on the likely case that the fluorescence quantum
efficiencies f B = f LB are equal. Otherwise the binding between B
and L could be reported directly by absolute fluorescence.
However, no change in absolute intensity under variation of the
ligand concentration was found. We find
Δ = −
= Δ
− +
− +
= Δ + Δ
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with ΔS = SLB − SB the difference between the apparent Soret
coefficients of the bound and unbound states. Only the total
concentrations of binder, cB0 = cB + cLB, and ligand, cL0 = cL +
cLB, are known. The mass action law with dissociation constant
KD reads
= = − −K c c
c
c c c c
c
( )( )
D
L B
LB
L0 LB B0 LB
LB (11)
Solving for the fraction of occupied binder B yields
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To conclude, the minimal and maximal levels of depleted
fluorescence are given by SB (no ligand bound) and SB + ΔS
(all ligands bound). In between, the depletion linearly reports
the fraction x of bound states according to eq 10. The fraction x
is modeled by the mass action law and fitted to the
experimental results to reveal the dissociation constant KD
and the unlabeled ligand concentration cL0.
Figure 3 shows that the dissociation coefficient KD and ligand
concentration cL0 of the antibody can be fitted independently.
An increasing ligand concentration shifts the binding curve
along the cB0 axis toward higher binder concentrations (Figure
3a). Contrary to intuition, the dissociation constant changes the
amplitude of the fraction of bound ligand L (antibody) (Figure
3b) as a higher percentage of the constant amount of ligands is
captured by the binder B (COR1). Only when the ligand
concentration is lower than the dissociation constant, cL0 ≤ KD,
do the above shift and amplitude change of the binding curve
become very similar. At low concentrations, 4cB0cL0/(cB0 + cL0 +
KD) ≪ 1, the bound fraction can be approximated by x ≈ cB0/
(cB0 + cL0 + KD).
Assay Sensitivity. What concentration of labeled ligand
COR1 should be used? When the concentrations reach KD, the
amplitude signal saturates and reduces the sensitivity. At lower
concentrations, the fluorescence signal diminishes. We assume
that the fluorescence intensity is photon shot noise limited,
scaling with the number of chromophores F ∝ cB0 and yielding
a relative error of ΔFerr/F ∝ 1/cB01/2. With eq 10, the signal-to-
noise ratio (SNR) of fluorescence depletion ΔF/F is SNR ∝
ΔTΔSxcB01/2. The temperature increase ΔT is typically limited
by the temperature dependence of the binding reaction, the
linearity of thermophoresis, and artifacts by thermal convection.
The change of apparent Soret coefficient upon binding ΔS is a
function of the molecules and might only be increased by
optimizing buffers or reducing the temperature dependence of
the chromophore. This leaves the product SNR ∝ xcB01/2 for
optimization (Supporting Information, Figure S-1). The
maximal signal-to-noise ratio ∂(SNR)/∂cB0 = 0 enforces that
the concentration of labeled binder
= +c K cB0
optimal
D L0 (13)
is given by the sum of the dissociation constant and
concentration of the ligand. Two regimes for a maximal
signal-to-noise ratio are thus found. The labeled binder should
be near the ligand concentration cB0 ≈ cL0 for highly affine
ligands (cB0 ≥ KD). However, for less affine ligands (cL0 ≤ KD),
the binder concentration should equal the dissociation constant
with cB0 ≈ KD. Only high-affinity binders with low KD lead to a
high SNR (Supporting Information, Figure S-1).
Affinity Measurement. In Figure 4, we initially measured
the affinity of COR1 to monoclonal and polyclonal antibodies
with the established spiking protocol in which both
concentrations are known.1−3 Monoclonal antibodies (mABs)
are produced by genetically identical lymphocytes, while pABs
Figure 3. Concentration and affinity inferred independently. The
fraction x of binder B (COR1) bound to ligand L (antibody) is plotted
against the binder concentration cB0 according to eq 12. The fraction x
is a linear function of thermophoretic depletion (eq 10). Thus, a
rescaled plot of the measured fluorescence ratio ΔF/F will show the
same behavior. (a) A change of the ligand concentration shifts the
thermophoretic depletion along the binder concentration axis under a
fixed dissociation constant, KD = 200 nM. (b) A change in the
dissociation constant modulates the amplitude of thermophoretic
depletion under constant ligand concentration cL0 = 200 nM. The
depletion is changed differently by both parameters and thus can be
fitted independently.
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are produced by various lymphocyte clones and directed against
one or several epitopes of a specific antigen. The autoantibodies
found in patients’ sera are polyclonal.
We titrated either monoclonal or polyclonal antibodies (see
the Supporting Informaiton) against labeled COR1 to infer the
dissociation constant in a spiked experimental setting. The
indexing for eqs 10 and 12 was i = {L, B} = {antibody, COR1}
with the binder B as the labeled species. The antibody has two
binding sites, and we used the assignment cL0 = 2cL0
AB with cL0
AB
denoting the antibody concentration. The experiment reports
ΔF/F with varying concentration of cL0 and a constant cB0. We
fitted the thermophoretic depletion for a fixed labeled COR1
concentration, cB0 = 20 nM (cB0 = 100 nM for the monoclonal
antibody), and varied antibody concentration cL0. The baseline
depletion was ΔTSB = 78.8% (79.2%) for monoclonal
(polyclonal) antibodies in buffer and 82.9% (80.6%) for
monoclonal (polyclonal) antibodies in 50% serum. Minor
discrepancies probably stem from differences in the heating
focus ΔT between runs and a slightly different thermophoretic
depletion in blood serum and PBS. The depletion amplitude
upon binding was ΔTΔS = 3.72% and 3.58% (3.49% and
2.39%) for mAB and pAB in PBS (and serum). With the
exception of the polyclonal antibody in serum, the depletion
amplitudes showed comparable values. The inverted measure-
ment protocol of detecting the change in thermophoretic
depletion of the antibody (150 kDa) upon binding to the much
smaller COR1 peptide (3 kDa) was not successful, most
probably due to the small size change upon binding in this
configuration.
The fitted dissociation constants KD of the COR1−antibody
binding are similar to each other and all within the range of
70−140 nM. We found KD = 101 ± 17 nM for the monoclonal
antibodies in PBS and KD = 136 ± 32 nM in serum. The
polyclonal antibody preparation showed comparable affinities,
KD = 70 ± 11 nM in PBS and KD = 66 ± 25 nM in serum. Error
bars are the result of the fitting procedure. Experiments were
performed at least three times, confirming the error bars of a
single measurement. We found a slightly higher affinity for the
polyclonal antibody compared to the monoclonal antibody. No
significant difference between measurements in buffer and
serum could be concluded from the data. It should be noted
that the depletion mostly stems from the size difference
between COR1 and COR1 + antibody. An additional increase
of thermophoretic depletion due to binding of COR1 to the
second arm of the antibody is not expected. Indeed, the
measurements show that a two-state model is sufficient to
describe the binding curves.
The specificity of binding is checked in Figure 4e, f. We
performed measurements with an unspecific antibody for
COR1, namely a monoclonal antibody against E-cadherin.
While the control shows no binding signal, the binding is
reproduced for the specific antibody (Figure 4e). The 2-fold
reduction in binding affinity as compared to the measurement
in Figure 4b could be the result of a new serum stock. In Figure
4f, COR1 was labeled with fluorescein to check for possible
interactions of the dye D2 with the antibody. Again specific
binding is detected, and we find no thermophoretic depletion
for the E-cadherin antibody. The binding with COR1-
fluorescein is slightly less affine as compared to that with
COR1. This could be due to the fluorescence correction which
was required for fluorescein (Supporting Information, S-7).
Autocompetition Assay. To determine both affinity and
concentration, a strategy to mix labeled and unlabeled COR1
was successful. Perturbations of the thermophoretic measure-
ment signal are minimal if both the labeled COR1
concentration and serum dilution are held constant. The total
concentration of COR1 was changed by adding unlabeled
COR1 in a protocol we termed “autocompetition”. The
assumption that both COR1 species bind to the antibody
with equal affinity was later tested successfully by model fits.
We thus assign the index i = {L, B} = {antibody, COR1labeled +
COR1unlabeled} with cL0 unknown and cB0 = cB0
labeled + cB0
unlabeled at a
fixed concentration of cB0
labeled. Again, the concentration of
binding sites of the antibody was quantified using cL0 = 2cL0
AB.
We started with cB0
labeled = 20 nM to ensure maximal sensitivity
also for low antibody concentrations. We first tested the
approach by spiking polyclonal antibody with concentrations
between 2 and 200 nM into 50% human serum. The goal was
Figure 4. Affinity. The affinity of labeled COR1 to monoclonal and
polyclonal autoantibodies was quantified in buffer and 50% human
serum. In contrast to the autocompetition assay described in Figure 3,
we first performed microscale thermophoresis without autocompeti-
tion: with fixed labeled COR1 concentration cB0, the antibody
concentration cL0 was varied. Again, eqs 10 and 12 were used for
fitting, but the traditional usage of the concentrations resulted in
inverted characteristics as compared to those of the autocompetition
described in Figure 3. (a, b) Binding of COR1 to monoclonal antibody
yielded a dissociation constant of KD = 101 ± 17 nM in PBS buffer
and KD = 136 ± 32 nM in 50% untreated human serum. (c, d)
Measurements of polyclonal antibody showed KD = 70 ± 11 nM for
PBS and KD = 66 ± 25 nM in 50% serum. The dissociation constant is
considered as per antibody molecule. Affinities per antigen binding site
would have yielded half of the above KD values. (e) The specificity of
binding was confirmed in serum by control experiments with an
unspecific monocloncal anti-E-cadherin antibody. A constant
thermophoretic depletion signal was found, indicating no binding.
(f) Measurements using a COR1 which was labeled with fluorescein
show the same specific binding signal; however, they yield a slightly
lower affinity.
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to recover both the KD and the concentration of the antibodies
from the experiment.
In Figure 5, we present the results with fitted theoretical
curves. In the inset, the fitted antibody concentrations are
plotted against the experimentally added concentrations for
three different fitting scenarios: the simple binding assumption
with one KD (eqs 10 and 12), label-dependent affinity with two
differing KD values for the labeled and unlabeled COR1
(Supporting Information, eqs S2−S4), and polyclonal binding
where we assume two different antibody subpopulations
(Supporting Information, eqs S5−S7).
For the simple binding assumption, the fitted antibody
concentrations were 0.9 ± 1.5, 26 ± 3.4, 108 ± 19, and 176 ±
21 nM, confirming within statistical errors the pipetted values
of 2, 20, 80, and 200 nM. Furthermore, the fit resulted in a
dissociation constant of KD = 74 ± 11 nM, matching the
previously measured value of 66 nM in 50% serum (Figure 4).
The thermophoretic depletion amplitude ΔTΔS was globally
fitted, but held constant for all four concentrations. Baselines
ΔTSB were fitted individually for each run as they showed a
minor variability of about 0.5%.
The label-dependent binding model assumes different
affinities of labeled and unlabeled probes. It did not describe
the measurements better and reported statistically indistin-
guishable values for the unlabeled COR1 of KD′ = 73.9 ± 25
nM and the labeled COR1 of KD = 75.8 ± 73 nM with very
similar antibody concentration values of 0.91 ± 1.8, 27 ± 14,
110 ± 49, and 170 ± 55 nM. The unlabeled COR1 and labeled
COR1 probes did not show a difference in binding, confirming
our initial assumption in performing a competitive assay with
unlabeled COR1 while keeping the labeled COR1 concen-
tration constant.
Similarly, the polyclonal labeling model did not improve the
description of the measurements. By assuming a polyclonal
distribution consisting of half more affine (KD) and less affine
(KD′) antibodies, the analysis could not distinguish statistically
between the fitted KD = 72.6 ± 3 nM and KD′ = 73.7 ± 4 nM.
The determined concentrations, 0.9 ± 1.6, 26 ± 5, 100 ± 19,
and 170 ± 32 nM, were also very similar to the above simple fit
results. Thus, no evidence for polyclonal binding was found.
To conclude, we measured the antibody concentration down
to 2 nM. At such low concentrations, significant errors arise as
the thermophoretic depletion amplitude approaches the
instrumentation error. Otherwise, the affinity and concentration
of the antibody were measured with errors on the 20% scale.
Concentration and Affinity Approach. In Figure 6, we
combine the autocompetition assay of Figure 5 with a moderate
5-fold dilution of the serum. As a result, we can fit both the
concentration and affinity of the antibody without any prior
knowledge. Two autocompetition curves were measured with
thermophoresis for a 50% serum dilution and a 10% serum
dilution. Both binding curves were fitted with an equal, but
unknown, dissociation coefficient and a common depletion
amplitude, ΔTΔS, considering the 5-fold concentration dilution
of the ligand. We found an antibody concentration of 187 ± 26
nM with a dissociation constant of KD = 73 ± 18 nM.
The combined dilution and autocompetition strategy reports
the pipetted concentration of 200 nM and the previously
measured dissociation constant of 66 nM (Figure 4) with a 13%
error in concentration and 25% error in affinity. For example, a
4-fold lower antibody concentration or 4-fold smaller affinity
shows a strongly differing autocompetition and dilution
response, although we treated the depletion amplitude ΔTΔS
as a fitted free parameter. This shows that thermophoresis
allows the concurrent determination of the affinity and
concentration of antibodies in 50% serum, under close to in
vivo conditions.
Discussion. The results show that thermophoresis, using an
autocompetition and dilution protocol, bodes well to detect
autoimmune antibody profiles directly in serum. We could
detect concentrations up to 35-fold below the affinity of the
antibody. The major limitation to detect antibodies in patient
samples is the affinity of the probe. As the antibody
concentrations in patient sera are estimated to be within the
low nanomolar range, a decrease of the dissociation constant by
an order of magnitude is necessary for any direct detection
Figure 5. Autocompetition assay. In 50% human serum, the
concentration of total COR1 is increased by adding unlabeled
COR1 to 20 nM labeled COR1. Thermophoresis only records the
depletion of the labeled species. Autocompetition reduces the
thermophoretic depletion as less labeled COR1 is bound to the
antibody. Four binding curves are recorded for antibody concen-
trations of 2, 20, 80, and 200 nM. We recover the concentrations from
the fit with 0.9 ± 1.5, 26 ± 3.4, 108 ± 20, and 176 ± 21 nM (SD), well
within the pipetting errors. Independently, the dissociation constant
was inferred to be 74 ± 11 nM. Inset: More complex binding models
assuming label-dependent affinity or polyclonal binding did not change
the fitted concentrations noticeably, confirming the simple binding
assumption.
Figure 6. Concentration and affinity assay. Two autocompetition
assays are performed in 50% human serum and the 5-fold dilution to
10% serum. This protocol allows the determination of both the
concentration and affinity of antibodies. We find an antibody
concentration of 187 ± 26 nM with a dissociation constant of KD =
73 ± 18 nM. The theoretical predictions for a 4-fold lower antibody
concentration (dotted line) and a 4-fold smaller dissociation constant
(dashed line) differ significantly from the measurements.
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scheme. A dimeric peptide probe should make this possible as
the avidity of binding with both antibody arms enhances the
affinity.33 In such a scenario, the signal-to-noise ratio is optimal
near the KD of the binder (Supporting Information, Figure S-
1); thus, sensitivity is increased with a parallel reduction of the
labeled antigen’s concentration. On the basis of the low noise of
the fluorescence signal (Figure 2c), a further reduction of
labeled antigen concentration to 1 nM is feasible. With both
improvements, the detection of antigen concentrations below
100 pM is expected to be achieved.
Such an improved sensitivity would facilitate screening for
binding and concentration profiles of antibody interactions with
labeled antigen libraries. Moreover, while the measurements
were conducted in a capillary, extensions of the approach to
specially designed multiwell plates appear realistic and would
allow for a highly increased throughput rate. This paves the way
toward probing for a large class of disease-related, elevated
levels of autoimmune antibodies which have been hard to
detect reliably up to now. Especially the possibility to probe not
only concentration but also affinity would allow us to obtain a
very quantitative picture.
From a more fundamental perspective, the shown experi-
ments could be scaled down to the single-molecule regime.
With optimized optics, a single chromophore might emit N =
100 000 photons. The fundamental photon noise limit would
allow the depletion to be detected with 1/√N ≈ 0.3%
accuracy, well below the typical thermophoretic amplitude
upon binding of 2−3% reported here. Given low background
levels, single-molecule thermophoresis appears feasible.
Recently, we have shown that thermophoresis is capable of
measuring the binding of pharmaceutically interesting small
molecules to proteins.1 While we have chosen to label the small
antigen here, the opposite protocol would also be feasible,
although it would lead to smaller depletion amplitudes.
However, with the protocols presented here, screening for
pharmaceutically relevant molecules in complex biological
liquids would reveal the affinity and concentration of the
binders in their native environment.
The thermophoretic approach does not include an
amplification step such as ELISA which concentrates the
initially diluted probes on the surface. However, amplification
steps are often problematic in that they introduce nonlinear
characteristics into the detection signal. Thermophoresis solely
relies on the mass action law in bulk fluid. Until now only
expensive and complex labeling methods using radioactive
labeling could give a similar straightforward prospect. We
expect that the closer the detection scheme to the natural
setting, the smaller the risk of introducing systematic errors.
■ CONCLUSION
We demonstrated that thermophoresis allows direct measure-
ments of antibody affinity and concentration in 50% serum.
Sensitivity was limited by the suboptimal affinity of the
antibody (KD = 70 nM), yielding a concentration detection
limit of 2−5 nM. Typical error bars for affinity and
concentration are on the order of 20%. The limited affinity
of the used monomeric antigen does not yet allow for the
screening of patient sera. The analysis, however, shows that
with an improved affinity, obtained, for example, by using a
dimeric probe, concentrations well below 1 nM should be
readily detected.
The advantage of the method is to detect both affinity and
concentration in the bulk volume of a biologically complex
liquid. Furthermore, it is not at the risk of possible surface
artifacts and requires only microliter sample volumes. Notably,
the approach developed here not only is applicable to serum-
based immunology, but also can detect concentration and
affinity in more complex biological fluids such as cell lysates.1
As biology becomes more quantitative in the future, our
approach is likely to find interesting applications.
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(30) Köhler, W. J. Chem. Phys. 1993, 98, 660−668.
(31) Wiegand, S.; Ning, H.; Kriegs, H. J. Phys. Chem. B 2007, 111,
14169−14174.
(32) Piazza, R.; Iacopini, S.; Triulzi, B. Phys. Chem. Chem. Phys. 2004,
6, 1616−1622.
(33) Randle, B. J.; Scoltock, S. J.; Scott, D. K. Biochem. Biophys. Res.
Commun. 2004, 324, 504−510.
(34) Wallukat, G.; Kayser, A.; Wollenberger, A. Eur. Heart J. 1995,
16, 85−88.
Analytical Chemistry Article
dx.doi.org/10.1021/ac202923j | Anal. Chem. 2012, 84, 3523−35303530
Supporting Information for 
Direct Detection of Antibody Concentration and Affinity in Human 
Serum using Microscale Thermophoresis 
Svenja Lippok,¥ Susanne A.I. Seidel,¥ Stefan Duhr,† Kerstin Uhland,‡ 
Hans-Peter Holthoff,‡ Dieter Jenne,¶ and Dieter Braun¥* 
¥ Systems Biophysics, Center for Nanoscience, Physics Department, Ludwig 
Maximilians Universität München, Amalienstr. 54, 80799 München, Germany;  
† NanoTemper Technologies GmbH, Flößergasse 4, 81369 München, Germany;  
‡ Corimmun GmbH, Lochhamer Str. 29, 82152 Martinsried, Germany;  
¶ Max Planck Institute of Neurobiology, Am Klopferspitz 18, 82152 Martinsried, 
Germany  
 
Address reprint requests and inquiries to dieter.braun@lmu.de 
S-1 
S1. Antibodies. The mouse monoclonal antibody 23-6-7, batch KD-250208-001 was 
produced by Biogenes GmbH, Germany by immunizing 8-week old BALB/c female mice 
subcutaneously over a period of 39 days with a GST fusion protein carrying the complete 
second extracellular domain (ARAES DEARR CYNDP KCCDF VTNRQ). The antibody 
produced from hybridoma cell clone 23-6-7 was purified by Protein A affinity 
chromatography and dissolved as 2 mg/ml stock solution in PBS. The goat polyclonal 
antibody (Lot: 28498) was generated by Biogenes GmbH, Germany. The immunization of the 
goat was carried out by six boosts over a period of 23 weeks with above GST fusion protein. 
The antibody containing serum was purified by affinity chromatography. The antibody was 
dissolved in Glycine buffer, pH 7.5, 250 mM NaCl, 0.02% Thimerosal as a 377 µg/ml stock 
solution. For control measurements a monoclonal antibody to Mouse E-cadherin from TaKara 
Bio Inc. (Otsu, Shiga, Japan) was used. 
 
S2. Imaging and Setup. Excitation was provided by a red high power LED (627 nm, 
Thorlabs, United Kingdom). For measurements in serum, D2 dyes were used to bypass the 
autofluorescence interference from serum at shorter wavelengths. A Cy5 filter set with an 
excitation range of 590-650 nm and emission range of 663-738 nm (F46-006, AHF-
Analysetechnik, Germany) was used. The infrared laser was coupled into the imaging path 
with an infrared dichroic mirror and focused into the fluid with the microscope objective (20x 
Plan-Apochromat, NA=0.8, Carl Zeiss, Germany) which was also used for epifluorescence 
imaging with a CCD camera (Sensicam UV, PCO AG, Germany). A region of 20 x 20 µm 
around the center of heating was used for analysis. The images were corrected for constant 
background fluorescence.  
Glass capillaries with low diameter variation and standardized surface condition 
(NanoTemper, Germany) were used with an inner diameter of 500 µm, an outer diameter of 
1 mm and a length of 50 mm. All measurements were performed twice at room temperature, 
error bars indicate the difference between measurements. 
 
S3. Temperature. According to the Lambert-Beer-Bouguer law I/I0 = exp(-αd) and an 
absorption coefficient of α= 2850 m-1 at 1480 nm, the intensity decreases to 1/e after 
d=350 µm. The temperature profile was imaged by the temperature dependence of the 
fluorescence dye BCECF in 10 mM Tris-HCl buffer [17]. Measurements confirmed that due 
to the fixed capillary thickness and constant infrared laser power, the temperature increase 
was reproducibly generated with a precision of <0.1 K.  
 
S4. Label dependent affinity. Let us assume that labeled and unlabeled binder ( B , B' ) 
differ in their affinity. Since we use a mixed protocol where we titrate the binder that is a 
mixture of labeled and unlabeled elements ( unlabeledB0labeledB0B0 c+c=c ) as a mixture of both labeled 
and unlabeled binder, it is important to check experimentally that both binders have the same 
dissociation constant. We extend the mass action law to two parallel binding reactions 
    LBL+B freefree ⇔  and LB'+LB' freefree ⇔    (S-1) 
with dissociation constants DK  and DK' . With the fraction of bound ligand ( ) LLB'LB cc+c=χ /  
both equilibria are given by  
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Solving for χ  and inserting it into equation (S-2) gives a fraction of occupied labeled binder 
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which can be then inserted into equation (10) to evaluate the experiments. On a numerical 
level, this means we have to solve a cubic equation. However, fitting the data with this 
approach did not lead to statistically significant differences in both affinities. 
 
S5. Polyclonal binding. For the case of polyclonal antibodies, the possibility of a broad 
distribution of binding affinities has to be considered. To explore this, we assume as a first 
approximation that the two ligands L  and L'  are of differing dissociation constants DK  and 
DK' , respectively. We extend the mass action law to two parallel binding reactions 
    LBL+B freefree ⇔  and BL'L'+B freefree ⇔    (S-5) 
With the fraction of bound ligand ( ) LBL'LB cc+c=ζ /  both equilibria are given by  
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Solving for ζ  and inserting it into equation (S-7) gives a fraction of occupied labeled binder ( ) B0BL'LB cc+c=x /  that can be inserted into equation (10). On a numerical level, this means we 
have to solve a cubic equation. As before, fitting the data with the more complex binding 
model did not yield differences in the respective affinities. 
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S6. Signal to Noise 
 
 
 
Figure S-1. Signal to noise ratio. The signal to noise ratio for detection is optimal at 
L0DB0 c+K=c . Thus detection is optimal at L0B0 c=c for highly affine binding reactions ( 
DB0 Kc . For less affine binders (≥ ) DL0 Kc ≤ ), detection is optimal for DB0 K=c . The shown 
curves were calculated with 20nM=cL0 . 
 
 
S7. Correction of concentration dependent Fluorescein fluorescence. For a control 
measurement with a fluorescein-labeled COR1 peptide (Figure 4f), we observed a consistent 
fluorescence drop in the raw depletion signal with increasing antibody concentration (Figure 
S-2a). A similar drop was not found for the D2-labeled COR1 used throughout the manuscript 
and therefore no correction for the measurements with the D2 chromophore was needed. We 
attribute this effect to changes in the temperature dependent fluorescence of fluorescein 
depending on the antibody concentration - similar effects of proximity enhanced fluorescence 
are known in literature. 
For account for this, we base both the warm and cold fluorescence FII and FI of fluorescein-
COR1 on the respective measurement FIIR and FIR using fluorescein without peptide. The 
fluorescence change IF
FF=
F
ΔF − III is now normalized to 
1
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F
F
F
F
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F
ΔF
. In other words, the depletion signal of the 
binding measurement III FF is divided by the depletion ratio measurement of the 
chromophore III RR FF . This results in a depletion binding curve which reveals the typical 3% 
S-4 
thermophoretic depletion known from the D2-Cor1 labeling. Interestingly, we did not observe 
a similar fluorescence drop in the presence of the E-Cadherin antibody used to control the 
specificity of the binding of both the COR1-D2 and COR1-fluorescein peptide (Figure S-2b). 
Data correction for both antibodies demonstrates the specifity of binding to Cor1 pAB (Figure 
S-2c). 
 
Figure S-2. Correction of Fluorescein concentration dependence. The fluorescence signal of 
fluorescein-COR1 varies with the concentration of the polyclonal antibody. Thermophoretic 
depletion of (a) titrated COR1-Polyclonal Antibody and (b) E-Cadherin Antibody with 
fluorescein-labeled COR1 (filled circles) and fluorescein (open circles) are used to correct 
the concencentration dependence of the chromophore. (c)  Corrected data shows the specifity 
of binding to Cor1 pAB (see Figure 4f). 
 
S-5 
